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ABSTRACT 
 
 
Palmitoylation refers to the covalent attachment of fatty acids, such as palmitate, 
onto the cysteine residues of proteins. This process may subsequently alter their 
localization and function.  Nearly all of the enzymes that catalyze palmitoylation, 
zDHHC protein acyl transferases (PATs), are implicated in neurological 
disorders, infectious diseases, and cancer in humans.  Of particular interest to 
those who study palmitoylation are Ras family GTPas and zDHHC9-GCP16, the 
zDHHC PAT that palmitoylates Ras proteins.  Erf2-Erf4 is the zDHHC PAT that 
palmitoylates Ras proteins in Saccharomyces cerevisiae.  Currently, there are no 
methods to therapeutically target palmitoylation for the treatment of disease.  
One of the barriers to identifying a modulator of palmitoylation is the lack of a 
reliable high-throughput screening system.  To date, few assay systems have 
been developed to examine the kinetics and mechanism of that palmitoylation 
reaction. This lab has developed a fluorescence-based coupled assay to gain 
insight into the enzymology, biochemical mechanism, and kinetics of the 
palmitoylation reaction. This assay may be used to identify specific inhibitors of 
autopalmitoylation. In the first step of this reaction, the palmitoyl-moiety from 
palmitoyl-CoA is transferred to the zDHHC9 PAT cysteine side chain to form a 
palmitoyl:enzyme intermediate.  The second step of palmitoylation is the 
subsequent transfer of the palmitoyl-moiety from the palmitoyl:enzyme 
	 ix 
intermediate to the cysteine residue of the substrate protein.  This fluorescence-
based coupled assay was utilized to screen a natural products library and a 
unique synthetic compound library for inhibitors of Erf2 autopalmitoylation.  
These screens led to the identification of fungal metabolite extracts and ten bis-
cyclic piperazine compounds that inhibit Erf2 autopalmitoylation in the low 
micromolar range.  This effect is similar to known inhibitors of palmitoylation that 
lack specificity for the palmitoylation reaction itself. 
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CHAPTER 1 
 
Protein Lipidation and the Function of Ras Oncogene Proteins 
 
1.1 Key Words and Abbreviations 
Enzymology; Inhibitor; Mechanism; Palmitoylation; Ras; zDHHC. 
Aβ , β-amyloid protein; AD, Alzheimer’s Disease; APP, Amyloid Precursor 
Protein; BACE1, β-secretase 1; CDKL5, Cyclin-Dependent Kinase-Like 5; CRD, 
Cysteine Rich Domain; eNOS, Endothelial Nitric Oxide Synthase; ER, 
Endoplasmic Reticulum; ERα , Estrogen Receptor α ; ERF, Effect on Ras 
Function; FTase, Farnesyl Transferase; GAP, GTPase activating protein; 
GCP16, 16 kDa Golgi Complex Protein; GEF, Guanine Nucleotide Exchange 
Factors; GGTase, Geranylgeranyl Prenyltransferase; HD, Huntington’s Disease; 
HIP-14, Huntingtin Interacting Protein 14; htt, Huntingtin; HVR, Hyper Variable 
Region; ICMT, Isoprenylcysteine Carboxyl Methyltransferase; MAPK, Mitogen-
Activated Protein Kinase; mBOAT, Membrane Bound O-acyltransferases; NSF, 
N-ethymaleimide-sensitive factor attachment protein receptor; PAT, Protein Acyl 
Transferase; PM, Plasma Membrane; PTM, Post-translational Modification; 
RCE1, Ras Converting CAAX Endopeptidase; REAM, Reduced Expression 
Associated with Metastasis (zDHHC2); SNP, Single Nucleotide Polymorphisms; 
TMD, Trans-membrane Domain, XLID, X-linked Intellectual Disability 
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1.2 Introduction to Protein Lipidation 
Protein lipidation refers to the covalent addition of lipids onto the side chains of a 
large and diverse group of eukaryotic proteins.  The lipids that are added are also 
diverse and include isoprenoids (farnesyl (C15) and geranylgeranyl (C20)), fatty 
acids (myristoyl (C14) and palmitoyl (C16)) and cholesterol (Fig. 1.1) [1-4].  The 
functional significance of lipidation depends on the protein and the subcellular 
location where it occurs.  For example, lipidated proteins destined for export from 
the cell, such as wnt and sonic hedgehog, undergo palmitoylation in the lumen of 
the ER during the export process [4].  The ER-localized enzymes that 
palmitoylate secreted proteins belong to a family called the MBOATs 
(membrane-bound O-acyltransferases) [5].  This is referred to as O-
palmitoylation and results in an oxyester bond [5].  Cytosolic proteins and integral 
membrane proteins can also be palmitoylated.  Cytosolic palmitoylation occurs 
as either a labile thioester bond on cysteine residues (S-palmitoylation), or as a 
stable amide bond on glycine residues (N-palmitoylation). Protein palmitoylation 
will refer to S-palmitoylation for the remainder of this dissertation. 
Palmitoylation occurs on a broad range of proteins and has a significant role in 
the localization and function of proteins.  Some of the cellular processes 
palmitoylation regulates are signal transduction, protein trafficking, protein 
turnover, vesicle fusion, and cell-cell interactions [6-9].  More than 400 
palmitoylated human proteins have been identified including G protein-coupled 
receptors, Golgi-localized mannosyltransferases, plasma-membrane-localized-
phosphatases, Gα subunits, Src family kinases, Ras proteins, neurotransmitter 
	 3 
receptors, endothelial nitric oxide synthase (eNOS), soluble N-ethylmaleimide-
sensitive factor attachment protein receptor (NSF), and amino acid permeases 
[10-14]. 
Palmitoylation is often coupled with other lipidations [15].  An example of a 
protein that undergoes dual-lipid modifications is Gα subunits that undergo 
myristoylation prior to palmitoylation [16].  Myristoylation is the irreversible 
addition of a 14-carbon saturated fatty acid onto an α -amino group of an N-
terminal glycine residue via an amide bond [17].  Another example of a dual-lipid 
modified protein is the Ras family of proteins that get farnesylated on a C-
terminal CAAX motif (a cysteine residue (C), followed by two aliphatic amino 
acids (A), and the terminal amino acid (X)) prior to palmitoylation [18].  
Farnesylation is the irreversible addition of a 15-carbon isoprenoid by the 
cytosolic enzyme farnesyltransferase (FTase) [2].  In the absence of FTase, 
some Ras proteins can be prenylated by geranylgeranyl transferase (GGTase) 
[19].  Geranylgeranylation is the irreversible addition of a 20-carbon isoprenoid 
onto a cysteine residue [20]. Unlike other lipid modifications, palmitoylation is 
reversible [21].   
 
1.3 Enzymology of Protein Palmitoylation 
For many years, the existence of an enzyme responsible for palmitoylation was a 
matter of controversy.  Twenty years passed between the identification of the first 
palmitoylated protein and the identification of the first enzyme responsible.  
Unlike other enzymatic reactions, substrates of palmitoylation lack an identifiable 
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consensus sequences suggesting that the mechanism is non-enzymatic [22]. 
Peptides derived from palmitoylated proteins, as well as the palmitoylated 
proteins rhodopsin and G-protein regulatory subunits, were able to undergo 
spontaneous palmitoylation further supporting that palmitoylation occurs non-
enzymatically [23-27].   
Conversely, mutagenesis studies suggest that the position of the cysteine 
residue is influential in palmitoylation outcome, and the palmitoylated proteins, 
SNAP-25, GAP-43, and Fyn kinase are not spontaneously palmitoylated in vitro 
supporting the enzymatic mechanism of palmitoylation [22, 26].  Thiolase A, a 
requirement for fatty acid β-oxidation, was observed to palmitoylate H-Ras in 
vitro, but is an unlikely physiological protein acyl transferase (PAT) candidate due 
to its in vivo location in peroxisomes [28, 29].  More support came for an 
enzymatic mechanism when a candidate PAT was identified for N-palmitoylated 
Hedgehog protein [30, 31].  Unfortunately, there was a failure to identify a 
physiologically relevant PAT enzyme for S-palmitoylation [22].   
The major impediments for identifying an enzyme that catalyzes palmitoylation 
are the insolubility of candidate PATs and the instability of the PAT activity.  
When PAT activity was identified, it required detergent solubilization to be 
purified and the subsequent chromatographic separation resulted in a loss of that 
activity [30-32]. 
The debate ended when Lobo et al. performed genetic screens in S. cerevisiae 
demonstrating that palmitoylation was an enzymatic reaction [33].  They 
constructed a yeast strain dependent on Ras2 palmitoylation for viability.  They 
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knocked down candidate proteins to identify an enzyme critical for Ras2 
palmitoylation in their constructed strain.  The identified enzyme is an Erf (Effect 
on Ras Function) complex, Erf2-Erf4 [33].  Erf4 was previously described as a 
partial suppressor of Ras [34, 35].  Palmitoylation of Ras2 in Saccharomyces 
cerevisiae did not occur when the enzyme was deactivated by heat shock 
treatment [33]. In the same year, another yeast PAT, Akr1, was also identified 
through genetic screens. The discovery of Erf2-Erf4 and Akr1 further supported 
that palmitoylation is an enzymatically catalyzed reaction [36]. 
The catalytic core of PATs is a highly conserved ~51 amino acid cysteine-rich 
domain (CRD) containing a zinc-binding domain and an Asp-His-His-Cys 
(zDHHC) motif [37].  zDHHC PATs are polytopic membrane proteins predicted to 
contain at least four trans-membrane-spanning domains (TMDs) with the CRD 
domain on the cytosolic face of the membrane [38, 39].  A conserved aspartic 
acid, proline, glycine (DPG) motif has been observed next to the second 
predicted TMD of zDHHC PATs, and a conserved threonine, threonine, x, 
glutamine (TTxE) motif has been observed next to the fourth predicted TMD of 
zDHHC PATs (Fig. 1.2) [38].  Both the DPG and TTxE motifs are predicted to be 
on the same side of the membrane but lack an identified functional significance 
[38].  Some zDHHC PAT enzymes contain SH3 domains, ankyrin repeats, and 
PDZ-binding motifs.  It is predicted that these additional motifs and domains may 
be important for substrate specificity but little research has elucidated this. 
Erf2 contains the DHHC catalytic motif, whereas Erf4 lacks any defined motifs or 
domains.  The half-life of Erf2 in the presence of Erf4 is ~100 minutes, where it is 
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reduced to only ~9 minutes in the absence of Erf4 [38].  Thus, it is predicted that 
Erf4 acts as an auxiliary protein critical for Erf2 function [33, 40].  The deletion of 
either Erf2 or Erf4 resulted in a reduction in Ras2 palmitoylation, suggesting a 
role for Erf4 in palmitoylation as well [33].  
The zDHHC enzyme family is observed in all eukaryotes examined to date with 
at least 22 zDHHC containing proteins identified in mammals and seven in yeast 
(Fig. 1.2) [14, 18, 41].  The additional zDHHC containing proteins were screened 
to confirm their role in palmitoylation [41]. Most of the zDHHC proteins are 
expressed ubiquitously, and they associate with all intracellular membrane 
compartments but the majority associate with the ER or the Golgi [41]. 
 
1.4 Protein Palmitoylation and Disease 
Nearly all of the zDHHC PATs have been associated with human disease (Table 
1.1).  Most notably, the dysregulation of zDHHC PATs has been implicated in   
neurological disorders, infectious disease, and cancer.  This section will highlight 
the key findings for the dysregulation of palmitoylation in disease with focus on 
neurological disorders and cancer. 
zDHHC PATs in neurological disorders: Dysregulation of palmitoylation is 
implicated in neuronal development, Huntington’s Disease (HD), Alzheimer’s 
Disease (AD), X-linked Intellectual Disability (XLID), and schizophrenia.  A 
significant role of palmitoylation has been described for axon growth, synaptic 
plasticity, and neurotransmitter release [42-45].  Compromised zDHHC PAT 
activity is linked to neurodevelopmental and neuropsychiatric disorders, 
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suggesting a fundamental role of palmitoylation in proper neuronal function.  In 
particular, zDHHC2 plays a critical role in synaptogenesis and synaptic plasticity 
by inducing specific, stoichiometric palmitoylation and synaptic accumulation of 
PSD-95 [46]. zDHHC2 senses changes in synaptic activity and rapidly 
translocates from dendrites to postsynaptic membranes. Zhu et al. demonstrated 
the critical role of palmitoylation in localizing CDKL5 to synapses and facilitating 
the normal development of dendritic spines [47].  These findings suggest that 
disruption of the interaction via mutations could be implicated in the pathogenesis 
of CDKL5-related disorders [47].  
zDHHC17, originally named Huntingtin Interacting Protein 14 (HIP14) for its 
interactions with the Huntingtin protein, transfers palmitate to the protein 
huntingtin (htt).  In the polyglutamine repeat expanded version of the disease 
form of HD, the interaction between htt and zDHHC17, as well subsequent 
palmitoylation of htt, is markedly decreased [45].  Depalmitoylated htt is less 
stable, which causes aggregation of the protein amyloid [45].  zDHHC17-deficient 
mice develop features of HD, supporting that zDHHC17 is dysfunctional in HD 
[45].  The addition of wild type zDHHC17 to two different HD mouse models was 
able to partially reverse the HD disease phenotype [48].  
Dysfunction of palmitoylation is also implicated in AD.  Amyloid precursor protein 
(APP) is palmitoylated by zDHHC12 [49].  β-Secretase (BACE1) is a neuron-
specific membrane-associated protease that cleaves APP to generate β-amyloid 
protein (Aβ) [50]. BACE1 and Aβ are both palmitoylated proteins. Motoki et al. 
discovered that mutant BACE1 lacking the palmitoylation modification was 
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markedly reduced in comparison to wild-type BACE1 in neuroblastoma cells and 
rat primary cortical neurons expressing BACE1 via recombinant adenoviruses 
[51].  
There are two nonsense mutations and two missense mutations of zDHHC9 that 
are implicated in XLID [52].  The two nonsense mutations result in a loss of the 
catalytic DHHC domain of zDHHC9 either through a truncation or a frame shift 
[52].  The two missense mutations (R148W and P150S) are on conserved 
residues within the CRD of zDHHC9 [52].  The Deschenes’ lab evaluated the 
effect of the missense mutations on zDHHC9 PAT activity and concluded that 
both mutations resulted in a reduction of steady-state autopalmitoylation of 
zDHHC9 [53]. This reduction was through different mechanisms; the R148W 
mutant decreased the stability of the palmitoyl-PAT intermediate, whereas the 
P150S mutant reduced the burst autopalmitoylation activity of zDHHC9 [53].  In 
both cases, it is predicted that this reduction of steady-state zDHHC9 
autopalmitoylation would subsequently reduce the amount of palmitoyl moiety 
available for transfer to the protein substrate.    
There has been conflicting evidence in regards to the role of zDHHC8 in the 
development of schizophrenia. Five single nucleotide polymorphisms (SNPs) 
included within the zDHHC8 coding frame in the vicinity of the 22q11 locus [54].  
Every tested variation of these five SNPs demonstrated a significant association 
with schizophrenia [54].  A case-controlled study in the Han Chinese population 
supported these findings in family-based linkage disequilibrium studies [55]. 
However, a Taiwanese cohort for zDHHC8 SNPs demonstrated an association 
	 9 
with schizophrenia in the presence of a deficit in sustained attention [56]. 
zDHHC8 may also influence smooth pursuit eye movement function in 
schizophrenia patients from a Korean population [57].  Unfortunately, many 
researchers produced negative findings, suggesting that there was no 
association between zDHHC8 and schizophrenia in Japanese and European 
populations [58-61].  A zDHHC8-knockout mouse lent support to the association 
between zDHHC8 and schizophrenia due to decreased exploratory activity and 
reduced sensitivity to dizocilpine, an NMDA antagonist used to treat 
schizophrenia [62].  Use of the 22q11 microdeletion mouse model demonstrates 
that the introduction of enzymatically active zDHHC8 can recapitulate the wild-
type phenotype [63].  This mouse also led to the characterization of PSD-95 as a 
substrate of zDHHC8 [63].  There still lacks any experimental validation outside 
of the mouse model that the loss of zDHHC8 function leads to the progression of 
schizophrenia. 
zDHHC PATs in Infectious Diseases:  The role of palmitoylation in several 
parasitic infections may yield novel therapeutic targets for diseases such as 
malaria, Chagas disease, and toxoplasmosis.  The palmitoyl-proteome of the 
schizont stage of Plasmodium falciparum suggests a role for palmitoylation in 
host cell invasion, protein export, and organelle biogenesis in malaria [64].  Over 
400 proteins regulated by palmitoylation in P. falciparum have been identified, 
including those involved in adherence, drug resistance, signaling, development, 
and invasion [65].  In 2013, Batista et al. identified and showed the subcellular 
localization of TcHIP, a presumptive Trypanosoma cruzi (responsible for Chagas 
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disease) zDHHC palmitoyl transferase [66].  zDHHC7 has a significant impact on 
host-cell invasion by Toxoplasma gondii (considered to be a leading cause of 
death related to foodborne illness) [64].  
Palmitoylation also plays a role in viral infections. Most notably, the Influenza 
virus has at least three palmitoylated viral proteins that are required for plasma 
membrane association, assembly and budding [67, 68].  Other studies suggest a 
role for palmitoylation in the pathogenesis of hepatitis V infection [69].  Thus, 
inhibiting palmitoylation may be a promising strategy for treating infectious 
diseases. 
zDHHC PATs in Cancer:  The extranuclear estrogen receptor α (ERα) [70].  
Cysteine residue 451 on ERα is palmitoylated by zDHHC7 and zDHHC21 [71, 
72].  It is suggested that ERα  requires chaperone proteins to uncover a 
conformationally buried cysteine residues for palmitoylation.  Although ERα 
exists as a monomer or dimer, only the monomers have been observed to get 
palmitoylated [73].  Heat shock protein 27 is predicted to promote the 
palmitoylation of ERα by allowing the zDHHC PAT to gain access to the site of 
palmitoylation by conformationally opening the monomeric structure of the ERα 
[74].  The palmitoylation of the internal cysteine residue of ERα promotes 
trafficking of ERα to the plasma membrane [75].  Increased palmitoylation may 
cause this localization of ER since its depalmitoylation disrupts membrane-
initiated steroid signaling.  Conversely, palmitoylation of CD44 in breast cancer 
has been shown to regulate cell migration and control metastasis in breast 
	 11 
cancer [76].  This suggests that inhibiting palmitoylation may not be beneficial in 
some breast cancers. 
It was first proposed that the human chromosome 8p21-22 locus harbored a 
tumor suppressor gene due to the observed loss of heterozygosity in multiple 
cancer samples [77-83].  Oyama et al. established that human REAM (reduced 
expression associated with metastasis), now referred to as zDHHC2, is down 
regulated in more than 50% of human colorectal cancers. It was subsequently 
shown that zDHHC2 is also reduced in approximately two-thirds of the cases with 
liver metastasis [84].  In addition, reduced expression of zDHHC2 is observed in 
lymph node metastasis and gastric adenocarcinomas [85].  Consistent with the 
idea that zDHHC2 is a tumor suppressor, overexpression of zDHHC2 reduced 
the proliferation and invasiveness of a hepatocellular carcinoma cell line [86]. 
Additionally, two substrates of zDHHC2, CKAP4 and CD9, have been shown to 
be tumor suppressors [87-89].  
Microarray analysis of colorectal tumor and gastric cancer samples show an 
upregulation of zDHHC9 protein compared to non-cancerous samples [90].  
zDHHC9 palmitoylates human Ras proteins [91].  The dysregulation of zDHHC9 
may affect the subcellular localization and signaling of H-/N-Ras, which are also 
associated with colorectal cancers [92].  
 
1.5 Ras Biology and Cancer 
There are four major Ras proteins in humans; K-Ras(4A), K-Ras(4B), H-Ras, and 
N-Ras.  The four proteins are >90% identical in their first 168-169 amino acids 
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that confer the GTPase activity and effector interaction sites, but differ in their 
remaining 20 C-terminal amino acids (Fig. 1.3).  The highly divergent, 20 C-
terminal residues comprise the hypervariable region (HVR) and are critical for 
membrane targeting [93, 94].  
Ras proteins are regulatory switch proteins that cycle between inactive (GDP-
bound) and active (GTP-bound) conformations and are activated by Receptor 
Tyrosine Kinases at the cell surface (Fig. 1.4).  Guanine Nucleotide Exchange 
Factors (GEFs) contain a CDC25 homology region responsible for the catalytic 
release of GDP from Ras [95].  GTP is approximately ten times more abundant in 
the cytosol than GDP allowing for GTP to bind Ras following the release of GDP. 
GTPase Activating Proteins (GAPs) increase the intrinsic GTPase activity of Ras, 
increasing the rate of GTP hydrolysis and returning Ras to the inactive GDP-
bound state [95]. 
Ras is trafficked between numerous subcellular compartments including the 
Golgi and the ER.  Although it is capable of signaling from multiple locations, Ras 
most frequently signals from the plasma membrane (PM) [96].  Ras proteins play 
a critical role in regulating cell growth and survival due to their downstream effect 
on transcription factors for actin cytoskeletal integrity, proliferation, differentiation, 
cell adhesion, apoptosis and cell migration [97, 98].  The signal from Ras can 
extend into intracellular compartments through a vast number of effector protein 
interactions (Fig. 1.5) [98-100].  For example, Ras is a key regulator in the 
mitogen-activated protein kinase (MAPK) cascade [101].  
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Ras genes are the most frequently mutated family of oncogenes in human 
cancers [102].  Ras is considered a driver of oncogenesis in several human 
cancers either through a conformationally active mutant Ras or through the 
increased activity of wild-type Ras resulting from the over stimulated receptor 
tyrosine kinases.  The overstimulation of Ras signaling often leads to malignant 
cell transformation through deregulated proliferation, survival, invasiveness, and 
angiogenesis.  This can lead to increased metastasis and decreased apoptosis 
[100, 103].  Mutations at residues G12, G13 and Q61 cause insensitivity to GAP 
(G12 and G13) and increased stability of GTP (Q61) resulting in the constitutive 
activity of Ras [104].  This leads to unregulated downstream effects of Ras in the 
absence of extracellular signals, and ultimately oncogenesis and cancer [105]. 
The most frequently found mutated Ras isoforms in human cancer are K-Ras 
and N-Ras [105].  Mutated forms of Ras are implicated in 20-25% of all human 
tumors [98].  Ras can also be overactive due to the high rate of mutational 
activation or overexpression of growth-factor receptors and their ligands, which 
accounts for a higher ratio of chronically active Ras to mutant Ras [106]. 
 
1.6 Ras Processing 
Ras is initially synthesized as a hydrophilic, soluble protein that immediately 
undergoes posttranslational modifications (PTMs) at the C-terminal CAAX motif. 
(Fig. 1.6) [93, 107].  These modifications are required for targeting Ras to the 
cytoplasmic surface of the plasma membrane, where it primarily elicits its 
interactions with effector proteins.  
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The first PTM of Ras, farnesylation occurs on the cysteine residue of the CAAX 
motif [18].  K-Ras and N-Ras, the two Ras proteins most frequently associated 
with cancer, may also be prenylated by GGTase in the absence of FTase [19].  
Following farnesylation, the terminal three amino acids of the CAAX motif are 
proteolytically removed.  The proteolytic cleavage of the terminal three amino 
acids is catalyzed by Ras Converting CAAX Endopeptidase 1 (RCE1) [108, 109]. 
A subsequent carboxyl methyl esterification of the newly terminal cysteine is 
catalyzed by Isoprenylcysteine Carboxyl Methyltransferase (ICMT) [110]. 
These PTMs enhance Ras association with endomembranes but are not 
sufficient for its binding to the plasma membrane.  K-Ras(4B) has a polybasic 
sequence in the HVR that enables an electrostatic interaction with negatively 
charged plasma membrane phospholipids (Fig. 1.3) [93].  K-Ras(4A), H-Ras, and 
N-Ras cycle between palmitoylated and depalmitoylated states [92].  Ras has 
been a model for the spatial organization, dynamics, and turnover of protein 
palmitoylation [93, 111, 112].  While palmitoylated Ras is found on the 
cytoplasmic surface of the plasma membrane, depalmitoylated Ras is found 
primarily on internal membranes, primarily the ER and Golgi [113, 114].  K-
Ras(4A) is palmitoylated at cysteine residue 180, H-Ras is dually palmitoylated at 
cysteine residues 181 and 184, and N-Ras is palmitoylated at cysteine residue 
181 [115].  
In yeast, Ras proteins are palmitoylated by Erf2-Erf4.  The gene product of 
zDHHC9 was a candidate human homolog zDHHC PAT of Erf2 due to its 70% 
sequence identity with the CRD domain and a 31% overall sequence identity with 
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Erf2 (Fig. 1.7) [91].  In early studies, the zDHHC9 protein could not recapitulate 
Erf2 activity, suggesting that zDHHC9 may similarly require an auxiliary protein to 
function.  Although there were no obvious candidates, a 16 kDa Golgi Complex 
Protein (GCP16) was eventually identified due to its limited sequence similarity to 
Erf4 [91].  zDHHC9 is unstable in the absence of GCP16 similar to Erf2 in the 
absence of Erf4 [91].  The direct interaction between zDHHC9 and GCP16 is not 
investigated as thoroughly as Erf2 and Erf4 but is expected to be similarly 
valuable [40].  Although the role of Erf4 and GCP16 subunits is currently 
unknown, experiments are underway to determine if these auxiliary subunits play 
a role in substrate specificity, enzyme kinetics, and PAT localization [116].   
 
1.7 Therapeutically Targeting Oncogenic Ras 
Prior attempts to target Ras therapeutically via its GTPase activity or early PTMs 
such as farnesylation, failed to be successful in the treatment of cancer.  
Attempts to inhibit GTP-binding and activation of Ras proteins were unsuccessful 
due to the high concentrations of GTP within the cell that binds Ras with a 
picomolar affinity, and attempts to inhibit specific GEFs was also ineffective [102, 
117-119].  Feedback loops and poor therapeutic windows resulted in a lack of 
success to target downstream signaling pathways of Ras as a means to inhibit 
Ras signaling [102]. Inhibitors of FTase were ineffective due to the ability of 
GGTase to restore the activity of K- and N-Ras after FTase inhibitor treatment 
[102, 117].  Palmitoylation remains an intriguing processing step to target in an 
attempt to block the oncogenic activity of Ras.  H- and N-Ras rely on 
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palmitoylation for association with the plasma membrane, whereas K-Ras has 
two isoforms; K-Ras(4A) which gets palmitoylated and K-Ras(4B) which relies on 
a polybasic sequence in the HVR for its association with the plasma membrane.  
Thus, targeting palmitoylation would not inhibit all Ras proteins.  K-Ras is the 
most frequently mutated Ras protein in cancer, but studies have yet to clearly 
distinguish between the palmitoylated and non-palmitoylated isoforms [120, 121].   
The reversibility of palmitoylation makes it an appealing target for modulation that 
can be regulated by physiological stimuli [122]. Because palmitoylation modifies 
proteins involved in cell growth, signaling, and synaptic transmission the 
enzymes responsible may become therapeutic targets.  Development of a PAT 
inhibitor could provide an important tool to explore palmitoylation, and has the 
potential to be a therapeutic strategy to target the previously untreatable 
oncogenic Ras or other diseases the dysregulation of palmitoylation is implicated 
in.  Recently, there has been some success in designing specific, small molecule 
inhibitors of oncogenic, K-Ras(4B) by targeting either the oncogenic mutation or 
specific protein-protein interactions [123, 124].  Due to the lack of success in 
targeting Ras function or upstream modifications, there is still a need for an 
inhibitor that specifically targets palmitoylated Ras isoforms. 
 
1.8 Central Hypothesis and Closing Remarks 
There is an urgent need to identify specific, sensitive modulators of palmitoylation 
to further understand the mechanism and influence of palmitoylation in human 
disease.  A specific, sensitive inhibitor of palmitoylation will allow for a more 
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accurate validation of palmitoylation targets, the enzymes involved, and 
subsequently the substrate/enzyme pairs.  An inhibitor of protein palmitoylation 
will have a great impact on understanding the role of palmitoylation in disease 
allowing for better therapeutic interventions. The goal of this project is to design a 
sensitive HTS for the detection and evaluation of palmitoylation.  The HTS will be 
implemented in inhibitor screens of Erf2 autopalmitoylation to identify specific 
inhibitors of Erf2-Erf4.  These inhibitors could lead to use in a clinical setting or 
for use as probes of palmitoylation in the research setting. 
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Table 1.1.  Human zDHHC Genes Implicated in Human Disease. 
 
zDHHC 
 
Disease/Disorder 
 
Substrate(s) 
 
Proposed 
Mechanism 
 
Reference 
zDHHC2 Gastric Cancer  3 [85] 
zDHHC3 Cervical Cancer  3 [125] 
zDHHC5 Schizophrenia GRIP1b 1 [126] 
zDHHC7 Breast Cancer AR, ERα, 
PR 
 
1 or 2 [71, 73, 76] 
zDHHC8 Schizophrenia GRIP1b 3 [126] 
zDHHC9 Colorectal Cancer H- and N-Ras 
 
1 [90] 
 Gastric Cancer H- and N-Ras 
 
1 [90] 
 X-Linked Intellectual Disability  4 [52, 53, 127] 
zDHHC11 Non-Small-Cell Lung Cancer  1 [128] 
zDHHC12 Alzheimer's Disease APP 1 [49] 
zDHHC13 Huntington’s Disease Htt, GLT-1, 
SNAP-25 
3 or 4 [129-131] 
 Osteoporosis (mouse)  3 [132, 133] 
zDHHC14 Acute Myeloid Leukemia  2 [134] 
 Gastric Cancer  1 [135] 
 Lymphomas  1 [136] 
 Testicular Germ Cell Tumors  3 [137] 
zDHHC15 X-Linked Intellectual Disability  4 [127, 138] 
zDHHC16 Apoptosis Regulation c-Abl 1 [139] 
zDHHC17 Huntington’s Disease Htt, GLT-1, 
GAD65 
3 or 4 [48, 129, 130, 
140-144] 
zDHHC21 Breast Cancer AR, ERα, 
PR 
1 or 2 [71, 73, 76] 
 
Proposed mechanisms include increase in expression (1), increase in activity (2), 
decrease in expression (3), and decrease in activity (4). 
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Figure 1.1.  Protein Lipidation Classifications.  A. Protein Farnesylation is the 
C-terminal thioether attachment of a 15-carbon isoprenoid.  B. Protein Geranyl-
geranylation is the C-terminal thioether attachment of a 20-carbon isoprenoid.  C. 
Myristoylation is the N-terminal amide attachment of a 14-carbon saturated fatty 
acid.  D. S-Palmitoylation is the thioester attachment of a 16-carbon saturated 
fatty acid.  E.  A cholesterol moiety forms an ester bond with the C-terminal 
glycine of proteins.  
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Figure 1.2.  List and Predicted Conformation of Human and Yeast zDHHC 
PAT Enzymes.  There are at least 22 zDHHC PATs identified in humans, and 
seven in yeast.  They are each predicted to have a minimum of four 
transmembrane domains (green), and a cytoplasmic DHHC motif within a 
Cysteine-Rich Domain (pink).  Ankyrin motifs have been identified in two of the 
human zDHHC PATs and two of the yeast zDHHC PATs (red).  Adapted from 
[41]. 
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Figure 1.3.  Sequence Alignment of Ras Protein Hyper Variable Regions.  K-
Ras(4A), K-Ras(4B), H-Ras, and N-Ras differ in their final 20 amino acids, but all 
contain the CAAX motif.  Adapted from [145]. 
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Figure 1.4.  Ras Isoforms are GTPases. Ras cycles between the GTP-bound 
active conformation and the GDP-bound inactive conformation.  Natural GTPase 
activity of Ras facilitates the removal of one phosphate group to go from GTP-
bound to GDP-bound Ras.  GTPase Activating Proteins can increase the 
GTPase activity of Ras.  Guanidine Exchange Factors facilitate the removal of 
GDP from Ras allowing for GTP to interact with Ras.  
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Figure 1.5.  Example Signal Transduction Pathways of Human Ras.  A 
majority of the pathways that Ras signaling is involved in result in cellular growth, 
survival and apoptosis.  The signaling pathways through RAL-GDS, RAF, PLC, 
and NORE1/RASSF1, and PI3K are the best understood, but are only a small 
subset of all Ras interactions.  Adapted from [146]. 
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Figure 1.6.  Ras CAAX Motif Processing. The four C-terminal amino acids (a 
cysteine (C) residue, two aliphatic (A) amino acids, and the terminal (X) amino 
acid) comprise the CAAX motif of Ras proteins.  Ras proteins undergo 
farnesylation of the CAAX motif cysteine residue by farnesyl transferase (FTase), 
the -AAX is proteolytically cleaved by Ras Converting CAAX Endopeptidase 1 
(RCE1), and the now-terminal cysteine residue gets carboxyl methylated by 
Isoprenylcysteine Carboxyl Methyltransferase (ICMT). 
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Figure 1.7.  Sequence Alignment of Erf2 and zDHHC9.  zDHHC9 and Erf2 
contain 70% sequence identity within the CRD domain and 31% sequence 
identity overall.  Adapted from [91]. 
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CHAPTER 2 
 
A Fluorescent-based Assay to Monitor Autopalmitoylation 
 
 
2.1 Note to Reader 
Portions of this chapter have been previously published in Anal. Biochem. (2014) 
1(460), 1-8 and have been reproduced with permission from Analytical 
Biochemistry (See Appendix A) [147]. 
 
2.2 Overview 
During autopalmitoylation, palmitate is transferred from palmitoyl-CoA to the 
PAT, creating a palmitoyl:PAT intermediate and releasing reduced CoA.  We 
have developed an in vitro, single-well, fluorescence-based enzyme assay that 
monitors the first step of the PAT reaction by coupling the production of reduced 
CoA to the reduction of NAD+ using the α -ketoglutarate dehydrogenase 
complex.  This assay is suitable for determining PAT kinetic parameters, 
elucidating lipid donor specificity and measuring PAT inhibition by 2-
bromopalmitate.  Finally, it can be used for High Throughput Screening (HTS) 
campaigns for modulators of protein palmitoylation. 
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2.3 Key Words and Abbreviations 
Autopalmitoylation; CoASH; Fluorescence-Based Assay; High Throughput 
Screening (HTS); Kinetics 
2-BP, 2-Bromopalmitic Acid; α-KDH, α-ketoglutarate dehydrogenase complex; 
ABE, Acyl-Biotin Exchange; APT, Acyl Protein Thioesterase; CMC, Critical 
Micelle Concentration; CoA, Coenzyme A; CoASH, Reduced Coenzyme A; 
FSH1, Family of Serine Hydrolases 1; HTS, High-Throughput Screen; MuDPIT, 
Multi-Dimensional Protein Identification Technology; PAT, Protein Acyl 
Transferase; PPT, Protein Palmitoyl Thioesterase; RAC, Resin Assisted Capture. 
 
2.4 Introduction 
Few assay systems have been developed to examine the acylation reaction 
kinetics despite the interest in identifying proteins that are palmitoylated and the 
understanding of the mechanism(s) that regulates the palmitoylation.  As a result, 
a limited number of specific inhibitors of protein palmitoylation have been 
developed.  There is a need for effective assays that can monitor the protein acyl 
transferase reaction.  Not only will a strong assay give insight into the 
enzymology of protein palmitoylation, it will provide insights into the biochemical 
mechanism(s) of substrate recognition and the kinetics of the reaction, and aid in 
the identification of specific inhibitors of protein palmitoylation.  
Protein palmitoylation proceeds by a two-step mechanism. In the first step, 
autopalmitoylation, the palmitoyl moiety from palmitoyl-CoA is transferred to the 
zDHHC cysteine side chain, forming the palmitoyl:enzyme intermediate and 
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producing reduced CoA (CoASH) (Fig. 2.1A).  Once the autopalmitoylation 
intermediate is formed, one of two reactions can occur: a) in the presence of the 
protein substrate, the palmitoyl group of the intermediate can be transferred to a 
substrate cysteine or b) in the absence of protein substrate, the palmitoyl group 
of the intermediate can by hydrolyzed, yielding the enzyme and palmitate.  The 
formation of the palmitoyl:enzyme intermediate has been monitored by SDS-
PAGE and autoradiography using radiolabeled palmitoyl-CoA as the lipid donor 
[33, 40, 91, 148-151].  However, there are several limitations to assays that rely 
on radiolabeled palmitate.  First, this assay measures the steady-state amount of 
palmitoyl:PAT intermediate, not the total amount [40, 149].  Secondly, the use of 
a radioactive reagent complicates high throughput screening techniques.  Finally, 
sensitivity is a key issue.  At the lower limit of the assay’s sensitivity, the reaction 
can accurately detect 5 fmols of transferred palmitate per min, which equates to 
a signal to noise ratio of approximately 1.5.  The main disadvantages of the 
radioactive assay as it pertains to a high throughput format are the cost of the 
reagents and the amount of time required to perform each step.   
 
2.5 Mechanism of Palmitoylation 
In some circumstances, the zDHHC PAT forms a complex with a heterologous 
subunit prior to autopalmitoylation. Therefore, there are five mechanistic phases 
of palmitoylation: enzyme complex formation, autopalmitoylation, substrate 
acylation, hydrolysis of the enzyme-palmitoyl moiety intermediate, and 
depalmitoylation of the substrate by thioesterases.   
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Complex formation:  Erf2-Erf4 and zDHHC9-GCP16 are examples of zDHHC 
PATs that are more active when in complex with an auxiliary subunit [40, 53].  
The subunits of the Erf2-Erf4 complex require co-translation to form an active 
enzyme, and greater than 4 M urea is required to dissociate the subunits once 
the complex is formed.  Other complexes may exist for other zDHHC PATs but 
have not been detected.  Whether that element is provided within the zDHHC 
subunits through the folding of variant amino acid domains or an accessory 
subunit is not yet determined.  
Autopalmitoylation:  Prior to transferring the palmitoyl moiety to Ras2, the 
zDHHC PAT enzyme undergoes self-acylation, referred to as autopalmitoylation 
[149].  By reducing the formation of the palmitoyl:PAT intermediate one would 
inherently be reducing the availability of the palmitoyl moiety for the transferase 
reaction.  Autopalmitoylation could be targeted by reducing the affinity of 
palmitoyl-CoA for the zDHHC PAT, or by reducing the burst activity of the 
formation of the palmitoyl-PAT intermediate.  Specificity is a concern due to 
sequence conservation and the use of the same lipid donor in the first step of all 
zDHHC reaction mechanisms.  Identified inhibitors of autopalmitoylation should 
be screened against additional zDHHC PATs to determine if they are specific to 
individual PAT enzymes or general inhibitors of all PATs, sometimes referred to 
as “pan” inhibitors. 
Substrate Acylation:  The large number of zDHHC PAT enzymes suggests that 
the individual zDHHC PATs may have substrate specificity and be specialized for 
certain pathways.  Unfortunately, little is known of which enzymes are specific for 
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which substrates.  Except for the cysteine residue that gets palmitoylated, 
palmitoylation sites lack an identifiable sequence requirement.  However, 
palmitoylation often occurs in the context of myristoylation and prenylation 
residues or TMDs [14].  This suggests that substrates of palmitoylation must 
have a preliminary membrane association that allows for palmitoylation to occur, 
and that palmitoylation mediates the stability of the attachment to the membrane 
rather than initiate it.  A kinetic trap model hypothesizes that myristoylation and 
prenylation promote transient interactions between the protein substrates and 
cellular membranes allowing for the protein substrates to migrate freely between 
internal cellular membranes [15, 92, 152].  The additional lipidation by palmitate 
now instills a stronger association with membranes causing the acylated protein 
substrates to be stably anchored and migrate by vesicle-mediated transport.  It is 
suggested that the localization of the specific zDHHC PAT enzymes may dictate 
which cellular membranes the protein substrates are then anchored to [15, 92, 
152].  Trapping refers to the reduced ability for the protein substrate to 
disassociate from the membranes [153]. 
Hydrolysis: An increase in the hydrolysis rate of the palmitoyl-enzyme 
intermediate would decrease the steady-state amount of palmitoyl:PAT 
intermediate.  This would reduce the available palmitate for transfer to the protein 
substrate [53, 149].  Conversely, decreasing the rate of hydrolysis may still 
impact the amount of palmitoylated substrate, as it would reduce the 
concentration of active enzyme.  Similar to autopalmitoylation, there is concern 
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over designing a pan-zDHHC PAT modulator of hydrolysis versus targeting 
specific zDHHC PATs.   
Thioesterase activity:  Many factors can contribute to the half-life of palmitate on 
palmitoylated proteins.  The number of acyl linkages, the activation state of the 
protein and the general esterase accessibility are just some examples [154, 155].  
Although the half-life of Ras protein is around 24 hours, the half-life of palmitate 
on Ras is much faster [156].  H-Ras has a palmitate half-life of 2.4 hours and N-
Ras has an even shorter half-life of palmitate at only 20 minutes [155-157].  
When H-Ras is in the GTP-bound (active) conformation, the half-life of palmitate 
on it is 2.4x faster than when H-Ras is GDP-bound [156].  Modulating the activity 
of depalmitoylation would have just as substantial an impact on disease as 
targeting any other step of autopalmitoylation.  The removal of the palmitate 
moiety from a protein is depalmitoylation.  The enzymes that catalyze 
depalmitoylation are either involved in lysosomal protein degradation (protein 
palmitoyl thioesterases (PPTs)) or in the regulation of palmitoylation for protein 
function in the cytosol (acyl protein thioesterases (APTs)) [154, 158].  
Ppt1 and 2 are two examples of lysosomal PPTs capable of removing palmitate 
from H-Ras in vitro [159-162].  The cytosolic APTs, Apt1 and Apt2, have been 
described to affect Ras subcellular localization and pathway flux [163, 164].  Apt1 
is a 29-kDa cytosolic protein that gets palmitoylated [165, 166].  Palmitoylation of 
Apt1 is predicted to allow for its access to the membrane-associated 
palmitoylated substrates [10].   Apt1 exhibits lysophospholipase activity towards 
palmitoylated glycerol-3-phosphocholine and removes palmitate from Gi, H-Ras 
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and eNOS in vitro [167-169].  Biochemical labeling support that both Apt1 and 
Apt2 are also substrates for palmitoylation [166].  However, deletion of the Apt1 
gene does not affect the half-life of Ras2 palmitoylation, the subcellular 
localization of Ras2, or the growth of palmitoylation-dependent Ras2 alleles in 
vivo.  Apt1 is the frontrunner for enzymes that catalyze depalmitoylation but 
ongoing studies aim to identify other potential thioesterases.  Both the identified 
PPTs and APTs contain the catalytic triad characteristic of serine hydrolases.  
These residues are required for their thioesterase activity.  Thus it is predicted 
that other serine hydrolases may elicit thioesterase activity.  In an in vitro study, 
the Deschenes’ lab compared the ability of yeast Apt1 to reduce palmitoylation of 
Ras2 to that of another serine hydrolase, Family of Serine Hydrolases 1 (FSH1).  
Their unpublished work suggests that Apt1 may be targeting the zDHHC PAT, 
Erf2, rather than directly targeting the palmitoylation of the substrate, Ras2.  
Conversely, FSH1 had no effect on either the enzyme or substrate.  Inhibiting 
depalmitoylation would be clinically desirable for many diseases that have 
decreased expression and/or activity of zDHHC PATs.  Similar to other aspects 
of palmitoylation regulation, a balance needs to be struck for depalmitoylation 
regulation, and effectiveness comes down to specificity. 
 
2.6 Strategies to Evaluate Palmitoylation 
Traditionally palmitoylation was evaluated through the use of [3H]palmitoyl-CoA.  
Although effective, [3H]palmitoyl-CoA is hazardous and requires lengthy 
exposure times.  The samples are run on an SDS-PAGE that is subjected to 
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auto-fluorography with a minimum exposure time of one week but sometimes as 
long as a month for accurate visualization [170].  [14C]palmitoyl-CoA has 
increased sensitivity over [3H]palmitoyl-CoA but it is also more hazardous. Tsai, 
et al. describes a method of intensifying detection with [3H]palmitoyl-CoA 
resulting in a reduction in experimental time to 1-3 days [171].  The use of non-
radioactive chemical labeling with biotin or alternatives has also made recent 
progress [172, 173]. 
In an attempt to identify additional protein palmitoylation substrates many 
researchers utilize mass spectrometry [174, 175].  Metabolic labeling and 
identification of palmitoylated proteins using acyl-biotin exchange (ABE) or 
Resin-Assisted Capture (RAC) followed by mass spectrometry, provides a 
comprehensive inventory of potentially palmitoylated substrates.  Large-scale 
profiling studies with ABE have identified approximately 50 palmitoylated proteins 
in yeast and several hundred in mammalian cells [14, 176-179].  Although this is 
less than has been described to date, the numbers are comparable to previous 
means of detection [10-12]. 
Additionally, algorithms for revealing putative palmitoylated protein substrates are 
becoming available.  These include CSS-Palm, WAP-Palm, and Palm-Pred [180-
182]. Oku, et al. successfully identified ten new substrates of protein 
palmitoylation through in silico screening with CSS-Palm 2.0 [183].  Further 
studies with ABE identified Neurochondrin as a substrate for zDHHC 1/11; a PAT 
subfamily that had no prior identified substrates [183].  This success at identifying 
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substrates highlights the abilities of in silico screening and lends optimism in the 
search for more substrate/enzyme pairs.   
More recently, work has been focused on designing assays that utilize copper-
catalyzed Huisgen 1,3-dipolar cycloaddition click chemistry to elucidate the 
palmitoylation story.  Groups have used biomimetic acyl azides or omega-alkynyl 
palmitate to identify proteins of palmitoylation through the copper-catalyzed 
reaction that combines an azide group with an alkyne group to form a triazole 
ring structure [184-187].  Others have conjugated Alk-C16-modified proteins to 
azide-tagged biotin, fluorescent dye, or for crosslinking with a photo-activatable 
diazirine [188].  The technique has also been used with fluorescently labeled 
probes for quantitative and compartmentalization studies of palmitoylated 
proteins in intact cells.  Recently a clickable long alkyl chain analog of cerulenin 
was designed for use as a chemical probe to profile zDHHC PATs [189, 190].  
Click chemistry was coupled with a proximity ligation assay to visualize 
palmitoylated proteins [191]. 
A relatively new technology, multi-dimensional protein identification technology 
(MuDPIT) has led to the identification of much of what is known of palmitoylation 
sites [11, 14, 192].  MuDPIT is a high-throughput, tandem mass spectrometry-
based proteomic technology [192].  After subjecting cellular membrane extracts 
to ABE, and affinity purifying the resulting biotinylated proteins on streptavidin 
agarose the resulting substrates can be identified with MuDPIT [11, 14, 192].  
MuDPIT and ABE are becoming the standard procedures for confirming the role 
of palmitoylation in in vivo systems [11, 14, 192].  
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Additionally, a light-inducible targeting system approach for achieving a better 
understanding of complex biological systems has been developed.  This system 
can be applied to visualize where a palmitoylated protein is localized [193].  A 
capillary electrophoresis assay may also be used to measure palmitoylation of a 
fluorescently labeled peptide in vitro [194]. 
 
2.7 High-Throughput Screening Palmitoylation 
In most high-throughput screens (HTS) each compound is only tested in singlet 
or duplicate.  Thus there is a critical need for accuracy and sensitivity to 
accurately identify active compounds (hits) [195].  To validate the accuracy and 
sensitivity of a HTS campaign a Z’-factor is calculated which determines optimal 
signal window for HTS.  In addition to a Z’-factor, standard deviation and 
coefficient of variance are also important factors in the validation of a HTS.  To 
calculate all of these, it is important to test the assay in triplicate each day for 
three days to determine variability in one day, as well as day-to-day variation 
[195].  Even with the validation of the assay, it is important to screen the hits by 
at least two different modes of activity detection, to remove false positives [195]. 
In this chapter, we describe and demonstrate the utility of a single well, 
fluorescence-based, coupled assay system that monitors the steady-state rate of 
autopalmitoylation of PAT in vitro.  This system measures the production of 
CoASH, a product of the autopalmitoylation reaction.  The CoASH is used in the 
conversion of α-ketoglutarate to succinyl-CoA with the corresponding reduction 
of NAD+ to the fluorescent NADH, a reaction that is catalyzed by α-ketoglutarate 
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dehydrogenase complex (α -KDH) [196-200].  Here, we use this assay to 
demonstrate lipid substrate specificity on the autopalmitoylation activity of the 
Erf2-Erf4 complex [40, 149].  In addition, we show that the coupled assay can be 
applied to studying inhibition by 2-bromopalmitate (2-BP), a known inhibitor of 
protein palmitoylation [201].  Finally, we present evidence that this assay system 
can be used in a High Throughput Screening format in an attempt to identify 
modulators of PAT enzymes.  
 
2.8 Development of an in vitro Fluorescence-Based Coupled Enzymatic 
Assay to Monitor Autopalmitoylation 
The first step in the palmitoylation reaction, autopalmitoylation, can be monitored 
by the production of CoASH.  The amount of CoASH produced in turn can be 
coupled to the reduction of NAD+ to NADH by α-KDH (Fig. 2.1A).  NADH has 
fluorescence excitation and emission maxima at wavelengths of 340 nm and 465 
nm, respectively [196].  The α-KDH reaction is essentially irreversible (-ΔGo (pH 
7.0) of approximately 10 kcal/mole) and has a KM value for CoASH of less the 0.1 
µM [197].  When NAD+ and α -ketoglutarate are present in molar excess 
compared to CoASH, the reaction proceeds to completion with approximately 
zero-order kinetics.  The source of α-KDH is pig heart, but historically was 
purified from ox heart [202].  NADH and succinyl-CoA can inhibit α-KDH to a 
slight degree.  This inhibition is abolished if the NAD+ concentration is in great 
excess relative to the concentration of CoASH being assayed [198].   
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As proof of principle, we performed a pilot study measuring yeast Erf2-Erf4 
autopalmitoylation activity.  The production of NADH was monitored 
fluorometrically in a single cuvette using a PTI Double-Double QuantaMaster 3 
Fluorometer (340 nm excitation/ 465 nm emission). The reaction is linear 
throughout the 5 min monitoring phase (Fig. 2.1B). Denaturing Erf2-Erf4 by 
boiling abolishes the formation of NADH demonstrating that there is no 
measurable background hydrolysis of palmitoyl-CoA (Fig. 2.1B).  In addition, an 
inactive mutant of Erf2, Erf2 C203S, that was purified in parallel with wild type 
Erf2-Erf4, does not produce NADH above that of the boiled wild type Erf2, 
demonstrating the increase in fluorescence is not due to a contaminating moiety 
from the enzyme preparation protocol.  These controls demonstrate that even 
though there is a small amount of drift of the fluorescence signal, the signal is 
specific for active, wild type Erf2-Erf4.  Similar results were obtained using the 
mammalian ortholog of Erf2-Erf4, zDHHC9-GCP16 as described in [53].  A 
standard curve of known amounts of exogenously added CoASH, ranging from 
0-3000 pmol CoASH, was used to quantify the amount of steady-state 
autopalmitoylation, as the formation of the intermediate and production of CoASH 
are in a 1:1 stoichiometry.   
 
2.9 Determination of the Kinetic Parameters for Erf2-Erf4 
Autopalmitoylation Using a 96-well Format. 
Similar reactions have been performed that couple CoASH production to the 
production of NADH through α -KDH that are detected by a change in 
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fluorescence in a microtiter plate reader [200]. The coupled fluorescence-based 
assay was developed for a 96-well plate format, thus allowing a number of 
samples to be run simultaneously.  As an initial evaluation of the assay, varying 
concentrations of palmitoyl-CoA were used to assess the activity of the enzyme 
over a 1 h period (Fig. 2.1C).  The palmitoyl-CoA concentrations varied from 0-
200 µM.  Plotting the initial change in fluorescence versus the concentration of 
palmitoyl-CoA, we observed a curve that approached saturation until 
approximately 100 µM of palmitoyl-CoA, and then showed an apparent decrease 
in the activity for the concentrations above 100 µM.  The observed decrease 
could be a result of inhibition of α-KDH by high concentrations of palmitoyl-CoA 
[198], or more likely the result of formation of palmitoyl-CoA micelles reducing the 
effective concentration of  palmitoyl-CoA.  The approximate critical micelle 
concentration for palmitoyl-CoA is in the range of 80-100 μM.  Accordingly, we 
limited the palmitoyl-CoA concentrations to below 100 µM and determined the 
Vmax, 43 pmols CoASH produced/(min.µg), and KM of the reaction to be 43 µM for 
palmitoyl-CoA, which agreed with the values we calculated using a single cuvette 
reaction in a PTI Double-Double QuantaMaster 3 Fluorometer.  The Vmax was 
calculated by fitting the data to the Michaelis-Menten equation using Prism 6 
software (GraphPad Software, San Diego, CA).  A direct linear plot was used to 
calculate the KM, the concentration of substrate that resulted in a reaction velocity 
half that of the calculated Vmax.     
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2.10 The Effect of Detergents in the Autopalmitoylation Reaction 
All zDHHC protein acyl transferases so far identified are integral membrane 
proteins with four or more TMDs [14, 41, 42, 203].  Therefore, isolation and 
characterization of zDHHC PATS requires detergent solubilization.  To determine 
the effect of different detergents on the autopalmitoylation reaction, we screened 
for changes in autopalmitoylation activity using a 72 detergent collection 
(Hampton Research, Aliso Viejo, CA).  The detergent was added to the reaction 
prior to the Erf2-Erf4 enzyme at a final concentration equal to the critical micelle 
concentration (CMC) for the respective detergent.  The ratio of autopalmitoylation 
in the presence of detergent to the autopalmitoylation in the “no detergent added” 
control for each detergent is shown in Table 2.1.  Over 50% of the detergents 
examined provided at least 70% of the autopalmitoylation activity when 
compared to the control.  Although there was no measurable difference observed 
amongst the non-ionic and zwitterionic detergents effect on autopalmitoylation, 
ionic detergents had the most consistently detrimental effect on activity.   
 
2.11 The Effect of Acyl-CoA Chain Length on Auto-acylation Activity 
The availability of acyl-CoAs of varying chain lengths and the non-radioactive 
nature of the coupled assay allowed us to test directly the specificity of the chain 
length of the acyl donor for Erf2-Erf4.  We determined the Vmax and KM kinetic 
parameters for acyl-CoAs of carbon lengths between 8 and 20 (C8:0 – C20:0), as 
well as palmitoleoyl CoA (C16:1 n7), cis-vaccenoyl CoA (C18:1 n7) and oleoyl 
CoA (C18:1 n9).  The mean KM values ranged between 9 and 90 µM for all the 
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hydrocarbon chains examined (Fig. 2.2; inset).  We also observed a similar 
phenomenon as for palmitoyl-CoA, where the velocity of the reaction decreased 
at higher concentrations of substrate, suggesting that perhaps, at higher 
concentrations of the longer chain lengths, the hydrocarbon was not as soluble.  
However, by lowering the concentrations of the acyl-CoA substrates, we were 
able to overcome the insolubility issues and obtain highly reproducible data to 
calculate the parameters.  
Given the purified system of this in vitro assay the concentration of substrate is at 
a higher concentration than the product, thus it can be assumed that the reaction 
is essentially irreversible.  Therefore, the catalytic efficiency can be established 
as kcat/KM.  We used the specificity constant (kcat/KM) to compare the relative 
rates of reaction of each of the substrates and plotted these values as a function 
of acyl chain length (Fig. 2.2).  Acyl chain lengths between 8 and 14 carbons 
produced the greatest activity followed by acyl chain lengths of 16 carbons.  
Saturated chain lengths of 18 and 20 carbons produced the lowest activities.  De-
saturating the 18 carbon chain length (cis-vaccenoyl-CoA) increased the activity 
between 2- and 3-fold.  These data demonstrate that protein acyl transferases 
may be able to utilize acyl-CoAs of various chain lengths with varying degrees of 
saturation as substrates for acylation and could serve as a possible explanation 
for the heterogeneity observed with acyl modifications to proteins [150, 175].    
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2.12 2-Bromopalmitate Covalently Modifies and Inhibits 
Autopalmitoylation Activity of Erf2-Erf4 
2-Bromopalmitate has been used as a lipid metabolism inhibitor for over 50 years 
[204, 205].  Initially, we observed that the Erf2-Erf4 activity inhibition by 2-BP 
could not be diluted or removed from the reaction (data not shown) suggesting 
the inhibition of palmitoylation was irreversible.  In addition, 2-BP covalently 
modifies native Erf2 at a rate of approximately 0.1 pmol/min (Fig. 2.3A; squares) 
as measured by incorporation of 3H-2-BP into Erf2-Erf4 complexes (Fig. 2.3A, 
lower panel).  On a molar ratio basis, 2-BP was in 172-fold excess compared to 
the amount of Erf2-Erf4 complexes.  A calculation of the amount of Erf2-Erf4 
complexes labeled reveals 5 pmols compared to the 5 nmols of 2-BP added to 
the reaction.  This results in one molecule of 2-BP reacting with an Erf2-Erf4 
complex for every 1000 molecules of 2-BP.  As bromide at the 2 position is a 
good leaving group and is most likely the site of covalent bond formation 
between Erf2 and 2-BP, the reaction product is not hydroxylamine labile.  
Interestingly, the incorporation of the tritium signal is not detectable if the Erf2-
Erf4 complex is denatured before addition of 3H-2-BP (Fig. 2.3A; diamonds) 
implying the native structure of the Erf2-Erf4 complex is required for labeling by 
2-BP.   
The effect of 2-BP on autopalmitoylation was examined using the coupled assay.  
The initial rate of autopalmitoylation with increasing concentrations of palmitoyl-
CoA was measured under conditions where the Erf2-Erf4 enzyme complex had 
been pre-incubated with 2-BP.  When no 2-BP was present, a curve of velocity 
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versus palmitoyl-CoA concentration was observed similar to previous curves for 
the wild type enzyme (Fig. 2.3B).  However, when 2-BP is pre-incubated with the 
enzyme, the velocities and the Vmax are decreased in a dose dependent manner.  
Three concentrations of 2-BP (50 µM, 100 µM and 150 µM) were compared, 
resulting in increasing levels of inhibition with an IC50 value of approximately 100 
µM.  Intriguingly, the amount of inhibition due to 2-BP was never as much as 
observed for the catalytically inactive Erf2 (C203S)-Erf4 mutant (approximately 
80% of the catalytically dead enzyme control).  Although it was previously 
reported that the Ki for 2-BP was 10 µM [148], a concentration of at least 100 µM 
is required to reduce the Vmax of Erf2-Erf4 complex by 50% in this assay.  The 
difference may be due to the effect of 2-BP on other steps required for 
palmitoylation in addition to covalent modification of the enzyme [206]. 
 
2.13 Discussion 
In the past, the method of choice for evaluating palmitoylation was through the 
use of radiolabeled palmitate.  The drawbacks of using a radiolabeled palmitate 
are that the steady-state levels of the palmitoylated species can be monitored, 
but the turnover of the enzyme cannot be easily quantified.  Secondly, 
visualization can require an inordinate amount of time.  Finally, the radiolabel is 
cost prohibitive.  The price of 3H-palmitoyl-CoA is approximately $33-50 per 
assay. For a library the size of 40,000 compounds, the cost of the 3H-palmitoyl-
CoA from commercial sources is therefore prohibitive (>$1M).  The cost can be 
reduced by synthesizing 3H-palmitoyl-CoA from 3H-palmitate, CoASH, and acyl 
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CoA synthetase; lowering the cost to approximately $0.30 per assay ($12,000 for 
a 40,000 compound screen), but detecting the radioactive signal is still 
problematic.  By comparison, the cost of performing the single well, fluorescence-
based coupled assay is approximately $0.07 per assay ($2800 for a 40,000 
compound library).  Included in this amount is the cost of expressing and 
purifying the PAT enzyme from the galactose-inducible S. cerevisiae over-
production system.   
Protein palmitoylation plays a role in a variety of cellular processes involved in 
cancer, cardiovascular disease, infectious disease, and neurological disorders 
[116] and is required for membrane association and neoplasm promoting activity 
of H- and N-Ras [107].  Palmitoylation has also been shown to play an important 
role in other cancer targets.  For example, estrogen signaling in breast cancer 
involves palmitoylation [73].  Despite the central role of palmitoylation in the 
subcellular localization and function of numerous signaling proteins involved in 
cancer and several neurological disorders, no specific, high affinity, 
palmitoylation inhibitors exist and a detailed understanding of the relationship 
between zDHHC enzyme and substrates is lacking.  Therefore, a potential 
application of this technology is to use high throughput screening procedures to 
identify inhibitors of protein palmitoylation.  A Z’-value is a measure of statistical 
effect size, and is commonly used to evaluate whether the response in a HTS is 
robust.   Z'-prime values range from 0 to 1, and designate the percent difference 
between mean positive control of an assay and mean negative control of an 
assay that falls between standard deviations of both controls, thus an assay with 
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a Z'-value greater than 0.5 is considered a robust assay.  The Coefficient of 
Variance, also known as relative standard deviation (RSD), of an assay is an 
indication of the reproducibility of an assay.  The autopalmitoylation/coupled 
assay is reproducible and robust (Table 2.2).  For the Erf2-Erf4 complex, the 
assay has a Z’-value of 0.87, a Coefficient of Variance of 6.2, and a signal-to-
noise ratio of 33.  In addition, the enzyme complex can be isolated in relatively 
large quantities from yeast and is stable for greater than 24 h at 4˚C.  The activity 
of the human ortholog of the Erf2-Erf4 complex, zDHHC9-GCP16, is similarly 
robust and reproducible with a Z’-value of 0.77, a Coefficient of Variance of 2.6 
and a signal-to-noise ratio of 21.   
In the present study, we have developed a fluorescence-based assay that can 
measure the turnover activity of the protein acyl transferase and to determine 
kinetic parameters.  We have demonstrated the usefulness of this assay to 
measure the auto-acylation activity of Erf2-Erf4 using several acyl-CoAs of 
varying chain lengths.  Finally, we have shown that this assay can be used to 
examine protein acyl transferase inhibition in a manner that is reproducible and 
robust, and therefore applicable to HTS applications. 
 
2.14 Experimental Procedures 
Strains, media, and yeast techniques-  Yeast and bacteria growth media were 
prepared as described previously [207].  Cells were grown in synthetic complete 
(SC) medium or YPD (1% yeast extract, 2% peptone, and 2% glucose) medium 
[207, 208].  Induction of GAL1, 10 promoters were achieved by adding 4% 
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galactose to SC medium.  Yeast transformations were performed using the 
lithium acetate procedure [209]. The yeast strains used in this chapter, RJY1842 
(MATa/α ade2-1/ade2-1 leu2-3,112/leu2-3,112 ura3-1/ura3-1 trp1-1/trp1-1 his3-
11,15/his3-11,15 can1-100/can1-100 erf4Δ::NATr/erf4Δ::NATr GAL+) [40, 149] 
and RJY1330 (MATα leu2-3,112 ura3-52 ade2Δ ade8Δ lys2-801 ras1::HIS3 
ras2::Ras2CS-Ext erf2::KANr <YCp52RAS2>) have been previously described 
[34, 40, 149].  
Plasmid construction-  The sequences of the deoxyoligonucleotide primers used 
to construct zDHHC9 alleles are available upon request.  The DNA sequences of 
all constructs were verified by DNA sequencing (GeneWiz, Plainfield, NJ).  The 
construction of B1302 and B1595 has been described previously [149, 208].  
zDHHC9 (accession number: BC006200) and GCP16 (BC001227) were 
obtained from the Image consortium (Image numbers: 2964425 (zDHHC9) and 
3456384 (GCP16)).  The zDHHC9 open reading frame was amplified by PCR 
using primers that would encode a C-terminal 6xHIS epitope as well as an in-
frame C-terminal FLAG epitope flanked by sequences homologous to MCS1 of 
B1192 (pESC-Trp (Stratagene, Santa Clara, CA)) to facilitate ligase-independent 
cloning (LIC), producing B1500 (pESC-Trp zDHHC9).  B1856 (pESC-Trp 
zDHHC9-GCP16) was constructed by inserting the PCR amplified GCP16 
possessing the proper flanking sequences into MCS2 of B1500 by LIC. 
Protein expression and purification-  Erf2-Erf4 enzyme complexes were 
expressed from the pESC-Leu divergent GAL1,10 promoter in strain RJY1842, 
which also harbored a second plasmid to enhance galactose induction, pMA210 
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[210] ([208]. Cultures were grown in synthetic medium containing 2% glucose 
and lacking leucine and histidine. zDHHC9-GCP16 enzyme complexes were 
expressed from the pESC-Trp divergent GAL1,10 promoter in strain RJY1842 
along with pMA210 and grown overnight at 30˚C with shaking (230 RPM) in 
synthetic medium containing 2% glucose and lacking tryptophan and histidine.  
Approximately 3x107 cells were inoculated into 50 mls of synthetic medium 
containing 2% glucose and lacking the appropriate amino acids and the cultures 
were grown at 30˚C with shaking (230 RPM) until the cell density was between 
1.6x107 cells/ml (OD600 0.8) and 2.4x107 cells/ml (OD600 1.2).  To induce the 
expression of the enzyme complexes, approximately 50 OD600 of cells (1x109) 
were seeded into 1 L of YEP containing 2% galactose and the culture was 
incubated at 30˚C with shaking (230 RPM) for 18 h. The cells were harvested by 
centrifugation at 3000xg for 15 min. The resulting pellet was resuspended in 
breaking buffer (50 mM Tris-Cl pH 8, 500 mM NaCl, 1 mM EDTA, 1 mM 
dithiothreitol (DTT), 1x protease inhibitor cocktail (PIC) (1 µM Leupeptin, 2 µM 
Pepstatin A, and 16 mM Benzamidine), and the cells were lysed using glass 
beads (400-600 mesh, Sigma-Aldrich, St. Louis, MO) for 40 min with 1 min 
pulses/1 min cooling (20 cycles) [40, 149, 208].  The resulting extract was spun 
at 3000xg for 15 min to remove cellular debris and unbroken cells, to yield a 
whole cell extract (WCE).   
The enzyme-containing particulate fraction (P19) was isolated from the WCE by 
centrifugation at 19,000xg for 30 min at 4˚C.  The soluble portion (S19) of the 
WCE was decanted and the particulate pellets were solubilized using 0.8% n-
	 47 
Dodecyl-β-D-maltoside (DDM) at 4˚C for at least 5 h with gentle agitation [40, 
149, 208].  Detergent insoluble particulates were removed from the P19 by 
centrifugation at 19,000xg for 30 min at 4˚C.  The soluble P19 samples were then 
moved to clean tubes.  To aid in purification of the 6xHis:Erf2-Erf4 complexes, 
urea and imidazole were added to a final concentration of 2 M and 1 mM, 
respectively (6xHis:zDHHC9-GCP16 complexes were supplemented with only 1 
mM imidazole). The resulting supernatant was incubated with Ni-NTA resin (Five-
Prime, Gaithersburg, MD) at 4˚C for 1h.  The resin was washed once with 
Solution W (50 mM Tris•HCl, pH 8.5, 0.08% DDM, 5 mM β-ME) containing 300 
mM NaCl, and then twice with Solution W containing 150 mM NaCl.  The protein 
was eluted with 50 mM Tris HCl, pH8.5, 150 mM NaCl, 0.08% DDM, 5% glycerol 
and 250 mM imidazole.  Eluents were desalted and the buffer changed to SPB 
(50 mM Sodium Phosphate Buffer, pH6.8, 10% glycerol) using a column of G-25 
resin.  Fractions containing 6xHis:Erf2-Erf4 complexes (or 6xHis:zDHHC9-
GCP16 complexes) were pooled to obtain approximately 0.5 mg of purified Ras 
PAT per liter of culture.  These samples were flash frozen with liquid nitrogen and 
stored at -80˚C for up to 3 years [149].  
Coupled Protein Acyl transferase (PAT) Assay-  The production of NADH was 
monitored in 96-well format with a Biotek Mx fluorimeter (Biotek, Winooski, VT) 
using an excitation of 340 nm and emission of 465 nm [149, 196-198].  The 200 
µl reaction contained 2 mM 2-oxoglutarate (α-ketoglutamic acid isolated from pig 
heart), 0.25 mM NAD+, 0.2 mM thiamine pyrophosphate, 2 µg of purified PAT 
complex, 1 mM EDTA, 1 mM dithiothreitol, and 32 mU 2-oxoglutarate 
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dehydrogenase (α -KDH, Sigma-Aldrich, St. Louis, MO) in 50 mM sodium 
phosphate buffer, pH 6.8.  The reaction was initiated by the addition of varying 
concentrations of palmitoyl-CoA and monitored for 30 min at 30˚C.  The first 10 
min of the reaction was analyzed to determine the initial rates of CoASH release.  
The PAT specific activity was determined from a standard curve of fluorescence 
values generated under reaction conditions using different CoASH 
concentrations.  In these reactions, CoASH was added to the standard PAT 
reaction mixture (without PAT complex) and the reaction was allowed to proceed 
to equilibrium before fluorescence was measured.  To further validate the assay, 
two types of controls were performed. For the first control, the PAT enzyme was 
boiled to inactivate the autopalmitoylation activity, and therefore the PAT-
dependent formation of NADH, to demonstrate that there is no measurable 
background hydrolysis of palmitoyl-CoA in the reaction. Boiled enzyme produced 
significantly less fluorescence (<20%) suggesting no significant contribution from 
sample heterogeneity or non-specific fluorescence.  Secondly, a catalytically 
inactive mutant form of the PAT complex (Erf2 (C203S)-Erf4 or zDHHC9 
(C169A)-GCP16) was used to determine the baseline activity of the reaction and 
to show no significant contribution of contaminating activities to the assay results. 
For reactions that incorporated 2-BP, Erf2-Erf4 complexes were incubated with 
different concentrations of the inhibitor, 2-BP (dissolved in DMSO), for 20 min at 
room temperature prior to incorporation into the assay.  Assay conditions 
permitted as much as 6% DMSO without affecting Erf2-Erf4 autopalmitoylation 
activity (Fig. 2.4). 
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The rate of the coupled reaction (α-KDH) must have a first-order dependence on 
the concentration of CoASH, a product of autopalmitoylation.  However, this 
assumes a Vmax rate of the autopalmitoylation reaction (the first reaction) and 
therefore the concentration of palmitoyl-CoA would need to be at saturation 
conditions.  This is not realistic for this reaction given the interference in the 
activity observed at higher concentrations of palmitoyl-CoA (Fig. 2.1C).  Instead, 
for measurements of the rate of the coupled reaction (at sub-Vmax concentrations 
of CoASH) to provide accurate information concerning the initial rate of 
autopalmitoylation, a steady-state concentration of CoASH must be reached 
before the rate of autopalmitoylation diminishes noticeably from its initial value.  
Using the method of Storer and Cornish-Bowden [211], we calculated the time 
needed to reach a steady-state concentration of CoASH (334pM) as 
approximately 2 seconds, where the rate of autopalmitoylation is about 3% of the 
limiting rate of the coupled reaction and where the ratio of the CoASH dependent 
rate of the coupled reaction to the rate of autopalmitoylation is 0.99.  Therefore, 
in practice, there is no appreciable time lag while the system reaches equilibrium.  
Therefore, the accumulation of NADH adequately represents the rate of 
autopalmitoylation. 
Radioactivity-based 2-BP labeling assay-  Covalent modification of Erf2-Erf4 by 
3H-2-BP was performed by combining 8 µg (approximately 29 pmols of Erf2-Erf4 
per time point) of native Erf2-Erf4 complex (or boiled Erf2-Erf4) and 100 μM 2-
BP (specific activity, 0.4 Ci/mmol) [9,10-3H] 2-BP (American Radiolabeled 
Chemicals, St. Louis, MO) in 200 µL of 50 mM sodium phosphate buffer, pH 7.4 
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and 0.5 mM dithiothreitol.  The reaction was incubated at 30°C and 50 µL 
samples removed to tubes containing 12 µL of 5x reducing protein loading buffer 
to stop the reactions at the indicated times.   Samples were boiled for 3 min, 
centrifuged for 3 min at 13,000xg to removed insoluble particulates and 
separated by SDS-PAGE (10%).  To visualize the radioactivity, after separation, 
the gel was soaked in En3Hance (Perkin-Elmer, Waltham, MA), as per the 
manufacturer’s instructions and dried under a vacuum.  Typical film exposure 
times ranged from 2-4 days.  To determine the number of dpm comprising each 
labeled Erf2 band, the bands corresponding to Erf2 were excised from the dried 
gel using the exposed film as a template and soaked in 500 µL Soluene S-350 
(Perkin-Elmer, Waltham, MA) and 81 µL of a 50% (w/v) solution of hydroxylamine 
(1 M; final) (Sigma/Aldrich, St. Louis, MO) for 18 h at 37˚C in scintillation vials to 
dissolve the acrylamide and release the radioactivity.  Scintillation cocktail (5 ml) 
was added directly to the Soluene S-350 dissolved samples in the vials. The 
samples were allowed to equilibrate for 2 h and the number of cpm determined 
by scintillation counting (Beckman-Coulter, LS6500, Indianapolis, IN). The 
counting efficiency of the tritium was determined by adding a known amount of 
tritium standard (dpm) (American Radio Chemicals, St. Louis, MO) to the vials 
containing samples and the vials recounted. Counting efficiency was calculated 
as the difference between the cpm from the combination of standard plus sample 
and the sample alone divided by the amount of dpm of the standard 
(approximately 90%). To determine the efficiency with which the tritium was 
released from the acrylamide, native Erf2-(FLAG)Erf4 bound with anti-FLAG 
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conjugated to agarose beads (Sigma-Aldrich, St. Louis, MO) was incubated with 
3H-2-BP for 30 min at 30˚C.  The free 3H-2-BP label was washed away 
extensively (5x 1 ml) with buffer.  The Erf2-(FLAG)Erf4 complexes were removed 
from the beads with 0.1 M glycine, transferred to a fresh tube and neutralized 
with 1 M Tris•Cl, pH 7.5.  One fifth of the sample was submitted for scintillation 
counting (with 500 µL Soluene S-350 added) and the remainder of the sample 
was separated by SDS-PAGE (10%).  The radioactivity was isolated and 
released under the same conditions as the time point samples.  Comparison of 
the dpm obtained directly from the control complexes and those obtained from 
the gel slices showed the procedure to be approximately 35% efficient. 
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Table 2.1.  Effect of Detergents on the Enzymatic Autopalmitoylation 
Activity of the Erf2-Erf4 Complex. 
 
Detergent Type* % Control 
No detergent NA 100 
Anapoe 35 NI 96 
n-Octyl-β-d-thioglucoside NI 90 
IPTG NI 87 
ZWITTERGENT 3-12 Z 87 
C12E9 NI 86 
DDMAB Z 85 
LDAO NI 85 
C12E8 NI 85 
CYMAL-1 NI 84 
CYPFOS-3 NI 83 
MEGA-9 NI 83 
ZWITTERGENT 3-14 Z 82 
n-Tetradecyl-β-d-maltoside NI 82 
n-Dodecyl-β-d-maltoside NI 82 
FOS-Choline-12 Z 82 
1-s-Nonyl-β-d-thioglucoside NI 81 
n-Undecyl-β-d-maltoside NI 80 
n-Dodecyl-N,N-dimethylglycine Z 80 
Pluronic F-68 NI 79 
DDAO NI 79 
Sucrose monolaurate NI 79 
n-Tridecyl-β-d-maltoside NI 78 
CYMAL6 NI 76 
n-Nonyl-β-d-maltoside NI 75 
ZWITTERGENT 3-08 Z 75 
n-Decyl-β-d-maltoside NI 75 
Triton X100 NI 75 
FOS-Choline-10 Z 75 
FOS-Choline-9 Z 74 
n-Hexadecyl-β-d-maltoside NI 74 
n-Decyl-β-d-thiomaltoside NI 74 
n-Nonyl-β-d-maltoside NI 74 
n-Decanoylsucrose NI 72 
CYMAL5 NI 72 
n-Dodecyl-β-d-maltotrioside NI 72 
HEGA-10 NI 71 
n-Nonyl-β-d-glucoside NI 66 
Big CHAP, Deoxy NI 64 
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Table 2.1.  (Continued). 
 
Detergent Type* % Control 
CYMAL-4 NI 63 
n-Octyl-β-d-thiomaltoside NI 62 
n-Octanoylsucrose NI 62 
n-Octyl-β-d-glucoside NI 61 
MEGA 8 NI 60 
HECAMEG NI 60 
Anapoe X-405 NI 58 
Anapoe X-305 NI 58 
CYMAL-2 NI 57 
C8E5 NI 57 
1-s-Heptyl-β-d-thioglucoside NI 54 
ZWITTERGENT 3-10 Z 52 
n-Heptyl-β-d-thioglucopyranoside NI 51 
Anapoe 20 NI 50 
Thesit NI 50 
OPOE NI 47 
CHAPS Z 46 
Anapoe 80 NI 44 
CYMAL 3 NI 44 
CHAPSO Z 43 
C-HEGA-11 NI 39 
FOS-Choline-8 Z 39 
Anapoe 58 NI 37 
n-Hexyl-β-d-glucopyranoside NI 36 
Anapoe X-114 NI 34 
Anapoe C10E9 NI 31 
Anapoe C13E8 NI 31 
Anapoe C10E6 NI 31 
HEGA-9 NI 30 
HEGA-8 NI 25 
C-HEGA 10 NI 24 
CTAB I 23 
C-HEGA-9 NI 20 
Anapoe C12E10 NI 14 
BAM I 0 
No enzyme NA 0 
* NA (not applicable), NI (non-ionic), Z (zwitterionic) and I (ionic). 
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Table 2.2.  Kinetic and HTS Parameters for zDHHC9-GCP16 and Erf2-Erf4 
Complexes. 
 
Parameter zDHHC9-GCP16 Erf2-Erf4 
Autopalmitoylation activity 
(pmol/min/µg) 47.0 ± 2.5 43.0 ± 3.0 
KM (µM) 45 ± 4 43 ± 8 
Yield (mg/L) 1 - 3 2 - 4 
Z'-value* 0.77 0.87 
Coefficient of variance* 2.6 6.2 
Signal-to-noise ratio* 21 33 
Stability (4 °C) >24H >24H 
*Values were determined on 3 successive days using the National Center for 
Advancing Translational Sciences high-throughput screening criteria. 
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Figure 2.1. Validation of an in vitro, Single Well, Fluorescence-based 
Coupled Assay that Measures Protein Acyl Transferase Catalyzed 
Autopalmitoylation Activity.  A.  Schematic of the coupled assay reaction.  B.  
Production of CoASH is dependent on active Erf2-Erf4 complexes.  The reaction 
was performed as described in the Experimental Procedures using 2 µg wild 
type Erf2-Erf4 complexes, catalytically dead Erf2 (C203S)-Erf4 complexes or 
boiled Erf2-Erf4 complexes (Blank).  Fluorescence was recorded continuously 
(ex. 340 nm/ em. 460 nm) for 5 min at 30˚C.  C.    Graphic representation of 
reaction rates using varying concentrations of palmitoyl-CoA substrate.  
Reactions were performed in quadruplicate and repeated three times (n=3) at 
30˚C with intermittent shaking.  The fluorescence values (ex. 340 nm/ em. 460 
nm) were recorded at 1 min intervals for 10 min.  The data were analyzed and 
fitted to the Michaelis-Menten equation using algorithm of Prism 6 (GraphPad 
Software, San Diego, CA).  The data were corroborated using the Direct Linear 
Plot method [212, 213].  The amount of CoASH produced was based on a 
standard curve using known concentrations of CoASH and expressed as 
pmols/s +/- SD.   
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Figure 2.2. The Effect of Acyl CoA Substrate Specificity on Erf2-Erf4 Auto-
acylation Activity.  Graphical representation of specificity constants (kcat/KM) for 
acyl CoAs of varying saturated hydrocarbon chain lengths (C8:0-C20:0; closed 
circles), unsaturated lengths (palmitoleoyl CoA (C16:1 n7), cis-vaccenoyl CoA 
(C18:1 n7) (open circles) and oleoyl CoA (C18:1 n9) open square) for the Erf2-
Erf4 steady-state auto-acylation activity.  The assays were performed in 
triplicate and repeated three times (n=3). (Inset) Graphical representation of the 
KM values used to calculate the kcat/KM values (above).  The saturated acyl 
hydrocarbon chains are denoted by closed circles, palmitoleoyl and cis-
vaccenoyl chains are denoted by open circles and the oleoyl chain denoted by 
an open square.		
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Figure 2.3. Covalent Modification and Inhibition of Erf2-Erf4 
Autopalmitoylation Activity by 2-Bromopalmitate.  A.  Native Erf2-Erf4 
complexes and boiled Erf2-Erf4 were incubated with 3H-2-BP for the times 
shown. The products of the reactions were separated by SDS-PAGE and 
subjected to autoradiography (bottom panel).  The intensities of the signals 
corresponding to palmitoyl-Erf2 were determined by cutting the bands from the 
gels, dissolving the gel slices in Soluene S-350 to release the tritium and the 
amount of radioactivity determined by scintillation counting [33].  Tritium-based 
counts were converted to pmols and plotted versus time (top panel).  Wild type 
Erf2-Erf4 complexes are denoted by closed squares and boiled Erf2-Erf4 
denoted by closed diamonds.  B.  Reaction rates of Erf2-Erf4 autopalmitoylation 
activity with increasing concentrations of palmitoyl-CoA in the presence of 2-BP.  
Samples include Erf2-Erf4 (closed circles), Erf2-Erf4 plus 50 µM 2-BP (closed 
squares), Erf2-Erf4 plus 100 µM 2-BP (closed triangles), Erf2-Erf4 plus 150 µM 
2-BP (open circles) and Erf2 (C203S)-Erf4 (Xs).  Reactions were performed in 
triplicate (n=3) at 30˚C.  The fluorescence values (ex. 340 nm/ em. 460 nm) were 
recorded at 1 min intervals for 10 min.  The data were analyzed and fitted using 
Prism 6 (Michaelis-Menten algorithm) (GraphPad Software, San Diego, CA).  
The values for Vmax and KM were corroborated using the Direct Linear Plot [212, 
213]. 
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Figure 2.4. Erf2-Erf4 Autopalmitoylation Activity Tolerates Relatively High 
Concentrations of Dimethylsulfoxide (DMSO). Erf2-Erf4 catalyzed 
autopalmitoylation reactions containing varying percentages of DMSO were 
performed as described in Materials and Methods using 2 µg wild type Erf2-Erf4 
complex. The reaction proceeded for 5 min at 30˚C while continuously monitoring 
the fluorescence intensity (ex. 340 nm/ em. 460 nm).  The reactions were 
performed eight times (n=8) and are expressed as the mean +/- SD.  The P-
values are given on the figure. The P-value for 0 and 6 percent DMSO is 0.7.	
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CHAPTER 3 
 
Inhibition of Erf2 Autopalmitoylation by Fungal Metabolites 
 
 
3.1 Overview 
The fluorescence-based autopalmitoylation assay was used to screen a library of 
fungal metabolite obtained from Dr. Baker (Department of Chemistry and the 
Center for Drug Discovery and Innovation, University of South Florida, Tampa, 
FL).  We screened 81 extracts for effect on Erf2 autopalmitoylation with the 
fluorescent-based coupled assay, and identified two lead fungal metabolite 
extracts that exhibited Erf2 autopalmitoylation inhibitory effects similar to that of 
2-bromopalmitic acid.  An orthogonal gel-based assay validated that these 
extracts were inhibitors of Erf2 autopalmitoylation.  Future work with individual 
metabolites will be performed to establish the selectivity and efficacy of the leads. 
 
3.2 Key Words and Abbreviations 
Autopalmitoylation; Enzyme Inhibitor; Erf2; Fungal Metabolite; High Throughput 
Screen (HTS) 
α-KDH, α-ketoglutarate dehydrogenase; 2-BP, 2-bromopalmitate; DNMTi, DNA 
Methyltransferase Inhibitor; HDI, Histone De-acetylase Inhibitor. 
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3.3 Introduction 
The reversibility of protein palmitoylation and the implications of its dysregulation 
in cancer, cardiovascular disease, and neurological disorders makes 
palmitoylation an ideal target for therapeutic intervention [214, 215].  There are 
few inhibitors of palmitoylation described, and the inhibitors available are limited 
in their selectivity and specificity. Known inhibitors of palmitoylation lack 
sensitivity and specificity, which interferes with their therapeutic potential and 
their ability to act as probes to further characterize palmitoylation. Despite their 
limitations, the inhibitors 2-bromopalmitate (2-BP), cerulenin, and tunicamycin 
have been used to validate palmitoylation.  
2-BP: The most commonly used inhibitor of protein palmitoylation is the 
halogenated fatty acid 2-bromohexadecanoic acid, more commonly known as 2-
BP.  2-BP was introduced nearly 50 years ago as a nonselective inhibitor of 
metabolism but was later identified as a non-metabolizable analog that may 
inhibit palmitoylation by interacting with proteins in the same manner as palmitate 
[201, 204, 205]. 2-BP has been shown to act as a covalent inhibitor of S-
palmitoylation of H-Ras, Src kinase, Rho family members and PSD-95 [216].  2-
BP is thought to inhibit protein palmitoylation by acting as a palmitate mimetic 
due to its structural similarity to the 16-carbon saturated fatty acid (Fig. 3.1).  
Similar palmitate analogs (e.g., 2-hydroxypalmitate, 16-hydroxypalmitate, and 
palmitoleic acid) do not inhibit palmitoylation, suggesting that the bromo- group 
may be aiding in the specificity [201].  Upon entering the cell, 2-BP is converted 
to 2-bromopalmitoyl-CoA in cells similarly to how palmitate is converted to 
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palmitoyl-CoA but with less efficiency.  2-BP blocks the formation of the PAT-acyl 
intermediate in vitro with an IC50 of ~10 μM, and ~15 μM in live cells [148, 217].  
For these reasons, along with the simplicity of use and ease of acquisition, 2-BP 
has been an attractive modulator of protein palmitoylation.  
Unfortunately, 2-BP exerts pleiotropic effects on cellular metabolism and inhibits 
carnitine palmitoyl transferase I, fatty acid CoA ligase, glycerol 3-phosphate acyl 
transferase, NADPH cytochrome c reductase, and glucose 6-phosphatase [1, 
218].  Initially reported as a β-oxidation inhibitor 2-BP also inhibits mono-, di-, tri-
glycerol transferases, fatty acyl-CoA ligase, glycerol-3-phosphate acyl 
transferases, non-lipid processing enzymes like NADPH cytochrome C reductase 
and glc-6-phosphatase at sub-millimolar concentrations [204, 205]. Recent mass 
spectrometry analysis identified >450 targets of 2-BP, including PAT enzymes, 
transporters, and many palmitoylated proteins, with no observable preference for 
CoA-dependent enzymes [206]. Additionally, reduced activity of the thioesterase 
APT1 demonstrates that 2-BP could inhibit both palmitoylation and 
depalmitoylation of protein substrates [216]. 2-BP may not be directly inhibiting 
the zDHHC PAT but may be acting in a non-specific manner to target reactive 
thiols.  Two analogs were synthesized to overcome the drawbacks of 2-BP and 
serve as activity-based probes of palmitoylation [219].  Unfortunately, the 
analogs, 2-bromohexadec-15-ynoic acid and 2-bromooctadec-17-ynoic acid, 
similarly lack in specificity.  These drawbacks associated with 2-BP reinforce the 
need for new sensitive and specific inhibitors of palmitoylation.  
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Cerulenin: 2,3-epoxy-4-oxo-7,10 dodecadienoylamide, Cerulenin, is a naturally 
derived antibiotic.  Cerulenin inhibits fatty acid synthesis by alkylating β -
ketoacyl-carrier protein synthase.  Cerulenin was implicated as an inhibitor of 
palmitoylation because it affects insulin uptake in rat adipocytes [220].  A 
cerulenin analog blocks palmitoylation of p21 Ras by alkylating the protein 
palmitoyl transferase, zDHHC17, without inhibiting fatty acid synthase [221].  
Cerulenin and its analogs inhibit palmitoylation at concentrations ranging from 7-
30 μM in a panel of human tumor cell lines but at 1 mM in in vitro studies [222, 
223].  Unlike 2-BP, the structure of Cerulenin does not resemble palmitate.  
Therefore it is not expected to act as palmitate mimetic (Fig. 3.1).  The proposed 
mechanism of action for cerulenin and its analogs include the inhibition of 
palmitoylation through alkylation effects or chemical modification of sulfhydryl 
groups [223]. Cerulenin may be interacting with critical thiols on enzymes or 
substrates involved with palmitoylation. However, cerulenin inhibits β-keto-acyl-
ACP synthase and HMG-CoA synthetase activity resulting in inhibition of fatty 
acid biosynthesis and cholesterol biosynthesis, respectively [224, 225].  
Tunicamycin: The nucleoside antibiotic tunicamycin was identified for its ability to 
inhibit N-glycosylation but has been demonstrated to also inhibit palmitoylation.  
The mechanism of action of tunicamycin is unknown but it may compete with 
palmitoyl-CoA for zDHHC PAT association.  Tunicamycin shares structural 
similarities with both palmitate and Coenzyme A (Fig. 3.1).  Tunicamycin inhibits 
the palmitoylation of GAP-43, N-type calcium channels, ER-α  variant, and 
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myelin proteolipid protein [222, 226-228] in the micromolar concentration range 
[222, 229].  
Mechanism-based inhibitors: Due to the lack of specific and sensitive 
palmitoylation inhibitors, Ducker et al. performed cell-based, high throughput 
screens to identify compounds that inhibited palmitoylation-dependent cell growth 
[230].  The inhibitors were categorized based on their ability to inhibit 
palmitoylation of Type I substrates (proteins like Ras that get farnesylated prior to 
palmitoylation) or Type II substrates (proteins like Src that get myristoylated prior 
to palmitoylation).  Through this process, they identified five chemical classes of 
inhibitors.  One representative compound (designated Compounds I-V) for each 
chemotype was selected and subjected to further characterization. The 
representative compounds inhibited the palmitoylation of fluorescently labeled 
peptides with IC50 values in the low micromolar range.  Unfortunately, the 
compounds failed to inhibit the activity of purified zDHHC2, zDHHC9-GCP16, 
Pfa3 and Erf2-Erf4 in in vitro studies at concentrations as high as 100 μM [148]. 
Compound V inhibited the PAT activity for the purified zDHHCs but lacked the 
specificity that Ducker, et  al. described [148, 230, 231].  Although this wave of 
inhibitor screening produced mixed results, the improvement to assays, 
screening techniques, and chemical libraries encourage the ability to identify 
new, specific inhibitors and modulators of palmitoylation. 
Thioesterase Inhibition: Initial attempts to identify inhibitors of Apt1 resulted in 
synthetic benzodiazepinediones with hexadecylsulfonamide that had IC50 values 
in the low nanomolar range [232, 233].  Although these compounds worked well 
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in vitro, they were never supported by in vivo studies.  Using “protein structure 
similarity clustering” as a bioinformatics-based strategy to design inhibitors for 
Apt1, Waldmann and colleagues have developed a depalmitoylation inhibitor 
consisting of palmostatins with β -lactone cores [163]. The palmostatins 
competitively inhibited Apt1 through a reversible covalent modification of the 
active site serine associated with protein depalmitoylation [163].  The most potent 
inhibitor of Apt1 was palmostatin B with an IC50 of 670 nM.  Apt1 was validated 
as a cellular target of palmostatin B in a Madine-Darby canine kidney cell line by 
demonstrating an interaction between palmostatin B and the thioesterase in vivo 
[163].  Palmostatin B inhibits depalmitoylation and causes a loss of the precise 
steady-state localization of palmitoylated Ras, and induces partial phenotypic 
reversion in oncogenic HRasG12V-transformed fibroblasts [163].  Thus, 
palmostatin B may be a valuable starting point for the development of modulators 
of pathological signaling for Ras proteins [163]. 
 
3.4 Fungal Metabolite Extracts 
Dr. Baker and colleagues have prepared extracts from entophytic fungi isolated 
from coastal Florida mangroves stands. Each fungal isolate was grown in rice 
media under three different growth conditions: in the presence of a histone de-
acetylase inhibitor (HDI), a DNA methyltransferase inhibitor (DNMTi), or vehicle 
control.  The cultures were extracted in ethyl acetate, dried, resuspended in 
100% DMSO at a concentration of 5mg/mL, and plated for the bioassay 
screening.  The provided fungal metabolite library will be applied to the 
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fluorescence-based coupled assay described in chapter 2. The different growth 
conditions are expected to activate latent pathways and produce novel 
metabolites that may not otherwise be detected in normal laboratory growth 
conditions [234].  These crude extracts are a mixture of metabolites that may 
contain non-polar natural products, lipids, small peptide chains, and possibly 
DNA intercalators.  This chapter presents the identification of two lead fungal 
metabolite extracts that inhibit Erf2 autopalmitoylation greater than 100 μM 2-
BP.   
 
3.5 Dose Response of 2-BP on Erf2 Autopalmitoylation 
The first step in a screening campaign is to establish the controls for the assay in 
the same solvent as the provided library.  The fungal metabolites are provided as 
extracts in 100% DMSO.  This assay has previously been optimized for a final 
1% DMSO, but for this screen it was optimized for 5% DMSO to allow for a 
greater concentration of metabolites. 
2-BP was screened on the fluorescence-based coupled assay in triplicate at 25 
μM, 50 μM, 100 μM, and 150 μM against vehicle control (5% DMSO) (Fig. 
3.2).  This was to determine an effective dose of 2-BP that would result in a 
~50% reduction of Erf2 autopalmitoylation.  The slopes (velocity of the reaction), 
indicative of increase in NADH over time, were consistent (Fig. 3.2A), yielding 
minimal standard deviation (Fig. 3.2B).  25 μM 2-BP resulted in a ~30% 
decrease in reaction velocity, 50 μM 2-BP resulted in a ~50% decrease in 
reaction velocity, 100 μM 2-BP resulted in a ~85% decrease in reaction velocity, 
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and 150 μM 2-BP completely inhibited the reaction.  Thus 50 μM 2-BP was 
selected as the Erf2 autopalmitoylation inhibition control for the fluorescence-
based coupled assay. 
 
3.6 The Fungal Metabolite Isolates Inhibit Erf2 Autopalmitoylation 
The fungal metabolite library consists of extracts from entophytic fungi isolated 
primarily from the Florida mangroves.   Fungal isolates were grown in the 
presence of HDAC or DNMT inhibitors, and were provided at approximately 
5mg/mL in 100% DMSO.  The fungal metabolites were diluted 1:20 in the 
reaction for a final concentration of approximately 2.5 mg/ml in 5% DMSO.  
Despite the complexity of the fungal metabolite samples the results obtained 
from the screen against Erf2 autopalmitoylation resulted in minimal standard 
deviation, similar to that of the 2-BP screen. 
The control samples from isolates CQ10-23A-1 (B), EG12-31A-6 (G), EG10-34E-
1 (H), EG12-16C-3 (K), and all three extracts from EG12-32A-2A (Z) elicited 
minimal inhibitory effects on Erf2 autopalmitoylation. The remaining fungal 
metabolite samples resulted in a decrease in Erf2 autopalmitoylation equal to or 
greater than 50 μM 2-BP (Fig. 3.3).   Extracts from all growth conditions of 
EG10-47C-1 resulted in decrease in NADH detection, suggesting that they were 
somehow quenching fluorescence of the assay. EG10-47C-1 samples were 
omitted from the remainder of this study. 
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3.7 Dose Response of CoASH on Fluorescence-based Coupled Assay 
Control Reaction 
To calibrate the results from the fluorescence-based coupled assay and 
determine a linear range of concentrations, the assay was performed in the 
absence of Erf2-Erf4, utilizing CoASH as a reaction catalyst, rather than 
palmitoyl-CoA.  A dose response for CoASH was performed to determine a 
working concentration of CoASH in the presence of 5% DMSO.  CoASH was 
screened in the control reaction at 0.5 μM, 1 μM, 2.5 μM, 5 μM, 7.5 μM, 10 
μM, 15 μM, 20 μM, 40 μM, and 80 μM. 
Due to the rapid conversion of NAD+ to NADH via α -ketoglutarate 
dehydrogenase (α-KDH) it is difficult to accurately capture the start of the 
reaction.  Thus, the detected rates of the reaction are inconsistent even from well 
to well. When the reaction is not coupled to the production of CoASH from 
autopalmitoylation it reaches Vmax prior to the first point of data collection (< 5 s).  
The control reaction is evaluated as relative end-point fluorescence after a 10 
min. reaction.  Reducing the concentration of CoASH resulted in a linear 
reduction in the end-point fluorescence for 7.5 μM CoASH and higher.  There is 
minimal difference in end-point fluorescence between baseline (0 μM CoASH) 
and 7.5 μM CoASH (Fig. 3.4).  This demonstrates that 20 uM CoASH falls within 
the linear range of the concentrations screened, which is consistent with prior 
studies [147].  Based on these findings 20 μM CoASH was selected for the 
control reaction as it falls below the KM of the control reaction (~40 μM) [147]. 
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3.8 The Fungal Metabolite Isolates have Minimal Background Effects on 
the Fluorescence-based Coupled Assay Independent of Erf2 
Autopalmitoylation 
To determine if the extracts have intrinsic fluorescence interfering with the assay, 
the background fluorescence of the fungal metabolite isolates was measured.  
The total end-point fluorescence after a 10 min. reaction was also measured.  
The initial relative fluorescence was subtracted from the total end-point 
fluorescence resulting in the normalized effect of the extracts on α-KDH. 
All of the fungal metabolite samples demonstrated a degree of background 
fluorescence (Fig. 3.5), which could be due to an artifact of the extraction 
technique, or a common metabolite present in all the samples.  Despite this, very 
few of the fungal metabolite samples demonstrated an effect on α-KDH activity. 
Isolates from the control treatment for isolate EG12-3C-2 (AA) resulted in a ~80% 
reduction in α-KDH activity.  All three treatments from EG12-24A-3A (F) and 
EG11-21B-1 (R), and DNMTi treatment for isolate EG12-18A-13 (W) resulted in a 
~10-25% reduction in α-KDH activity.  All three treatments from EG10-60E-1 (I) 
resulted in ~60% increase in α-KDH activity.  All three treatments from EG10-
47C-4 (D) resulted in a 40-fold increase in background fluorescence (Fig. 3.5).  
The background effects may be driving their effects in the fluorescence-based 
coupled assay.  The remaining isolate samples did not elicit a background effect. 
The results from the Erf2 autopalmitoylation screen were then normalized for 
effect on the α -KDH reaction (total end-point relative fluorescence minus 
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background fluorescence) to establish specific effect of the fungal metabolite 
samples on Erf2 autopalmitoylation (Fig. 3.6).  The lead isolates were selected 
for Erf2 steady-state autopalmitoylation screens.  These isolates are the HDI-
treated CQ10-23A-1 (B), control treated EG10-52E-2 (Q), DNMTi-treated EG12-
24A-3A (F), DNMTi-treated EG10-47C-4 (D), DNMTi-treated EG10-52E-2 (Q), 
HDI-treated EG12-24A-5 (X), HDI-treated EG12-18A-13 (W), and control treated 
EG12-31A-9 (Y) isolates.  Two of these isolates resulted in a reduction in α-KDH 
activity (DNMTi treated EG12-24A-3A and HDI-treated EG12-18A-13). 
 
3.9 Evaluating Erf2 Steady-State Autopalmitoylation 
The fluorescent-based coupled assay is an indirect means of evaluating 
autopalmitoylation through the production of NADH.  It is possible that the 
extracts could be eliciting this effect through targeting hydrolysis of the enzyme-
palmitoyl moiety complex rather than targeting the autopalmitoylation reaction.  
Steady-state autopalmitoylation was evaluated on the gel-based assay that 
exploits BODIPY®-C12-CoA as a fluorescent mimic of palmitoyl-CoA [40] (Fig. 
3.7).  The reactions were separated by SDS-PAGE and steady-state 
autopalmitoylation was determined by co-migration of the BODIPY® fluorophore 
with Erf2.  This demonstrates that Erf2 was acylated by BODIPY®-C12 [40]. A 
reduction in the co-migrating BODIPY® fluorescence with Erf2 would be 
indicative of a reduction in Erf2 steady-state auto-acylation.  The fungal 
metabolite isolates were applied to the gel-based assay to determine the effect 
on Erf2 autopalmitoylation.  At ~2.5 mg/ml in 5% DMSO the HDI-treated CQ10-
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23A-1 (B), and control and DNMTi treated-EG10-52E-2 (Q) isolates resulted in 
an ~85% reduction in Erf2 steady-state autopalmitoylation (Fig. 3.8).  The 
remaining isolates; DNMTi treated EG10-47C-4 (D), HDI-treated EG12-24A-5 
(X), HDI-treated EG12-18A-13 (W), and control treated EG12-31A-9 (Y) resulted 
in a ~60% reduction in Erf2 steady-state autopalmitoylation.  The DNMTi-treated 
EG12-24A-3A (F) isolate had the least effect on Erf2 steady-state 
autopalmitoylation (a ~25% reduction).  This isolate was discarded as it inhibited 
α-KDH activity.  100 μM 2-BP was an inhibition control of Erf2 steady-state 
autopalmitoylation as it resulted in a >50% reduction in co-migrated BODIPY® 
fluorescence with Erf2 on the gel-based assay.  
To compare the different treatments of the lead isolates on Erf2 steady-state 
autopalmitoylation, the three isolates that resulted in the greatest reduction in 
Erf2 steady-state autopalmitoylation were evaluated.  The HDI treated CQ10-
23A-1 (B), and control and DNMTi-treated EG10-52E-2 (Q) isolates were 
screened by the gel-based assay against the remaining treatment samples from 
their respective isolate groups; control and DNMTi-treated CQ10-23A-1 (B), and 
HDI-treated EG10-52E-2 (Q). Similar to the fluorescence-based coupled assay, 
the HDI-treated CQ10-23A-1 (B) isolate resulted in a greater degree of steady-
state Erf2 autopalmitoylation inhibition compared to control and DNMTi-treated 
CQ10-23A-1 (B) isolates. Conversely, there was no discernable difference 
between growth treatments for isolate EG10-52E-2 (Q). They each inhibited Erf2 
steady-state autopalmitoylation to a similar degree as 100 μM 2-BP, ~95% (Fig. 
3.9). 
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3.10 Discussion 
The current inhibitors of palmitoylation interact with a variety of cellular pathways 
in addition to palmitoylation [1, 206, 218, 222, 224-228].  As the field of 
palmitoylation expands, the need for specific and sensitive inhibitors to validate 
the involvement of palmitoylation, and probe for new substrates becomes urgent.  
Unfortunately, the lack of specificity of currently available inhibitors is not ideal for 
either purpose.  The involvement of protein palmitoylation in signaling pathways 
and disease states is often validated by 2-BP, but 2-BP also inhibits carnitine 
palmitoyl transferase I, fatty acid CoA ligase, glycerol 3-phosphate acyl 
transferase, NADPH cytochrome C reductase, and glucose 6-phosphatase in 
addition to >450 interactions identified by mass spec [1, 206, 218].  More 
recently, analogs of another protein palmitoylation inhibitor, cerulenin, have been 
used as probes for substrates of palmitoylation, but cerulenin lacks specificity, 
and inhibits fatty acid and cholesterol biosynthesis [190, 224, 225].  This further 
justifies the need for a more specific inhibitor of protein palmitoylation.   
The Florida mangroves have a diverse inventory of fungal organisms that 
researchers are only now just starting to investigate.  Furthermore, the novel 
concept of modifying the fungal growth conditions to introduce a greater variety 
of fungal metabolites increases the odds of detecting a metabolite of interest. 
In that context, the CQ10-23A-1 (B) isolate extracts are of great interest as 
modifying the growth conditions resulted in a range of inhibitory effects on Erf2 
autopalmitoylation.  This suggests that under different growth conditions isolate 
CQ10-23A-1 (B) produces different metabolites or expresses existing metabolites 
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more efficiently. Thus, there is a great opportunity for one of those metabolites to 
be an effective inhibitor in either this screen or even a completely different 
screen.  
Conversely, for our purposes of identifying a novel inhibitor of protein 
palmitoylation, samples from both isolates, CQ10-23A-1 (B), and EG10-52E-2 
(Q), are of interest.  Both isolates were able to produce metabolites that resulted 
in a 75% reduction of Erf2 autopalmitoylation, and a 95% reduction in steady-
state autopalmitoylation; suggesting that they are producing metabolites that 
inhibit the formation of the Erf2-palmitoyl moiety intermediate. 
This is especially encouraging as the fungal metabolite samples are not 
individual purified individual metabolites, but complex mixtures of not-yet-
characterized non-polar extracts.  Once the metabolites have been fractionated 
and can be screened individually, it will be interesting to observe if they have a 
greater or weaker effect individually.  There is the potential that the metabolites 
within a sample are acting in an additive manner to elicit the inhibitory effects on 
Erf2 autopalmitoylation, and that when they are fractionated to individual 
metabolites, they will have lost efficacy from synergistic effects.  It is also feasible 
that individual metabolites are causing the inhibition, and by fractionating to 
remove inactive constituents will result in more potent inhibition. 
The metabolite samples from the lead isolates are currently being fractionated so 
that individual metabolites may be screened.  Following the identification of lead 
individual metabolites, they will be further optimized for structure-activity 
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relationship, and screened against additional zDHHC PATs to evaluate their 
specificity. 
Screening the fungal metabolite library has highlighted the screening capabilities 
of the fluorescence-based coupled assay.  81 fungal metabolite samples were 
evaluated on a 96-well plate format for specific effects on Erf2 autopalmitoylation, 
which lead to the identification of lead samples for additional screens. 
Previously established inhibitors of protein palmitoylation were first characterized 
for their inhibitory effects on other cellular mechanisms, but these potential 
inhibitors were identified by virtue of their ability to inhibit purified zDHHC protein 
autopalmitoylation [204, 205, 224-226].  These findings could ultimately lead to 
the identification and characterization of first in class zDHHC inhibitors, creating 
an opportunity to explore the therapeutic potential of specific PAT inhibitors. 
 
3.11 Experimental Procedures 
Coupled PAT Assay-  As discussed in chapter two, the production of NADH was 
monitored with a Biotek Mx fluorimeter (Biotek, Winooski, VT) using 340 nm 
excitation/ 465 nm emission.  The 50 µl reaction contained 2 mM 2-Oxoglutarate 
(α-ketoglutamic acid), 0.25 mM NAD+, 0.2mM Thiamine Pyrophosphate, 0.5 µg 
of purified 6xHIS-Erf2/FLAG-Erf4, 1 mM EDTA, 1 mM dithiothreitol, 32 mU 2-
oxogluarate dehydrogenase (α-ketoglutarate dehydrogenase), 50 mM sodium 
phosphate, pH 6.8, and 0 - 100 µM inhibitor in 5% DMF. The addition of 40 μM 
palmitoyl-CoA initiated the reaction, which was monitored for 30 min. at 30˚C.  
The first 10mins of the reaction was analyzed to determine the initial rates of 
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CoASH release.  The PAT specific activity was determined from a standard curve 
of NADH production with different CoASH amounts.  In these reactions, CoASH 
was added to the standard PAT reaction mixture (without Erf2/Erf4 complex or 
palmitoyl-CoA) and the reaction was allowed to proceed to equilibrium (~10 min.) 
before fluorescence was measured. The assay can be assembled as a kit for 
consistency between experiments. Each 96-well plate experiment uses ~1.5 ml 
of a 4x reaction buffer, ~3 ml of a 2x Palmitoyl-CoA stock, and 50 μl of purified 
Erf2-Erf4 (~0.5 μg per reaction).  The volume of Erf2-Erf4 is based off of a ~1 μ
g/μl preparation.  To avoid cycles of freezing and thawing the 4x reaction buffer 
and palmitoyl-CoA can be produced in bulk and stored at -20oC in appropriate 
aliquot volumes for one 96-well plate experiment.  We maintain 50 μl aliquots of 
Erf2-Erf4 at -80oC.  Because all the elements of the assay are prepared in bulk, 
and stored in workable aliquots, there is an increased reproducibility and 
reliability from the fluorescent-based coupled assay.  This has allowed for the 
reliable evaluation of compound libraries for their effects on Erf2 
autopalmitoylation. 
Coupled Assay Control Screen- The 50 µl reaction contained 2 mM 2-
Oxoglutarate ( α -ketoglutamic acid), 0.25 mM NAD+, 0.2mM Thiamine 
Pyrophosphate, 1 mM EDTA, 1 mM dithiothreitol, 32 mU 2-oxogluarate 
dehydrogenase (α-ketoglutarate dehydrogenase), 50 mM sodium phosphate, 
pH 6.8, and 0 - 100 µM inhibitor in 5% DMF. The addition of 20 μM CoASH 
initiated the reaction, which was monitored for 30 min. at 30˚C.  The value of the 
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first reading was subtracted from the value of the last reading at the end of the 
reaction to determine the effect of the inhibitors on α-ketoglutamic acid activity.  
BODIPY®-C12:0 Autopalmitoylation Assay-  BODIPY®-C12:0-CoA (40 µM final, 
unless specified otherwise) was added to a 50 µl reaction containing 
approximately 0.5 µg enzyme (6xHis-Erf2/FLAG-Erf4) and 2.5 mg/ml inhibitors in 
5% DMSO in 50mM sodium phosphate buffer, pH 6.8.  The reactions were 
incubated 10 min with inhibitor, and then the reaction was initiated by the addition 
of BODIPY®-C12:0-CoA, and incubated 15 min. at 30˚C.  The reaction was 
terminated by the addition of 5x non-reducing protein loading buffer.  Each 
reaction was then subjected to SDS-PAGE (12%).  The gel was washed three 
times in ddH2O and visualized on the Typhoon 9410 Variable Mode Imager (GE 
Healthcare, Piscataway, NJ) for BODIPY® fluorescence (ex. 488 nm / em. 532 
nm) to visualize co-migration of the BODIPY® signal with 6xHIS-Erf2/FLAG-Erf4.  
The amount of 6xHIS-Erf2/FLAG-Erf4 was determined empirically using SDS-
PAGE/western blot analysis under reducing conditions against a standard curve 
of bovine serum albumin. 
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Figure 3.1.  Current Inhibitors of Palmitoylation Compared to Palmitate and 
Coenzyme A.  2-Bromopalmitate is structurally the same as palmitate with the 
exception of the 2-bromo group.  Half of tunicamycin is reminiscent of palmitate, 
where the other half of tunicamycin is reminiscent of coenzyme A.  Cerulenin is 
similar in hydrophobicity and chemical space to palmitate. 
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Figure 3.2.  Dose Response of 2-BP on Erf2 Autopalmitoylation.  A. The 
fluorescence-based coupled assay is performed in the presence of varying 
concentrations of 2-BP in 5% DMSO. The resulting fluorescent units are graphed 
against time (seconds) in triplicate, where the slope is equal to the velocity of the 
reaction.  B. The average velocity of Erf2 autopalmitoylation is presented as a 
fraction of vehicle control (5% DMSO) +/- standard deviation.  The velocity of 
Erf2 autopalmitoylation was detected as an increase in fluorescence over time.  
A reaction lacking Erf2 ( - ) was a control for the baseline activity of the assay. 
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Figure 3.3.  Fungal Metabolite Screen for Erf2 Autopalmitoylation Inhibition.  
The fungal metabolites were screened at ~2.5 mg/ml, and the average relative 
velocity of Erf2 autopalmitoylation of three reactions is presented as a fraction of 
vehicle control (5% DMSO) +/- standard deviation. The velocity of Erf2 
autopalmitoylation was detected as an increase in fluorescence over time. The 
fungal isolate samples are CQ10-15C-1 (A), CQ10-23A-1 (B), EG10-42B-2 (C), 
EG10-47C-4 (D), EG11-13B-1 (E), EG12-24A-3A (F), EG12-31A-6 (G), EG10-
34E-1 (H), EG10-60E-1 (I), EG11-15C-3 (J), EG12-16C-3 (K), EG12-31A-3B (L), 
EG12-49E-5 (M), EG12-8A-3 (N), CC10-10B-1 (O), CQ10-17B-1 (P), EG10-52E-
2 (Q), EG11-21B-1 (R), EG12-33D-3 (S), KML12-2MG-C1 (T), CQ10-28A-4 (U), 
EG11-15C-3 (V), EG12-18A-13 (W), EG12-24A-5 (X), EG12-31A-9 (Y), EG12-
32A-2A (Z), and EG12-3C-2 (AA). For a visual aid, results from every other 
isolate group is shaded by a gray box behind the graph. 50 μM 2-BP is a control 
for inhibition of Erf2 autopalmitoylation, and a reaction lacking Erf2 ( - ) was a 
control for baseline activity in the assay. 
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Figure 3.3.  (Continued). 
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Figure 3.4.  Dose Response of CoASH on Control Experiment of 
Fluorescence-based Coupled Assay.  The fluorescence-based coupled assay 
was performed in the absence of Erf2-Erf4 using CoASH as substrate rather than 
palmitoyl-CoA.  Varying concentrations of CoASH were applied to the reaction in 
the presence of vehicle control (5% DMSO).  The average relative end point 
fluorescence of three 10 min. reactions is represented as the total relative 
fluorescent units +/- standard deviation.  
	 81 
 
 
Figure 3.5.  Fungal Metabolites on Background Fluorescence and α-KDH 
Activity.  The fluorescence-based coupled assay was performed in the absence 
of Erf2-Erf4 using CoASH as substrate rather than Palmitoyl-CoA.  The fungal 
metabolites were screened at ~2.5 mg/ml, and the average relative end point 
fluorescence (dark grey), background fluorescence (light grey), or α-KDH 
Activity (end point fluorescence – background fluorescence; white) of three 10 
min. reactions is presented as total relative fluorescent units +/- standard 
deviation.  The fungal isolate samples are CQ10-15C-1 (A), CQ10-23A-1 (B), 
EG10-42B-2 (C), EG10-47C-4 (D), EG11-13B-1 (E), EG12-24A-3A (F), EG12-
31A-6 (G), EG10-34E-1 (H), EG10-60E-1 (I), EG11-15C-3 (J), EG12-16C-3 (K), 
EG12-31A-3B (L), EG12-49E-5 (M), EG12-8A-3 (N), CC10-10B-1 (O), CQ10-
17B-1 (P), EG10-52E-2 (Q), EG11-21B-1 (R), EG12-33D-3 (S), KML12-2MG-C1 
(T), CQ10-28A-4 (U), EG11-15C-3 (V), EG12-18A-13 (W), EG12-24A-5 (X), 
EG12-31A-9 (Y), EG12-32A-2A (Z), and EG12-3C-2 (AA).  50 μM 2-BP is a 
control for inhibition of Erf2 autopalmitoylation, and a reaction lacking Erf2 ( - ) 
was a control for baseline activity in the assay. 
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Figure 3.5.  (Continued). 
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Figure 3.5.  (Continued). 
  
	 84 
 
 
Figure 3.6.  Fungal Metabolite Screen Normalized to Background 
Fluorescence and α-KDH Activity.  The fungal metabolites were screened at 
~2.5 mg/ml, and the average relative velocity of Erf2 autopalmitoylation of three 
reactions normalized to background effects on the reaction is presented as a 
fraction of vehicle control (5% DMSO). The velocity of Erf2 autopalmitoylation 
was detected as an increase in fluorescence over time. The fungal isolates were 
treated with either vehicle control (dark grey), DNMT (light grey), or HDAC 
(white), and are samples CQ10-15C-1 (A), CQ10-23A-1 (B), EG10-42B-2 (C), 
EG10-47C-4 (D), EG11-13B-1 (E), EG12-24A-3A (F), EG12-31A-6 (G), EG10-
34E-1 (H), EG10-60E-1 (I), EG11-15C-3 (J), EG12-16C-3 (K), EG12-31A-3B (L), 
EG12-49E-5 (M), EG12-8A-3 (N), CC10-10B-1 (O), CQ10-17B-1 (P), EG10-52E-
2 (Q), EG11-21B-1 (R), EG12-33D-3 (S), KML12-2MG-C1 (T), CQ10-28A-4 (U), 
EG11-15C-3 (V), EG12-18A-13 (W), EG12-24A-5 (X), EG12-31A-9 (Y), EG12-
32A-2A (Z), and EG12-3C-2 (AA).  50 μM 2-BP is a control for inhibition of Erf2 
autopalmitoylation, and a reaction lacking Erf2 ( - ) was a control for baseline 
activity in the assay. 
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Figure 3.7.  Schematic of Orthogonal Gel-based Screen of Steady-state 
Autopalmitoylation.  In the orthogonal screen a BODIPY®-C12-CoA is 
combined in reaction with a zDHHC PAT.  If auto-acylation occurs then 
BODIPY®-C12 will label the zDHHC PAT, and CoASH will be released.  The 
reaction can be separated by SDS-PAGE and viewed on a fluorescent flatbed 
scanner to detect BODIPY® fluorescence (ex. 485 nm / em. 528 nm) that co-
migrated with zDHHC PAT, indicative of autopalmitoylation.  An inhibitor of 
autopalmitoylation is expected to reduce the amount of steady-state zDHHC PAT 
acylated by BODIPY®-C12, and thus will be detected as a decrease in 
fluorescence in the SDS-PAGE at the apparent molecular weight of the zDHHC 
PAT. 
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Figure 3.8.  Fungal Metabolite Screen Hits on Gel-Based Assay.  An 
orthogonal screen of steady-state Erf2 autopalmitoylation with ~2.5 mg/ml of 
each of the lead fungal metabolite isolate samples; CQ10-23A-1 (B), EG10-52E-
2 (Q), EG12-18A-13 (W), EG10-47C-4 (D), EG12-24A-3A (F), EG12-24A-5 (X), 
EG12-31A-9 (Y).  The relative BODIPY® fluorescence that co-migrated with Erf2 
is presented as a fraction of vehicle control (5% DMSO).  A reaction lacking Erf2 
( - ) represents baseline activity in the assay.  100 μM 2-BP is a control for 
inhibition of Erf2 steady-state autopalmitoylation. 
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Figure 3.9.  Complete Isolate Sets for the Fungal Metabolite Screen Hits on 
the Gel-based Assay.  An orthogonal screen of steady-state Erf2 
autopalmitoylation with ~2.5 mg/ml of each of the complete isolate sets for the 
lead fungal metabolite isolate samples; CQ10-23A-1 (B) and EG10-52E-2 (Q). 
The average relative BODIPY® fluorescence from three reactions that co-
migrated with Erf2 is presented as a fraction of vehicle control (5% DMSO) +/- 
standard deviation.  A reaction lacking Erf2 ( - ) represents baseline activity in the 
assay.  100 μ M 2-BP is a control for inhibition of Erf2 steady-state 
autopalmitoylation. 
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CHAPTER 4 
 
Identification of Protein Palmitoylation Inhibitors from a Scaffold Ranking 
Library 
 
 
4.1 Note to Reader 
Portions of this chapter have been submitted for publication to J. Biol. Chem. 
(2015) and the manuscript is under revision. 
 
4.2 Overview 
This chapter describes a mixture based screening approach to identify inhibitors 
of Erf2 activity, the Saccharomyces cerevisiae PAT responsible for catalyzing the 
palmitoylation of Ras2, an ortholog of the human Ras oncogene proteins. A 
chemical library developed by the Torrey Pines Institute for Molecular Studies 
consists of more than 30 million compounds designed around 68 molecular 
scaffolds that are systematically arranged into positional scanning and scaffold 
ranking formats.  We have used this approach to identify and characterize 
several scaffold backbones and R-groups that reduce or eliminate the activity of 
Erf2 in vitro.  Here, we present the analysis of one of the scaffold backbones, bis-
cyclic piperazine.  We identified compounds that inhibited Erf2 autopalmitoylation 
activity using a fluorescence-based, coupled assay in a high throughput 
screening (HTS) format and validated the hits utilizing an orthogonal gel-based 
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assay.  Finally, we examined the effects of the compounds on cell growth in a 
yeast cell-based assay.  Based on our results, we have identified specific, high-
affinity palmitoyl transferase inhibitors that will serve as a foundation for future 
compound design. 
 
4.3 Key Words and Abbreviations 
Acyl transferase; Enzyme Inhibitor; High Throughput Screening (HTS); 
Palmitoylation; zDHHC 
2-BP, 2-bromopalmitic acid; APT, acyl protein thioesterase; CoA, Coenzyme A; 
DCM, dichloromethane; DIC, diisopropylcarbodiide; DIEA, diisopropylethylamine; 
DMF, dimethylformamide; HOBt, 1-hydroxybenzotriazole hydrate; HTS, high 
throughput screen; MEOH, methanol; MBHA, p-methylbenzyhydrylamine; PAT, 
protein acyl transferase; SAR, Structure and Activity Relationship; TFA, 
trifluoroacetic acid; THF, tetrahydrofuran. 
 
4.4 Introduction 
Dysregulation of the enzymes which catalyzed the palmitoyl addition and/or the 
substrates of these enzymes have been linked to cancer, cardiovascular, and 
neurological disorders, implying these enzymes and substrates are valid targets 
for pharmaceutical intervention. However, current chemical modulators of 
zDHHC PAT enzymes lack specificity and affinity, underscoring the need for 
screening campaigns to identify new specific, high affinity modulators.   
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Alterations in palmitoylation have been implicated in the etiology of cancer, 
cardiovascular disease, and neurological disorders [214, 215]. However, there 
are currently no drugs that target palmitoylation and the limited numbers of 
inhibitors that do exist exhibit low affinity and lack specificity. 2-BP continues to 
be the primary experimental inhibitor of palmitoylation due to the lack of a more 
suitable alternative, despite a recent mass spectrometry study where its 
preference for palmitoylated substrates or PAT enzymes was not detectable 
[206]. Furthermore, 2-BP also inhibits the depalmitoylating thioesterase, APT 
[216]. Thus, the need to identify specific, high affinity inhibitors of protein 
palmitoylation is critical for the progression of palmitoylation research, and for the 
regulation of palmitoylation for therapeutic intervention.  
We will be applying the described high-throughput screening technique for 
quantifying autopalmitoylation in a screening campaign for inhibitors of 
palmitoylation from a unique compound scaffolding chemical library.  This 
approach allows us to interrogate millions of compounds with only hundreds of 
reactions through positional scanning synthetic combinatorial libraries [147, 235-
237].  This is a unique and highly efficient means of rapidly acquiring data where 
the accuracy for predicting hits and prioritization of compounds is increased due 
to the conditional probalistic analysis [236, 237].  Using combinatorial chemistry 
to synthesize compound libraries allows for the rapid production, and the 
application of “isokinetic mixtures” allows for the production of equimolar mixtures 
[235, 238]. 
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In the present study, we describe the use of this assay for the identification of a 
unique class of compounds, based on a bis-cyclic piperazine scaffold, that inhibit 
the autopalmitoylation activity of the yeast Ras PAT, Erf2.   
 
4.5 Inhibition of Erf2 Autopalmitoylation using a Fluorescence-based 
Coupled Assay 
The identification of palmitoylation inhibitors has been hampered by the lack of 
assays amenable to high throughout screening applications.  Previously, we 
validated an assay that monitors the rate of autopalmitoylation by measuring the 
production of CoASH generated from the reduction of palmitoyl-CoA [147].  The 
intention of this assay is to couple the amount of CoASH formed (and hence, 
enzyme:palmitoyl intermediate formed) to the production of NADH, which is 
fluorescent.  This assay can be used to monitor autopalmitoylation in real time or 
as an end point assay, thus providing flexibility when screening small molecule 
compounds.  Compounds with internal fluorescence or that affect the assay 
components are easily identified and excluded, allowing for the rapid 
identification of the compounds that inhibit or activate PAT autopalmitoylation 
activity.   
As an initial step in our screening campaign, we interrogated a scaffold ranking 
library developed by the Torrey Pines Institute for Molecular Studies [147, 235, 
236].  This strategy allows for the evaluation of >30 million synthetic compounds 
while screening exponentially fewer reactions (Fig. 4.1A-E).  This is achieved by 
organizing a large number of chemically diverse compounds into 68 core 
	 92 
scaffolds.  Each scaffold contains between 2,000 to 700,000 unique compounds 
at approximately equivalent molar concentrations (Fig. 4.1A).  It is predicted that 
structural similarities will dictate additive effects increasing the chance that 
individual modulators will be detected despite being between nanomolar to sub-
nanomolar concentrations [236, 239].  The vast number of compounds in each 
library increases the probability of identifying a compound with useful chemical 
characteristics and properties [240] (Fig. 4.1B).  Figure 4.1 highlights a flow 
diagram of the stages involved in the identification and optimization of the 
compounds.  As a first step, we screened compounds representing 68 scaffolds 
to determine the optimal scaffold structure.  Once we identified a scaffold or 
scaffolds, positional scanning libraries, which are organized by R-groups at each 
position around a given scaffold, are utilized.  This allows for the prediction of 
optimal R-groups for each position on the core scaffold (Fig. 4.1C).  Based on the 
optimized scaffold and knowledge of the active R-groups, individual compounds 
can be designed and synthesized to determine the positional effects of the R-
groups on activity (Fig. 4.1D).  Finally, based on the level of inhibition, we 
selected a subset of lead compounds for further analysis (Fig. 4.1E). This 
approach allows us to expedite the screening process of millions of compounds 
and to generate structure-activity relationship (SAR) information early in the 
screening process.  A description of the library construction and use can be 
found in recent reviews [235, 240-243]. 
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4.6 Scaffold Ranking of the Erf2 Autopalmitoylation Inhibitors 
We screened 68 scaffold ranking samples, each at a concentration of 100 μ
g/ml/scaffold (Fig. 4.2).  Each scaffold sample was pre-incubated with Erf2 
enzyme for 10 min at 30˚C before initiating the reaction with the addition of 
palmitoyl-CoA.  We monitored the production of CoASH for 30 min to ensure a 
linear response over time and determined the rate of the reaction for each 
scaffold sample.  Incubation of the enzyme with several of the scaffold samples 
resulted in a reduction in the production of CoASH.  As an initial criterion, we 
defined inhibition as a reduction in activity greater than three standard deviations 
from the mean activity value.  We identified eight of the scaffold libraries that fit 
this definition.  Scaffolds 2103, 2236, 2165, 2220, 1509, 2160, 2228, and 2221 
caused at least a 50% reduction in Erf2 autopalmitoylation activity.  This is similar 
to the level of inhibition (60%) caused by 2-BP at a comparable compound 
concentration (100 µM).  With the exception of scaffold sample 1509, none of the 
samples had an effect on the reaction in the absence of Erf2-Erf4, when 20 μM 
CoASH replaced 40 μM Palmitoyl-CoA as substrate (Fig. 4.3).  Thus, scaffold 
sample 1509 was excluded from further analysis.  The data from two of the 
scaffolds, 2165 and 2228, were inconsistent and not reproducible.  Therefore, 
these scaffolds were also excluded. Finally, we established a baseline of 
inhibition using boiled and catalytically inactive enzyme.   
We next screened the remaining 5 scaffolds for dose responsiveness at 200 μ
g/ml, 100 μg/ml, and 50 μg/ml (Fig. 4.4A).  Similar to the dosage response 
observed for 2-BP, three of the five scaffold libraries (2160, 2220 and 2236) 
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demonstrated some degree of dosage response at these concentrations.  
Interestingly, these three scaffold libraries included a piperazine-analog feature.  
Scaffold 2220 is a piperazine, scaffold 2221 is a pyrolidine piperazine, and 
scaffold 2160 is a bis-cyclic piperazine (Fig. 4.4B).  
Additionally, we want to consider Lipinski’s Rule of 5 [244]. Our lab is not 
equipped to calculate the octanol-water partition coefficient, but we can establish 
that the scaffolds have less than 5 hydrogen bond donors, 10 hydrogen bond 
acceptors, and a molecular mass less than or equal to 500 g/mol. Scaffold 2103, 
a dithiazole, only has one hydrogen bond donor and four hydrogen bond 
acceptors with a molecular weight of ~252 g/mol. Scaffold 2236, a bis-cyclic 
lipopeptide, has 13 hydrogen bond donors and 21 hydrogen bond acceptors, with 
a molecular weight of ~1621 g/mol. Scaffold 2220 only has one hydrogen bond 
donor and two hydrogen bond acceptors with a molecular weight of ~86 g/mol. 
Scaffold 2160 only has one hydrogen bond donor and four hydrogen bond 
acceptors with a molecular weight of ~250 g/mol. Scaffold 2221 only has one 
hydrogen bond donor and three hydrogen bond acceptors with a molecular 
weight of ~181 g/mol. Therefore, scaffold 2236 would not be an ideal candidate 
for therapeutic intervention as it is unlikely to be absorbed, distributed, 
metabolized, or excreted efficiently according to Lipinski’s Rule of 5 [244]. 
Conversely, the other four lead scaffolds, without consideration of their side 
groups, fall well within the limits of the Rule of 5. 
Of these, scaffold 2160 reproducibly decreased PAT activity in a dose dependent 
fashion to the greatest extent. Structurally, scaffold 2160 has a core bis-cyclic 
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piperazine with three R-groups, and a total diversity of 45864 compounds (Fig. 
4.1C).   
The 45864 compounds in scaffold 2160 were synthesized into 110 mixture 
samples organized by R-group to optimize activity (Fig. 4.1C).  At position R1 
and R3 there were 42 carboxylic acids (samples 2160.001-2160.042 and 
2160.069-2160.110, respectively), and 26 amino acids at the R2 position 
(samples 2160.043-2160.068).  Thus, samples organized by R1 or R3 positions 
contain 1092 (42 x 26) compounds per sample, and samples organized by the 
R2 position contain 1764 (42 x 42) compounds per sample. 
The 110 samples were screened for inhibitory effects on Erf2 autopalmitoylation 
in the fluorescence-coupled assay at 100 μg/ml.  Most had mild to no effect on 
Erf2 autopalmitoylation as represented by a yellowish-orange color designation in 
Tables 4.1, 4.2, and 4.3.  Others resulted in a greater percent reduction of Erf2 
autopalmitoylation as represented by darker shades of green in Tables 4.1, 4.2, 
and 4.3.  A cutoff for hits was set at 25% reduction in Erf2 autopalmitoylation.  
There were six functional groups at position R1 that resulted in a greater than 
25% reduction of Erf2 autopalmitoylation (Table 4.1).  Of those, the functionalities 
from samples 2160.001, 2160.014, 2160.016, and 2160.038 were selected for 
design of individual compounds.  There were three consistent functional groups 
at the R2 position that reduced Erf2 autopalmitoylation by at least 25%; 
2160.051, 2160.065, and 2160.066 (Table 4.2).  The functionality for sample 
2160.060 was also included for design of individual compounds despite only 
resulting in a 24% decrease in Erf2 autopalmitoylation.  Three functionalities 
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were selected that resulted in a greater than 25% decrease in Erf2 
autopalmitoylation at the R3 position; 2160.082, 2160.084, and 2160.108 (Table 
4.3).  Thus, the four functionalities at position R1, four functionalities at position 
R2, and three functionalities at position R3 were combined for a total diversity of 
48 individual compounds. 
 
4.7 Individual Compounds Screened for Inhibition of Erf2 
Autopalmitoylation 
The 48 compounds were screened with five of the positional scanning samples 
(2160.066, 2160.082, 2160.001, 2160.065, and 2160.108) and the complete 
2160-scaffold sample (Fig. 4.5). Scaffold 2160 and positional scanning samples 
inhibited Erf2 autopalmitoylation consistent with prior screens and demonstrated 
that as the complexity decreased from 45864 compounds (scaffold 2160), to 
1000-2000 compounds (positional scanning), and finally, to individual 
compounds, there was a concomitant increase in the inhibition of 
autopalmitoylation (Fig. 4.5).  As an additional control, we included non-optimized 
compounds (compounds 49-54), which were designed with side groups that did 
not pass the original cutoff in the positional scanning screen.  These compounds, 
as anticipated, demonstrated poor inhibition of Erf2 autopalmitoylation in 
comparison to the compounds whose design was based on the positional 
scanning results.  From this screen the top ten compounds were selected for 
further examination; 13, 14, 19, 22, 25, 27, 28, 30, 34, 43.  The top ten 
compounds were purified, and then screened for dose responsiveness on the 
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fluorescence-based coupled assay (Fig. 4.6).  All ten purified compounds 
demonstrated a dose-responsiveness effect on Erf2 autopalmitoylation, and 
inhibited to a similar degree or better than 2-BP at the same doses.  We 
determined the inhibition constant (Ki) for the ten compounds by determining the 
rate of autopalmitoylation activity for varying amounts of inhibitor compound.  The 
autopalmitoylation inhibition constants ranged from ~63-142 µM for the ten 
compounds identified in this study, and 59 μM for 2-BP (Fig. 4.7, right panel).  
There did not appear to be a preference within the top 40 compounds for the R2 
position amongst the four possibilities; hydroxybenzyl, phenyl, and (L or D) 
naphthymethyl groups (Fig. 4.7). There were three possibilities at the R3 
position, and it was at this position that the greatest preference was observed.  2-
(4-isobutyl-phenyl)-propyl was the optimal group at this position and is present in 
seven of the top ten hits.  2-(3,5-bis-trifluoromethyl-phenyl)-ethyl is the most 
prevalent in the next 15, and the completely aliphatic functional group, 
adamantan-1-yl-methyl, is in this position for a majority of the remaining top 40 
individual compounds.  The R1 position also showed similar specificity for the 
functional groups utilized in the individual compounds.  At the R1 position, nearly 
all of the top 30 compounds have either 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl or 
2-(4-isobutyl-phenyl)-propyl, the same top two groups for the R3 position. A 
>50% reduction in Erf2 autopalmitoylation was observed for most of the 
optimized individual compounds, but only the top ten were selected for additional 
analysis. 
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To determine if the ten compounds identified in this study were inhibiting 
autopalmitoylation, and not targeting hydrolysis of the enzyme, steady-state 
autopalmitoylation was evaluated at 100 μM of each compound compared to 
100 μM 2-BP and DMF (vehicle) alone.  This was performed in a gel-based 
reaction using BODIPY®-C12-CoA [40].  The reactions were separated by SDS-
PAGE and steady-state autopalmitoylation was determined by the relative 
BODIPY® fluorophore that co-migrated with Erf2, demonstrating that Erf2 was 
acylated by BODIPY®-C12 [40].  At 100 μM, the ten compounds each resulted 
in a 50% or greater decrease in steady-state Erf2 autopalmitoylation compared to 
vehicle alone.  All of the compounds inhibited autopalmitoylation to either an 
equal or greater extent compared to 2-BP (Fig. 4.8).  Dose response curves of 
steady-state autopalmitoylation activity were examined to determine the Ki for 
each compound (Fig. 4.9).  The steady-state autopalmitoylation inhibition 
constants ranged from ~34-72 µM for the ten compounds identified in this study, 
and 79 μM for 2-BP (Fig. 4.7, right panel).  
 
4.8 The Mode of Erf2 Autopalmitoylation Inhibition by Compounds 13 
and 25 is Different than 2-BP 
We selected compounds 13 and 25 for further analysis, based on our screening 
results and criteria for inhibition.  To elucidate if these compounds are 
mechanistically different from 2-BP, we approached the analysis of the reaction 
using Michaelis-Menten kinetics by varying the amount of compound 13 (or 
compound 25) and palmitoyl-CoA.  Unfortunately, the critical micelle 
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concentration is between 40 µM and 80 µM for palmitoyl-CoA limiting the ability 
to screen concentrations of palmitoyl-CoA higher than 80 µM due to poor 
solubility [245-247].  For both compounds 13 and 25, we observed that addition 
of increasing concentrations of inhibitor compound increased the KM (palmitoyl-
CoA) of the reaction while having little effect on the Vmax, thus suggesting that 
compounds 13 and 25 act through predominantly a competitive inhibition 
mechanism (Fig. 4.10). The KM and Vmax values calculated are summarized in 
Table 4.4.  The limitation to the concentration of palmitoyl-CoA limited the 
reaction in that it is possible that the activity could increase more at higher 
substrate concentrations.  Thus, the calculated KM and Vmax values may not be 
completely accurate, and the mode of inhibition cannot be accurately determined.  
The mode of inhibition was also explored for effects on steady-state 
autopalmitoylation using the gel-based orthogonal assay.  Compound 13 exhibits 
a greater dosage response for Erf2 autopalmitoylation inhibition at lower 
BODIPY®-C12-CoA concentrations rather than at higher BODIPY®-C12-CoA 
concentrations, further supporting that compound 13 is acting competitively with 
BODIPY®-C12-CoA (Fig. 4.11). Conversely, 2-BP has been previously 
demonstrated as an uncompetitive or mixed inhibitor of Erf2 autopalmitoylation 
[147], demonstrating that compounds 13 and 25 utilize a different inhibitory 
mechanism compared to 2-BP.  Thus, we have identified a new class of 
palmitoylation inhibitors that are structurally distinct and utilize a mode of action 
different from the most used palmitoylation inhibitor, 2-BP.  
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4.9 Inhibition of Ras2-dependent Growth in a Palmitoylation-sensitive 
Saccharomyces cerevisiae Strain 
To examine the inhibition of Ras palmitoylation in vivo, we utilized a strain of S. 
cerevisiae we developed that requires Ras2 palmitoylation for viability [34]. The 
RJY1942 (palmitoylation sensitive strain) was grown in the presence (or 
absence) of our inhibitor candidates and the growth monitored every 30 min for 
24 hrs compared to an isogenic wild type control strain (RJY1941) (Fig. 4.12A).  
EC50 values were calculated using Prism 6 (GraphPad Software, San Diego, CA) 
to extrapolate the effective concentration of each inhibitor that caused a 50% 
reduction in growth. The ten compounds identified in this study have EC50 values 
ranging from 2 μM to an EC50 value of 7.5 μM in the sensitive strain, compared 
to 12.5 μM for 2-BP in the sensitive strain (Fig. 4.12B).  These data demonstrate 
that a) these compounds are able to permeate the yeast cell wall to exert their 
effects and b) these compounds inhibit at a lower concentration than that of 2-
BP.  Compounds 13, 25, and 2-BP show a modest selectivity for the sensitive 
strain, RJY1942, over the control strain, RJY1941, resulting in a 2-fold greater 
EC50 value in the control strain as compared to the sensitive strain (Fig. 4.12B, 
values listed in Fig. 4.7, right panel). 
We next compared the ability of Compounds 13, 14, 25 to inhibit growth of the 
Ras-dependent palmitoylation strain compared to an isogenic wild type strain. 
Serial dilutions of RJY1941 (control) and RJY1942 (sensitized) were spotted on 
agar plates following incubation for 24 hrs with varying inhibitor concentrations. 
Compounds 13, 25, and 14 completely inhibited growth of RJY1941 (control) at 
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20 µM, but had no detectable effect at lower concentrations.  Conversely, 
compound 13 inhibited (100%) the growth of the sensitized strain at 5 µM.  
Compound 25 also inhibited at 5 μM, albeit at approximately 90% of that 
observed for compound 13 for the sensitized strain.  Compound 14 demonstrated 
partial inhibition (approximately 10%) at 5 µM, however, total inhibition could be 
observed for the sensitized strain at higher inhibitor concentrations. 2-BP did not 
inhibit at the dose range screened, most likely due to poor permeability of 2-BP in 
yeast (Fig. 4.13).  The remaining compounds were similarly selective to 
compounds 13, 14, and 25, with the exception of compound 19.  Compound 19 
partially inhibited (approximately 25%) the growth of RJY1941 (control) at 20 μ
M, but also only partially inhibited (approximately 10%) the growth of RJY1942 
(sensitized) at 20 μM, suggesting a mild selection for sensitized over control, but 
not to the same degree as the other compounds.  Interestingly, Compounds 13, 
14, and 25 have the same functional group at the R2 position, but differ at their 
R1 and R3 positions.  Compound 13 has 2-(4-Isobutyl-phenyl)-propyl on both the 
R1 and R3 positions.  Compound 14 has the same functional group on position 
R1, but has 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl on the R3 position.  
Compound 25 has the same functional groups as Compound 14, but has 2-(3,5-
bis-trifluoromethyl-phenyl)-ethyl on the R1 position, and 2-(4-Isobutyl-phenyl)-
propyl on the R3 position (Fig. 4.7).  Further SAR studies and compound design 
will be necessary to increase the sensitivity and selectivity of these compounds. 
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4.10 Discussion 
Protein palmitoylation is a posttranslational modification that regulates the 
subcellular localization and activity of a diverse set of signaling and structural 
proteins.  Dysregulation of protein palmitoylation has been linked to a number of 
diseases.  Examples include up-regulation of zDHHC9 in colorectal cancer [90] 
and down-regulation of zDHHC9 in leukemogenesis [248]; zDHHC3/GODZ is 
linked to cervical cancer [125]; and zDHHC2 mutations have been found in 
several colorectal cancers [84].  The importance of palmitoylation in physiology 
and pathophysiology suggests that modulators of catalyzed palmitoyl transfer 
may play a role in disease treatment.  The availability of protein acyl transferase 
(PAT) inhibitors is very limited.  2-Bromo-palmitate (2-BP), cerulenin, and 
tunicamycin have been reported to inhibit palmitoylation [201, 203, 223, 249], but 
2-BP is now known to be highly promiscuous, with no preference for CoA-
dependent enzymes, including zDHHC PATs [206].  Similarly, cerulenin and 
tunicamycin inhibit palmitoylation within cells but also inhibit other cellular 
process including fatty acid synthesis [250] and N-glycosylation [251], 
respectively.  In addition, there are few assays available that can measure 
palmitoylation [147, 149] in a high throughput platform.  There is therefore an 
urgent need to establish methods to identify small molecule PAT inhibitors for 
use in vitro and in vivo.   
The current failure to find the desired high affinity, specific inhibitors is due to 
difficulties purifying biochemical quantities of PATs, limited information on the 
enzymatic mechanism, and the lack of a 3D crystal structure.  We have 
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developed methods to purify stable, active zDHHC PATs, along with a validated 
HTS method to identify inhibitors.  We have approached the search for chemical 
modulators of PAT enzymes by developing several innovative protocols.  First, 
we have developed a system for the expression and purification of the zDHHC 
proteins. Secondly, we have developed and validated a simple, coupled 
fluorescence assay that allows us to screen for inhibitors of enzyme 
autopalmitoylation in an HTS platform.  Thirdly, we have developed counter 
screens, orthogonal and cell-based assays, to characterize and analyze 
candidate inhibitors.  With these tools in hand we are able to identify compounds 
that regulate Erf2 and establish a methodology to identify modulators of other 
zDHHC PATs as well.  
Through the use of a scaffold ranking approach to screen for novel inhibitors of 
Erf2 autopalmitoylation, we have identified a group of inhibitors based on the bis-
cyclic piperazine backbone. This is the first time piperazines have been shown to 
modulate palmitoylation, but their analogues have already been demonstrated to 
be effective drug-like compounds. Piperazine analogs are currently being used 
as pharmaceutical modulators of GPCR activity and piperazine-like compounds 
and analogs are currently being used as pharmaceuticals to treat cancer, 
behavioral disorders, and insomnia (e.g.,imatinib, quetiapine, and eszopiclone) 
[252-254].  It has not yet been determined if the compounds identified in this 
study inhibit Erf2 specifically.  They could be pan-palmitoylation inhibitors that 
alter the activity of other zDHHC PATs, but they could also lack in specificity like 
2-BP.  As they were identified in a purified system and lack sequence similarity to 
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palmitoyl-CoA, it is predicted that they will not suffer the same degree of a lack in 
specificity as 2-BP, but it has yet to be established if they modulate other zDHHC 
PATs.  To further explore their specificity for use as modulators of palmitoylation, 
there is ongoing work to address any inhibitor:enzyme specificity issues by 
establishing if the inhibitors identified in this study act specifically on Erf2-
dependent palmitoylation, or if they act on one or more of the other PAT 
enzymes.  Further screens in the fluorescent-based couple assay with other 
zDHHC PATs will be needed to validate these compounds as pan inhibitors of 
palmitoylation, which could still be used as probes to further understand the field 
of palmitoylation and would be beneficial over 2-BP due to the extent of non-
specific inhibition that occurs with the use of 2-BP.  If it is found that these 
compounds are specific inhibitors of Erf2 and its human homolog, zDHHC9, then 
they could lead to anti-cancer drug therapy interventions.  Understanding how 
the different functional groups lend to their activity and specificity is key to further 
optimize these compounds.  The compounds best align with the Ki and EC50 
values from the respective screens when they were organized by the R3 position 
with consideration of the R1 and R2 positions (Fig. 4.7).  Of the functionalities 
used at the R1 and R3 positions both 2-(4-Isobutyl-phenyl)-propyl and 2-(3,5-bis-
trifluoromethyl-phenyl)-ethyl seemed to be the most preferential for both 
positions.  This, along with the apparent symmetry of bis-piperazine, suggests 
that perhaps these compounds can act as symmetrical entities.  The lack of 
preference, other than for an aromatic group, in the R2 position supports this 
notion. Overall, we have identified a novel class of bis-cyclic piperazines that 
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inhibit Erf2 autopalmitoylation to a greater extent than 2-BP in our fluorescence-
based coupled assay, orthogonal gel-based assay and cell growth assay by 
selectively inhibit palmitoylation in vitro at low μM concentrations and reducing 
the Ras2 palmitoylation-dependent growth rate of S. cerevisiae in vivo.   
 
4.11 Experimental Procedures 
Synthesis of Library 2160 and Individual Compounds and Construction of 
Scaffold Ranking Plate-  General Synthesis of bis-cyclic piperazine (Fig. 4.14):  
Library 2160 as well as the individual compounds reported herein (Compounds 
1-54) were synthesized following the same synthetic scheme (Fig. 4.14) [255, 
256].  Utilizing the “tea-bag” methodology [257], 100 mg of p-
methylbenzhydrylamine (MBHA) resin (1.1 mmol/g, 100-200 mesh) was sealed in 
a mesh “tea-bag”, neutralized with 5% diisopropylethylamine (DIEA) in 
dichloromethane (DCM) and subsequently swelled with additional DCM washes.  
Fmoc-L-Lys(Boc)-OH was coupled in Dimethylformamide (0.1M DMF) for 120 
mins in the presence of Diisopropylcarbodiimide (DIC, 6 equiv.) and 1-
Hydroxybenzotriazole hydrate (HOBt, 6 equiv.) (Fig. 4.14, Step 1).  The Fmoc 
protecting group was removed with 20% piperidine in DMF for 20 mins and the 
R1 carboxylic acids was coupled (10 equiv.) in the presence of DIC (10 equiv.) 
and HOBt (10 equiv.) in DMF (0.1 M) for 120 mins (Fig. 4.14, Step 2).  The Boc 
protecting group was then removed with Trifluoroacetic Acid (TFA) in DCM for 30 
mins and subsequently neutralized with 5% DIEA/DCM (3x).  Boc-Amino Acids 
(R2) were coupled utilizing standard coupling procedures (6 equiv.) with DIC (6 
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equiv.) and HOBt (6 equiv.) in DMF (0.1 M) for 120 mins.  The Boc group was 
removed with 55% TFA/DCM for 30 mins and subsequently neutralized with 5% 
DIEA/DCM (3x).   Carboxylic acids (R3) were coupled using (10 equiv.) in the 
presence of DIC (10 equiv.) and HOBt (10 equiv.) in DMF (0.1 M) for 120 mins 
(Fig. 4.14, Step 3). All coupling reactions were monitored for completion using 
Ninhydrin.  The reduction was performed in a 4000 mL Wilmad LabGlass vessel 
under nitrogen.  1.0 M Tetrahydrofuran (THF) borane complex solution was used 
in 40-fold excess for each amide bond.  The vessel was heated to 65°C and 
maintained at this temperature for 96 hrs.  The solution was then removed and 
the bags were washed with THF and methanol (MeOH).  Once completely dry, 
the bags were treated overnight with piperidine at 65°C and washed several 
times with DMF, DCM and methanol (Fig. 4.14, Step 4).  As previously reported 
by our group and others, the reduction of polyamides with borane is free of 
racemization [258-260].  Before proceeding, completion of reduction was 
monitored by LCMS analysis of a control compound (Fig. 4.14, Step 4) that was 
cleaved from the solid support (HF, anisole, 0°C 7 hr).  Cyclization was 
performed with a 5-fold excess (for each cyclization) of oxalyldiimidazole in a 0.1 
M anhydrous DMF solution overnight.  Following the cyclization, the bags were 
rinsed with DMF and DCM and the resulting diketopiperarzines were reduced 
down to their corresponding piperazines (Fig. 4.14, Step 5) using the same 
borane reduction procedure as above.  The resin was cleaved with HF in the 
presence of anisole in an ice bath at 0°C for 7 hours (Fig. 4.14, Step 6).  After 
removal of the HF by gaseous N2, the products were then extracted from the 
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vessels with 95% acetic acid in water, transferred to scintillation vials, frozen and 
lyophilized.  The compounds were then reconstituted in 50% acetonitrile and 
water, frozen and lyophilized three more times.  For initial screening (Fig. 4.4) the 
individual compounds were tested as crude material in case the activity is driven 
by some side reaction that was also present in the original positional scanning 
library.  After this initial screening, compounds, 13, 14, 19, 22, 25, 27, 28, 30, 34, 
and 43 were selected for purification and NMR characterization; all data reported 
in Figures 4.6-4.9 are from the purified stock of these compounds.   
LCMS analysis-  The purity and identity of all compounds was verified using a 
Shimadzu 2010 LCMS system, consisting of a LC-20AD binary solvent pump, a 
DGU-20A degasser unit, a CTO-20A column oven, and a SIL-20A HT 
autosampler. A Shimadzu SPD-M20A diode array detector was used for 
detection. A full spectra range of 190-600 nm was obtained during analysis. 
Chromatographic separations were obtained using a Phenomenex Luna C18 
analytical column (5 µm, 50 x 4.6 mm i.d.) preceded by a Phenomenex C18 
column guard (5 µm, 4 x 3.0 mm i.d.). All equipment was controlled and 
integrated by Shimadzu LCMS solutions software version 3.  Mobile phases for 
LCMS analysis were HPLC grade or LCMS grade obtained from Sigma Aldrich 
and Fisher Scientific. The mobile phases consisted of a mixture LCMS grade 
Acetonitrile /water (both with 0.1% formic acid for a pH of 2.7).  The initial setting 
for analysis was set at 5% Acetonitrile (v/v), then was linearly increased to 95% 
Acetonitrile over 6 mins. The gradient was then held at 95% Acetonitrile for 2 
mins, linearly decreased to 5% over 0.10 mins and held for an additional 1.90 
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mins. The total run time was equal to 12 mins. The total flow rate was set to 0.5 
mL/minute. The column oven and flow cell temperature for the diode array 
detector was set at 30°C. The autosampler temperature was held at 15°C. 5 μl 
of compound was injected for analysis.   
HPLC Purification (Compounds 13, 14, 19, 22, 25, 27, 28, 30, 34, and 43)-  All 
purifications were performed on a Shimadzu Prominence preparative HPLC 
system, consisting of LC-8A binary solvent pump, a SCL-10A system controller, 
a SIL-10AP autosampler, and a FRC-10A fraction collector. A Shimadzu SPD-
20A UV detector was used for detection. The wavelength was set at 214 nm 
during analysis. Chromatographic separations were obtained using a 
Phenomenex Luna C18 preparative column (5 µm, 150 x 21.5 mm i.d.) preceded 
by a Phenomenex C18 column guard (5 µm, 15 x 21.2 mm i.d.). Prominence 
prep software was used to set all detection and collection parameters. The 
mobile phases for HPLC purification were HPLC grade obtained from Sigma 
Aldrich and Fisher Scientific. The mobile phase consisted of a mixture of 
Acetonitrile/water (both with 0.1% formic acid). The initial setting for separation 
was set at 2% (v/v) Acetonitrile, which was held for 2 mins and the gradient was 
linearly increased to 20% (v/v) Acetonitrile over 4 mins. The gradient was then 
linearly increased to 55% (v/v) Acetonitrile over 36 mins. The HPLC system was 
set to automatically flush and re-equilibrate the column after each run for a total 
of 4 column volumes. The total flow rate was set to 12 mL/min and the total 
injection volume was set to 3900 μl. The fraction collector was set to collect from 
6 to 40 mins. The corresponding fractions were then combined and lyophilized. 
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NMR analysis of purified compounds-  The 1H spectra were obtained utilizing the 
Bruker 400 Ascend (400 MHz).  NMR chemical shifts were reported in δ (ppm) 
using the δ 7.26 signal of CDCl3 (1H NMR). 
4-(((2S)-1-(2-(4-isobutylphenyl)propyl)-4-(4-((2S)-1-(2-(4-
isobutylphenyl)propyl)piperazin-2-yl)butyl)piperazin-2-yl)methyl)phenol 
(Compound 13)-  Using the synthetic approach described in Figure 4.14 for the 
synthesis of  compound 13 was synthesized using the following reagents: 4-
Isobutyl-alpha-methylphenylacetic acid (R1), Boc-L-Tyrosine(BrZ) (R2), 4-
Isobutyl-alpha-methylphenylacetic acid (R3).  Final crude product was purified by 
HPLC as described above. 1H NMR (400 MHz, CHLOROFORM-d): δ  ppm 7.28 
(br. s., 1 H) 7.08 - 7.16 (m, 4 H) 7.05 (br. s., 4 H) 6.92 (br. s., 2 H) 6.80 (br. s., 3 
H) 2.98 (br. s., 8 H) 2.64 - 2.84 (m, 5 H) 2.58 (br. s., 4 H) 2.45 (t, J=8.01 Hz, 6 H) 
2.32 (d, J=16.26 Hz, 2 H) 2.01 (br. s., 1 H) 1.86 (d, J=6.60 Hz, 2 H) 1.52 (br. s., 1 
H) 1.42 (br. s., 1 H) 1.36 (br. s., 1 H) 1.30 (br. s., 3 H) 1.12 - 1.26 (m, 4 H) 1.01 
(br. s., 1 H) 0.91 (br. s., 12 H). LCMS (ESI+) Calcd for C45H68N4O: 681.54, 
found [M+H]+:681.25.  
4-(((2S)-1-(3,5-bis(trifluoromethyl)phenethyl)-4-(4-((2S)-1-(2-(4-
isobutylphenyl)propyl)piperazin-2-yl)butyl)piperazin-2-yl)methyl)phenol 
(Compound 14)-  Using the synthetic approach described in Figure 4.14 for the 
synthesis of  compound 14 was synthesized using the following reagents: 4-
Isobutyl-alpha-methylphenylacetic acid (R1), Boc-L-Tyrosine(BrZ) (R2), 3,5-
Bis(Trifluoromethyl)-Phenylacetic Acid (R3). Final crude product was purified by 
HPLC as described above. 1H NMR (400 MHz, CHLOROFORM-d): δ ppm 7.75 
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(br. s., 1 H) 7.65 (br. s., 3 H) 7.28 (s, 1 H) 7.00 - 7.08 (m, 4 H) 6.95 (br. s., 2 H) 
6.81 (br. s., 3 H) 3.07 (br. s., 5 H) 2.93 (br. s., 5 H) 2.76 (br. s., 4 H) 2.65 (br. s., 4 
H) 2.43 (d, J=6.36 Hz, 4 H) 2.36 (br. s., 2 H) 2.19 (br. s., 1 H) 2.01 (br. s., 1 H) 
1.84 (br. s., 1 H) 1.47 (br. s., 2 H) 1.39 (br. s., 1 H) 1.27 (br. s., 1 H) 1.22 (br. s., 3 
H) 1.05 (br. s., 1 H) 0.90 (d, J=5.50 Hz, 6 H). LCMS (ESI+) Calcd for 
C42H56F6N4O: 747.44, found [M+H]+:747.20.  
(2S)-1-(2-(4-isobutylphenyl)propyl)-4-(4-((2S)-1-(2-(4-
isobutylphenyl)propyl)piperazin-2-yl)butyl)-2-(naphthalen-2-ylmethyl)piperazine 
(Compound 19)-  Using the synthetic approach described in Figure 4.14 for the 
synthesis of  compound 19 was synthesized using the following reagents: 4-
Isobutyl-alpha-methylphenylacetic acid (R1), Boc-3-(2-naphthyl)-L-alanine (R2), 
4-Isobutyl-alpha-methylphenylacetic acid (R3).  Final crude product was purified 
by HPLC as described above. 1H NMR (400 MHz, CHLOROFORM-d): δ ppm 
7.78 (d, J=9.05 Hz, 3 H) 7.61 (br. s., 1 H) 7.44 (br. s., 2 H) 7.29 (br. s., 1 H) 6.99 - 
7.20 (m, 7 H) 4.16 (br. s., 1 H) 3.09 - 3.34 (m, 1 H) 3.00 (d, J=12.59 Hz, 3 H) 2.91 
(br. s., 2 H) 2.84 (br. s., 2 H) 2.78 (br.s., 2 H) 2.58 (d, J=12.84 Hz, 2 H) 2.45 (dd, 
J=15.89, 6.72 Hz, 7 H) 2.28 (br. s., 3 H) 2.20 (br. s., 2 H) 1.97 (br. s., 1 H) 1.86 
(dd, J=13.08, 6.85Hz, 2 H) 1.60 (br. s., 1 H) 1.18 - 1.46 (m, 9 H) 1.15 (br. s., 2 H) 
0.70 - 0.95 (m, 12 H). LCMS (ESI+) Calcd for C49H70N4: 715.56, found 
[M+H]+:715.30.  
(2R)-1-(2-(4-isobutylphenyl)propyl)-4-(4-((2S)-1-(2-(4-
isobutylphenyl)propyl)piperazin-2-yl)butyl)-2-(naphthalen-2-ylmethyl)piperazine 
(Compound 22)-  Using the synthetic approach described in Figure 4.14 for the 
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synthesis of  compound 22 was synthesized using the following reagents: 4-
Isobutyl-alpha-methylphenylacetic acid (R1), Boc-L-Tyrosine(BrZ) (R2), 4-
Isobutyl-alpha-methylphenylacetic acid (R3).  Final crude product was purified by 
HPLC as described above. 1H NMR (400 MHz, CHLOROFORM-d): δ ppm 7.71 
- 7.85 (m, 3 H) 7.60 (br. s., 1 H) 7.44 (br. s., 2 H) 7.28 - 7.35 (m, 1 H) 7.01 - 7.26 
(m, 8 H) 3.19 (d, J=10.15 Hz, 1 H) 2.94 - 3.07 (m, 3 H) 2.89 (d, J=9.66 Hz, 3 H) 
2.82 (br. s., 3 H) 2.60 - 2.74 (m, 2 H) 2.55 (br. s., 1 H) 2.24 - 2.50 (m, 10 H) 2.19 
(br. s., 2 H) 1.97 (br. s., 1 H) 1.74 - 1.92 (m, 2 H) 1.34 (d, J=8.68 Hz, 7 H) 1.22 
(br. s., 3 H) 1.13 (br. s., 2 H) 0.91 (br. s., 13 H). LCMS (ESI+) Calcd for 
C49H70N4: 715.56, found [M+H]+:715.20.  
4-(((2S)-4-(4-((S)-1-(3,5-bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)-1-(2-
(4-isobutylphenyl)propyl)piperazin-2-yl)methyl)phenol (Compound 25)-  Using the 
synthetic approach described in Figure 4.14 for the synthesis of  compound 25 
was synthesized using the following reagents: 3,5-Bis(Trifluoromethyl)-
Phenylacetic Acid (R1), Boc-L-Tyrosine(BrZ) (R2), 4-Isobutyl-alpha-
methylphenylacetic acid (R3).  Final crude product was purified by HPLC as 
described above. 1H NMR (400 MHz, CHLOROFORM-d): δ ppm 7.74 (br. s., 2 
H) 7.62 (br. s.,1 H) 7.29 (s, 2 H) 7.07 - 7.26 (m, 4 H) 6.93 (s, 1 H) 6.96 (s, 1 H) 
6.82 (d, J=6.97 Hz, 2 H) 3.19 (br. s., 2 H) 3.10 (br. s., 2 H) 3.00 (br. s., 5 H)  2.84 
(br. s., 5 H) 2.70 (br. s., 4 H) 2.62 (br. s., 3 H) 2.46 (d, J=6.60 Hz, 3 H) 2.19 (br. 
s., 1 H) 2.02 (br. s., 1 H) 1.86 (br. s., 1 H) 1.56 (br. s., 1 H) 1.43 (br. s., 2H) 1.30 
(br. s., 3 H) 1.17 (d, J=6.24 Hz, 1 H) 1.10 (br. s., 2 H) 0.91 (d, J=6.11 Hz, 6 H). 
LCMS (ESI+) Calcd for C42H56F6N4O: 747.44, found [M+H]+:747.10.  
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4-(((S)-1-(adamantan-1-ylmethyl)-4-(4-((S)-1-(3,5-
bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)piperazin-2-yl)methyl)phenol   
(Compound 27)-  Using the synthetic approach described in Figure 4.14 for the 
synthesis of  compound 27 was synthesized using the following reagents: 3,5-
Bis(Trifluoromethyl)-Phenylacetic Acid (R1), Boc-L-Tyrosine(BrZ) (R2), 1-
Adamantanecarboxylic Acid (R3).  Final crude product was purified by HPLC as 
described above. 1H NMR (400 MHz, CHLOROFORM-d): δ ppm 8.44 (br. s., 
1H) 8.05 (br. s., 1 H) 7.96 (br. s., 1 H) 7.83 (br. s., 1 H) 7.73 (br. s., 1 H) 7.63 (br. 
s., 2 H) 7.28 (s, 1 H) 7.00 (br. s., 2 H) 6.83 (d,J=6.48 Hz, 2 H) 3.17 (br. s., 1 H) 
2.91 - 3.13 (m, 5 H) 2.84 (br. s., 5 H) 2.54 - 2.77 (m, 7 H) 2.40 (br. s., 2 H) 2.10 
(br. s., 1 H) 1.99 (d, J=6.36 Hz, 4 H) 1.69 - 1.85 (m, 3 H) 1.64 (d, J=11.37 Hz, 4 
H) 1.50 (br. s., 8 H) 1.28 (br. s., 1 H) 1.13 (br. s., 2 H). LCMS (ESI+) Calcd for 
C40H54F6N4O: 721.42, found [M+H]+:721.15.  
(2S)-4-(4-((S)-1-(3,5-bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)-1-(2-(4-
isobutylphenyl)propyl)-2-phenylpiperazine (Compound 28)-  Using the synthetic 
approach described in Figure 4.14 for the synthesis of  compound 28 was 
synthesized using the following reagents: 3,5-Bis(Trifluoromethyl)-Phenylacetic 
Acid (R1), Boc-L-Phenylglycine (R2), 4-Isobutyl-alpha-methylphenylacetic acid 
(R3).  Final crude product was purified by HPLC as described above. 1H NMR 
(400 MHz, CHLOROFORM-d): δ ppm 7.74 (br. s., 1 H) 7.65 (br. s., 2 H) 7.28 - 
7.40 (m, 2 H) 7.12 - 7.26 (m, 2 H) 6.85 - 7.07 (m, 5 H) 3.43 - 3.66 (m, 1 H) 3.36 
(br. s., 1 H) 3.30 (d, J=7.58 Hz, 1 H) 3.22 (d, J=11.37 Hz, 1 H) 3.15 (br. s., 1 H) 
3.02 (br. s., 2 H) 2.83 - 2.96 (m, 6 H) 2.78 (d, J=11.37 Hz, 1 H) 2.53 - 2.72 (m, 2 
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H) 2.36 - 2.52 (m, 4 H) 2.26 - 2.36 (m, 3 H) 2.21 (br. s., 1 H) 1.98 - 2.16 (m, 2 H) 
1.76 - 1.96 (m, 2 H) 1.48 (br. s., 3 H) 1.36 (br. s., 1 H) 1.27 (br. s., 1 H) 1.20 (d, 
J=6.24 Hz, 2 H) 1.08 (d, J=6.24 Hz, 2 H) 0.96 (d, J=5.99 Hz, 3 H) 0.88 (d, J=6.11 
Hz, 3 H). LCMS (ESI+) Calcd for C41H54F6N4: 717.43, found [M+H]+:17.15.  
(S)-1-(adamantan-1-ylmethyl)-4-(4-((S)-1-(3,5-
bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)-2-phenylpiperazine (Compound 
30)-  Using the synthetic approach described in Figure 4.14 for the synthesis of  
compound 30 was synthesized using the following reagents: 3,5-
Bis(Trifluoromethyl)-Phenylacetic Acid (R1), Boc-L-Phenylglycine (R2), 1-
Adamantanecarboxylic Acid (R3).  Final crude product was purified by HPLC as 
described above. 1H NMR (400 MHz, CHLOROFORM-d): δ ppm 7.74 (br. s., 1 
H) 7.66 (br. s., 2 H) 7.35 (br. s., 2 H) 7.28 - 7.32 (m, 2 H) 3.49 - 3.76 (m, 3 H) 
3.34 - 3.49 (m, 1 H) 3.15 - 3.33 (m, 2 H) 3.03 (d, J=10.64 Hz, 2 H) 2.78 - 2.96 (m, 
6 H) 2.59 - 2.73 (m, 2 H) 2.48 - 2.58 (m, 1 H) 2.45 (br. s., 1 H) 2.28 - 2.43 (m, 4 
H) 2.20 (t, J=9.90 Hz, 1 H) 2.10 (d, J=13.57 Hz, 1 H) 2.01 (br. s., 1 H) 1.87 (br. 
s., 3 H) 1.71 (br. s., 1 H) 1.64 (d, J=11.98 Hz, 3 H) 1.55 (d, J=12.10 Hz, 4 H) 1.35 
- 1.51 (m, 6 H) 1.25 (s, 3 H) 1.23 (s, 2 H). LCMS (ESI+) Calcd for C39H52F6N4: 
691.41, found [M+H]+:691.10.  
(2R)-4-(4-((S)-1-(3,5-bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)-1-(2-(4-
isobutylphenyl)propyl)-2-(naphthalen-2-ylmethyl)piperazine (Compound 34)-  
Using the synthetic approach described in Figure 4.14 for the synthesis of  
compound 34 was synthesized using the following reagents: 3,5-
Bis(Trifluoromethyl)-Phenylacetic Acid (R1), Boc-3-(2-naphthyl)-D-alanine (R2), 
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4-Isobutyl-alpha-methylphenylacetic acid (R3).  Final crude product was purified 
by HPLC as described above. 1H NMR (400 MHz, CHLOROFORM-d): δ ppm 
7.71 - 7.82 (m, 4 H) 7.59 (s, 1 H) 7.63 (s, 2 H) 7.43 (br. s., 2 H) 7.28 (br. s., 1 H) 
7.07 - 7.20 (m, 4 H) 3.54 (br. s., 2 H) 3.33 (br. s., 1 H) 3.19 (d, J=10.64 Hz, 1 H) 
3.01 (br. s., 3 H) 2.89 (br. s., 4 H) 2.83 (br. s., 4 H) 2.61 (br. s., 2 H) 2.56 (br. s., 2 
H) 2.40 - 2.52 (m, 5 H) 2.36 (br. s., 1 H) 2.26 (br. s., 1 H) 2.19 (br. s., 2 H) 1.88 
(d, J=5.99 Hz, 1 H) 1.39 (br. s., 3 H) 1.27 - 1.37 (m, 4 H) 1.23 (br. s., 1 H) 1.16 
(br. s., 1 H) 0.92 (br. s., 6 H). LCMS (ESI+) Calcd for C46H58F6N4: 781.46, 
found [M+H]+:781.15.  
(2S)-4-(4-((S)-1-((4-(tert-butyl)cyclohexyl)methyl)piperazin-2-yl)butyl)-1-(2-(4-
isobutylphenyl)propyl)-2-(naphthalen-2-ylmethyl)piperazine (Compound 43)-  
Using the synthetic approach described in Figure 4.14 for the synthesis of  
compound 43 was synthesized using the following reagents: 4-tert-Butyl-
Cyclohexanecarboxylic Acid (R1), Boc-3-(2-naphthyl)-L-alanine (R2), 4-Isobutyl-
alpha-methylphenylacetic acid (R3).  Final crude product was purified by HPLC 
as described above. 1H NMR (400 MHz, CHLOROFORM-d): δ ppm 7.71 - 7.84 
(m, 3 H) 7.60 (br. s., 1 H) 7.45 (br. s., 2 H) 7.29 (br. s., 1 H) 7.02 - 7.26 (m, 4 H) 
3.18 (d, J=9.54 Hz, 1 H) 3.04 (br. s., 2 H) 2.97 (br. s., 2 H) 2.91 (br. s., 3 H) 2.83 
(br. s., 1 H) 2.73 (d, J=9.54 Hz, 2 H) 2.52 - 2.67 (m, 2 H) 2.48 (br. s., 3 H) 2.41 
(br. s., 2 H) 2.31 (br. s., 2 H) 2.22 (br. s., 2 H) 1.91 - 2.09 (m, 2 H) 1.88 (d, J=7.34 
Hz, 1 H) 1.75 (d, J=13.94 Hz, 2 H) 1.60 (d, J=13.20 Hz, 1 H) 1.50 (br. s., 3 H) 
1.43 (br. s., 3 H) 1.26 - 1.38 (m, 5 H) 1.21 (br. s., 2 H) 0.89 - 1.06 (m, 9 H) 0.65 - 
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0.89 (m, 10 H). LCMS (ESI+) Calcd for C47H72N4: 694.58, found 
[M+H]+:694.40.  
Strains, media, and yeast techniques-  Yeast growth media were prepared as 
described previously [207].  Cells were grown in synthetic complete (SC) medium 
or YPD (1% yeast extract, 2% peptone, and 2% glucose) medium [207].  
Induction of GAL1, 10 promoters were achieved by adding 4% galactose to SC 
medium.  Yeast transformations were performed using the lithium acetate 
procedure [209]. Three yeast strains were used for this study: RJY1941 (S288C) 
MATα  leu2-3,112 ura3-52 ade2 ade8 lys2 ras1::HIS3 Ras2(CS-ext) erf2Δ
::KANr erg6Δ::TRP1 [YCp52-RAS2], RJY1942 (S288C) MATα leu2-3,112 ura3-
52 ade2 ade8 lys2 ras1::HIS3 Ras2(CS-ext) erf2Δ::KANr erg6Δ::TRP1 [YCp52] 
and RJY1842 (MATa/α ade2-1/ade2-1 leu2-3,112/leu2-3,112 ura3-52/ura3-52 
trp1-1/trp1-1 his3-11,15/his3-11,15 can1-100/can1-100 GAL+/GAL+ psi+/psi+ erf4
Δ::NATr/erf4Δ::NATr [34].  
Protein purification-  Strain RJY1842 was transformed with pESC(-Leu)-6xHIS-
Erf2-(Flag)-Erf4 and grown in SC(-Leu) medium containing 2% (v/v) ethanol/ 2% 
(v/v) glycerol at 30˚C with shaking and grown to 2 x 107 cells/ml.  50 mls (1x109 
cells) were added to 1 liter of YEP medium supplemented with 4% galactose for 
induction.  Cells were induced with shaking (230 RPM) for 18h (30˚C) and then 
harvested by centrifugation at 3000xg for 15 mins. The resulting pellet was 
resuspended in breaking buffer (50mM Tris-Cl pH 8, 500ml NaCl, 1mM EDTA, 
1mM DTT, 1xPIC, 8µl/ml saturated PMSF/isopropyl alcohol), and the cells were 
lysed using glass beads (400-600 mesh, Sigma) for 40 mins with 1 min pulses (1 
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minute cooling).  The resulting extract was spun at 3000xg for 15 mins to remove 
cellular debris and unbroken cells, followed by a crude membrane fraction (P13) 
by centrifugation (13,000xg) for 0.5 hours at 4˚C.   The supernatant was 
discarded and the pellet was resuspended in Tris buffered saline, pH 8, with the 
aid of a Dounce homogenizer.  The resulting extract was adjusted to a final 
concentration of 1% Triton-X100.  To solubilize the membranes, the extract was 
incubated at 4˚C (1.5h).  Insoluble material was then removed by centrifugation 
(13,000xg) for 0.5 hours at 4˚C.  The supernatant was incubated with Ni-NTA 
resin at 4˚C for 1h.  The resin was washed 3x with Solution W (50mM Tris-HCl, 
pH 8, 150mM NaCl and 1% Triton-X100). The protein was eluted with 50mM 
Tris-HCl, pH8, 150mM NaCl, 1% Triton-X100, 5% glycerol and 250mM 
imidazole.  Eluates were desalted and concentrated using  (50mM Tris-Cl, pH 8, 
150mM NaCl, 1% Triton-X100 and 5% glycerol.  Fractions containing 6xHis-
Erf2/FLAG-Erf4 were pooled to obtain approximately 0.2 mg of purified Ras PAT 
per liter of culture as determined by SDS-PAGE against a standard curve of 
bovine serum albumin.  The complexes were divided into 50µL aliquots and 
frozen at -80˚C until use. 
Coupled PAT Assay-  The HTS of protein palmitoylation was recently described 
[147], but was adjusted for this study.  The production of NADH was monitored 
with a Biotek Mx fluorimeter (Biotek, Winooski, VT) using 340 nm excitation/ 465 
nm emission.  The 50 µl reaction contained 2 mM 2-Oxoglutarate (α -
ketoglutamic acid), 0.25 mM NAD+, 0.2mM Thiamine Pyrophosphate, 0.5 µg of 
purified 6xHIS-Erf2/FLAG-Erf4, 1 mM EDTA, 1 mM dithiothreitol, 32 mU 2-
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oxogluarate dehydrogenase (α-ketoglutarate dehydrogenase), 50 mM sodium 
phosphate, pH 6.8, and 0 - 100 µM inhibitor in 5% DMF.  The reaction was 
initiated by the addition of 40 μM palmitoyl-CoA and monitored for 30 mins at 
30˚C.  The first 10mins of the reaction was analyzed to determine the initial rates 
of CoASH release.  The PAT specific activity was determined from a standard 
curve of NADH production with different CoASH amounts.  In these reactions, 
CoASH was added to the standard PAT reaction mixture (without Erf2-Erf4 
complex or palmitoyl-CoA) and the reaction was allowed to proceed to 
equilibrium before fluorescence was measured.  
Scaffold Ranking Library-  The scaffold ranking library contains one sample for 
each of the 68 positional scanning libraries tested.  Each of these samples 
contains an approximate equal molar amount of each compound in that library.  
So, for example, the sample 2160 in the scaffold ranking library contains 45,864 
compounds in approximately equal molar amounts.  These samples can be 
prepared by mixing the cleaved products of the complete positional scanning 
library, as was the case for sample 2160, or they can be synthesized directly as a 
single mixture [236, 261]. 
Positional Scanning Library 2160-  Positional scanning library 2160 was 
synthesized using the general Figure 4.14.  The positional scanning library 
incorporates both individual and mixtures of amino acids (R2) and carboxylic acid 
(R1 and R3).  The synthetic technique facilitates the generation of information 
regarding the likely activity of individual compounds from the screening of the 
library [235, 262, 263].  Equimolar isokinetic ratios have been previously 
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determined and calculated for each of the amino and carboxylic acids utilized for 
the respective mixtures [261, 264].  The bis-piperazine library 2160 has a total 
diversity of 45,864 compounds (42x26x42=45,864).  The R1 and R3 positions as 
shown in Figure 4.1 each consist of 42 carboxylic acids and the R2 contains 26 
amino acids.  
BODIPY®-C12:0 Autopalmitoylation Assay-  BODIPY®-C12:0-CoA (40 µM final, 
unless specified otherwise) was added to a 50 µl reaction containing 
approximately 0.5 µg enzyme (6xHIS-Erf2/FLAG-Erf4) and 100 µM inhibitors in 
5% DMF in 50mM sodium phosphate buffer, pH 6.8.  The reactions were 
incubated 10 min with inhibitor, and then the reaction was initiated with the 
addition of BODIPY®-C12:0-CoA, and incubated 15 mins at 30˚C.  The reaction 
was terminated by the addition of 5x non-reducing protein loading buffer.  Each 
reaction was heated at 65˚C for three min and then subjected to SDS-PAGE 
(12%).  The gel was washed three times in ddH2O and visualized on the 
Typhoon 9410 Variable Mode Imager (GE Healthcare, Piscataway, NJ) for 
BODIPY® fluorescence (ex. 488 nm / em. 532 nm) to visualize co-migration of 
the BODIPY® signal with 6xHIS-Erf2/FLAG-Erf4.  The amount of 6xHIS-
Erf2/FLAG-Erf4 was determined empirically using SDS-PAGE/western blot 
analysis under reducing conditions against a standard curve of bovine serum 
albumin. 
Growth Inhibition Assay-  The in vivo effect of the inhibitors on Ras2 
palmitoylation was investigated by comparing the growth of S. cerevisiae strains 
previously described for our complementation assay [34].  Briefly, the cells 
	 119 
contain a defective allele of RAS2 that is balanced by an episomal copy of RAS2 
linked to URA3.  Under these conditions, the yeast strain cannot grow unless the 
episomal copy of RAS2 is palmitoylated.  Varying concentrations of the inhibitors 
were added to 200 µl volumes of the yeast cells at an OD600 between 0.8 and 1.2 
in a 96-well plate format.  The OD600 was observed every 30 mins for 24 hours 
and EC50 values were determined by graphing rate of growth against 
concentration of inhibitor for each inhibitor. 
Yeast cell spot assay-  Following 24 hour incubation with varying concentrations 
of the inhibitors in 1% DMF, S. cerevisiae strains RJY1941 and RJY1942 were 
then diluted 1/100, and spotted onto SC-URA plates with 2% glucose.  
Cytotoxicity data was obtained by detecting the colony growth, following 48 hours 
incubation at 30˚C,  with white light detection on the Bio-Rad Molecular Imager® 
ChemiDocTM XRS+ (Hercules, CA) and performing densitometry with Bio-Rad 
ImageLabTM software (Hercules, CA).  Triplicate reactions were plated in 
triplicate.  Values were normalized to vehicle control (1% DMF) for each plate, 
and then the averages of each reaction were compared for statistical analysis. 
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Table 4.1.  Percent inhibition of Erf2 autopalmitoylation for R1 positional 
scanning library. 
 
# R1 100 μg/ml 
 2160.001 (1-phenyl-cyclopropyl)-methyl 16% 21% 27% * 
2160.002 2-phenylbutyl -2% -1% 5% 
 2160.003 3-phenylbutyl 7% 8% 18% 
 2160.004 m-tolylethyl 3% 8% 9% 
 2160.005 2-(3-fluoro-phenyl)-ethyl 2% 6% 7% 
 2160.006 2-(3-bromo-phenyl)-ethyl 12% 14% 15% 
 2160.007 2-(3-trifluoromethyl-phenyl)-ethyl 14% 16% 17% 
 2160.008 p-tolylethyl 1% 4% 6% 
 2160.009 2-(4-fluoro-phenyl)-ethyl -3% 2% 4% 
 2160.010 2-(3-methoxy-phenyl)-ethyl 0% 8% 13% 
 2160.011 2-(4-bromo-phenyl)-ethyl 16% 18% 23% 
 2160.012 2-(4-methoxy-phenyl)-ethyl 8% 8% 10% 
 2160.013 2-(4-ethoxy-phenyl)-ethyl 4% 12% 16% 
 2160.014 2-(4-Isobutyl-phenyl)-propyl 26% 32% 37% * 
2160.015 3,4-dichlorophenethyl 8% 15% 19% 
 2160.016 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 12% 23% 26% * 
2160.017 3-(3,4-dimethoxy-phenyl)-propyl -2% 10% 15% 
 2160.018 phenethyl 5% 12% 13% 
 2160.019 3,4,5-trimethoxy-benzyl 3% 10% 11% 
 2160.020 butyl -8% -6% 11% 
 2160.021 heptyl -2% 8% 11% 
 2160.022 isobutyl -1% 2% 6% 
 2160.023 2-methylbutyl -5% 0% 3% 
 2160.024 3-methylbutyl -6% 1% 2% 
 2160.025 3-methylpentyl -3% 2% 3% 
 2160.026 4-methylpentyl -2% 5% 6% 
 2160.027 4-methyl-benzyl 10% 14% 17% 
 2160.028 cyclopently-methyl -5% 6% 10% 
 2160.029 cyclohexyl-methyl -1% 1% 6% 
 2160.030 cyclohexyl-ethyl 1% 6% 10% 
 2160.031 cyclohexyl-butyl 9% 15% 17% 
 2160.032 cycloheptyl-methyl 1% 5% 9% 
 2160.033 2-methylcyclopropyl-methyl -4% 8% 25% 
 2160.034 cyclobutyl-methyl -10% 6% 20% 
 2160.035 3-cyclopentyl-propyl 9% 11% 17% 
 2160.036 cyclohexyl-propyl 3% 11% 12% 
 2160.037 4-methyl-1-cyclohexyl-methyl 0% 6% 13% 
 2160.038 4-tert-butyl-cyclohexyl-methyl 18% 23% 24% * 
2160.039 2-Biphenyl-4-yl-ethyl 21% 27% 30% 
 2160.040 adamantan-1-yl-methyl 8% 16% 18% 
 2160.041 adamantan-1-yl-ethyl 5% 15% 18% 
 2160.042 2-Bicyclo[2.2.1]hept-2-yl-ethyl -1% 8% 17% 
 * Functionalities fixed for each of the R groups in the 48 individual compounds 
synthesized and tested (1-48). 
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Table 4.2.  Percent inhibition of Erf2 autopalmitoylation for R2 positional 
scanning library. 
 
# R2 100 μg/ml 
 2160.043 S-methyl 0% 3% 10% 
 2160.044 S-benzyl 15% 22% 23% 
 2160.045 hydrogen -5% 3% 9% 
 2160.046 S-2-butyl 2% 11% 12% 
 2160.047 S-isobutyl -1% 10% 12% 
 2160.048 R-hydroxymethyl -9% 1% 5% 
 2160.049 (R,R)-1-hydroxyethyl 1% 2% 14% 
 2160.050 S-isopropyl 3% 8% 13% 
 2160.051 S-4-hydroxybenzyl 24% 25% 27% * 
2160.052 R-methyl 0% 1% 4% 
 2160.053 R-benzyl 13% 16% 24% 
 2160.054 R-2-butyl -4% 5% 6% 
 2160.055 R-isobutyl 0% 4% 8% 
 2160.056 S-hydroxymethyl 3% 8% 11% 
 2160.057 (S,S)-1-hydroxyethyl -11% 2% 7% 
 2160.058 R-isopropyl -7% 1% 5% 
 2160.059 R-4-hydroxybenzyl 13% 18% 19% 
 2160.060 S-phenyl 13% 21% 24% * 
2160.061 S-propyl -3% 9% 10% 
 2160.062 R-propyl -12% -2% 0% 
 2160.063 S-butyl -1% 7% 13% 
 2160.064 R-butyl -7% 2% 3% 
 2160.065 S-2-naphthylmethyl 31% 32% 39% * 
2160.066 R-2-naphthylmethyl 32% 37% 40% * 
2160.067 S-cyclohexyl 15% 16% 21% 
 2160.068 R-cyclohexyl 10% 13% 16% 
 * Functionalities fixed for each of the R groups in the 48 individual compounds 
synthesized and tested (1-48). 
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Table 4.3.  Percent inhibition of Erf2 autopalmitoylation for R3 positional 
scanning library. 
 
# R3 100 μg/ml 
 2160.069 (1-phenyl-cyclopropyl)-methyl -2% 2% 9% 
 2160.070 2-phenylbutyl 5% 9% 12% 
 2160.071 3-phenylbutyl -1% 8% 8% 
 2160.072 m-tolylethyl -5% 7% 12% 
 2160.073 2-(3-fluoro-phenyl)-ethyl 0% 2% 7% 
 2160.074 2-(3-bromo-phenyl)-ethyl 10% 12% 20% 
 2160.075 2-(3-trifluoromethyl-phenyl)-ethyl 16% 20% 21% 
 2160.076 p-tolylethyl 2% 3% 5% 
 2160.077 2-(4-fluoro-phenyl)-ethyl 0% 4% 10% 
 2160.078 2-(3-methoxy-phenyl)-ethyl 2% 5% 13% 
 2160.079 2-(4-bromo-phenyl)-ethyl 1% 8% 9% 
 2160.080 2-(4-methoxy-phenyl)-ethyl -4% 1% 3% 
 2160.081 2-(4-ethoxy-phenyl)-ethyl -2% 3% 8% 
 2160.082 2-(4-Isobutyl-phenyl)-propyl 19% 26% 28% * 
2160.083 3,4-dichlorophenethyl 8% 8% 10% 
 2160.084 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 13% 24% 29% * 
2160.085 3-(3,4-dimethoxy-phenyl)-propyl -5% 0% 12% 
 2160.086 phenethyl 3% 6% 7% 
 2160.087 3,4,5-trimethoxy-benzyl 0% 1% 3% 
 2160.088 butyl 0% 1% 1% 
 2160.089 heptyl 0% 0% 2% 
 2160.090 isobutyl -6% -6% -3% 
 2160.091 2-methylbutyl -5% -3% -1% 
 2160.092 3-methylbutyl -6% -1% 0% 
 2160.093 3-methylpentyl -6% -1% 3% 
 2160.094 4-methylpentyl -2% 0% 4% 
 2160.095 4-methyl-benzyl 4% 6% 13% 
 2160.096 cyclopently-methyl 0% 1% 5% 
 2160.097 cyclohexyl-methyl 0% 3% 5% 
 2160.098 cyclohexyl-ethyl 1% 5% 8% 
 2160.099 cyclohexyl-butyl 11% 11% 14% 
 2160.100 cycloheptyl-methyl 7% 7% 10% 
 2160.101 2-methylcyclopropyl-methyl -3% 0% 8% 
 2160.102 cyclobutyl-methyl -5% 5% 7% 
 2160.103 3-cyclopentyl-propyl 2% 11% 16% 
 2160.104 cyclohexyl-propyl 3% 7% 14% 
 2160.105 4-methyl-1-cyclohexyl-methyl 3% 4% 7% 
 2160.106 4-tert-butyl-cyclohexyl-methyl 8% 12% 15% 
 2160.107 2-Biphenyl-4-yl-ethyl 18% 24% 31% 
 2160.108 adamantan-1-yl-methyl 19% 25% 26% * 
2160.109 adamantan-1-yl-ethyl 11% 13% 21% 
 2160.110 2-Bicyclo[2.2.1]hept-2-yl-ethyl 2% 3% 10% 
 * Functionalities fixed for each of the R groups in the 48 individual compounds 
synthesized and tested (1-48).  
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Table 4.4.  The effect of varying the concentration of compounds 13 and 25, 
and 2-BP on the KM and Vmax for the Palm-CoA substrate. 
 
Compound 
13 KM Vmax R
2 
(μM) (μM) (μM) 
 0 3 +/- 1 210 +/- 11 0.9 
25 11 +/- 3 243 +/- 20 0.87 
50 38 +/- 6 354 +/- 26 0.97 
100 145 +/- 30 631 +/- 94 0.98 
    Compound 
25 KM Vmax R
2 
(μM) (μM) (μM) 
 0 3 +/- 1 296 +/- 17 0.88 
25 11 +/-3 307 +/- 30 0.83 
50 23 +/- 6 344 +/- 34 0.91 
100 79 +/- 15 542 +/- 60 0.98 
    2-BP KM Vmax R2 
(μM) (μM) (μM) 
 0 4 +/- 1 222 +/-7 0.96 
25 2 +/-1 160 +/-5 0.95 
50 10 +/-6 126 +/- 23 0.53 
100 14 +/- 7 51 +/-8 0.71 
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Figure 4.1.  Schematic Representation of the Chemical Library Screen.  A. 
The Torrey Pines Institute for Molecular Studies scaffold library approach starts 
with >30 million compounds that are organized by 68 core scaffolds with 2,000 – 
700,000 different compounds per scaffold.  B. A lead scaffold is selected for the 
positional scanning screen.  C. All of the compounds in the positional scanning 
screen contain the same core scaffold structure and are organized by the R-
groups at each position.  Each of the plates contains the same compounds 
organized by the different R-group position to determine if a particular functional 
group is optimal at one of the positions.  The positional scanning library screened 
in this study contained 110 positional scanning samples that each comprise of 
1,000 – 2,000 individual compounds for a total diversity of 45864 individual 
compounds.  D. The selectivity for the different R-groups is predicted for each 
position based on the positional scanning results. In this study, 48 individual 
compounds were synthesized.  E. Of the 48 individual compounds synthesized 
ten were selected for further analysis in additional assays.  In total 226 samples 
were tested; 68 Scaffolds, 110 positional scanning scaffolds, 48 individual 
compounds. 
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Figure 4.2.  Result of the Screen for Inhibition of Erf2 Autopalmitoylation.  
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Figure 4.2.  (Continued).  The scaffold ranking library screen of 68 scaffolds 
was screened at 100 μg/ml, and the average velocity of Erf2 autopalmitoylation 
of three reactions is presented as a fraction of vehicle control (1% DMF).  The 
velocity of Erf2 autopalmitoylation was detected as an increase in fluorescence 
over time.  No effect on Erf2 autopalmitoylation would fall at 1 arbitrary unit (solid 
line).  Scaffolds that resulted in a reduction in Erf2 autopalmitoylation 3 standard 
deviations (dashed line) or greater were considered hits of this assay. A heat 
inactivated Erf2 (Boiled) and a catalytically inactive mutant of Erf2 (C203S) 
represent baseline activity in this assay.  100 μM 2-BP is a control for inhibition 
of Erf2 autopalmitoylation. 
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Figure 4.3.  Background Effects of the Lead Scaffold Ranking Library 
Samples on the α -KDH Reaction.  Scaffold ranking library samples that 
resulted in a reduction in Erf2 autopalmitoylation of 3 standard deviations or 
greater were screened  against α-KDH activity on the same assay lacking Erf2-
Erf4, with 20 μM CoASH as substrate rather than 40 μM palmitoyl-CoA. 
Samples were screened at 100 μg/ml and the relative fluorescence detected 
after a 30 minute reaction is presented as a fraction of vehicle control (1% DMF).  
Samples that resulted in any increase in fluorescence 1.5 times greater or more 
relative to vehicle control were omitted from further analysis. 50 μM 2-BP was 
included as a reference. 
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Figure 4.4.  Inhibition of Erf2 Autopalmitoylation by Varying the 
Concentration of the Library Samples.  A. The velocity of Erf2 
autopalmitoylation on the coupled assay with the lead scaffold ranking library 
samples (2160, 2220, 2236, 2221, 2103).  The velocity of Erf2 autopalmitoylation 
was detected as an increase in fluorescence over time.  Average values of three 
reactions are presented as a fraction of vehicle control (1% DMF) +/- standard 
deviation.  Samples were screened at 50 μg/ml (dark grey bars), 100 μg/ml 
(light grey bars), and 200 μg/ml (white bars) compared to 2-BP at 50 μM (dark 
grey bars), 100 μM (light grey bars), and 200 μM (white bars).  A reaction 
lacking Erf2 ( - ) represents baseline activity in the assay.  B. Structures of lead 
scaffolds and 2-bromopalmitic acid.  Positions for varying functional groups are 
denoted by R1-R4.  Scaffold 2160 contains three R-group positions, scaffolds 
2220, 2221, and 2103 each contain two R-group positions, and scaffold 2236 
contains four R-group positions. 
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Figure 4.5.  Inhibition of Erf2 Autopalmitoylation by Individual Compounds 
Derived from the 2160 Scaffold.   
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Figure 4.5.  (Continued).  Relative velocity of Erf2 autopalmitoylation with 100 
μ g/ml of optimized individual compounds (1-48), non-specific individual 
compounds (49-54), positional scanning samples (2160.066, 2160.082, 
2160.001, 2160.065, and 2160.108), and lead scaffold ranking library sample 
(2160).  The velocity of Erf2 autopalmitoylation was detected as an increase in 
fluorescence over time. Average values of three reactions presented as a fraction 
of vehicle control (1% DMF) +/- standard deviation. A reaction lacking Erf2 ( - ) 
represents baseline activity in the assay.  50 μM 2-BP is a control for inhibition 
of Erf2 autopalmitoylation. 
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Figure 4.6.  Inhibition of Erf2 Autopalmitoylation by Varying the 
Concentration of Individual Compounds Derived from the 2160 Scaffold.  
Relative velocity of Erf2 autopalmitoylation with purified lead individual 
compounds.  The velocity of Erf2 autopalmitoylation was detected as an increase 
in fluorescence over time. Average values of three reactions are presented as a 
fraction of vehicle control (1% DMF) +/- standard deviation.  Compounds were 
screened at 25 μM (dark grey bars), 50 μM (light grey bars), and 100 μM 
(white bars) compared to 2-BP.  A reaction lacking Erf2 ( - ) represents baseline 
activity in the assay.   
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Figure 4.7.  Structure of the Scaffold 2160 Derived Compounds.  The 
structure for scaffold 2160, bis-cyclic piperazine has three R-group positions 
designated R1, R2, and R3. The lead functional groups are 2-(4-Isobutyl-phenyl)-
propyl (i), 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl (ii), 4-tert-butyl-cyclohexyl-
methyl (iii), S-4-hydroxybenzyl (iv), S-phenyl (v), S-2-naphthylmethyl (vI), and 
adamantan-1-yl-methyl (vii).  The curved lines on the functional group structures 
designate where they will share a bond with the core scaffold.  Positions for each 
functional group are described in the right panel.  Ki values for the fluorescence-
based coupled assay of the rate of Erf2 autopalmitoylation (FCA) and the 
orthogonal gel-based assay of steady-state Erf2 autopalmitoylation (GBA) are 
listed for each compound (14, 13, 25, 28, 34, 19, 22, 43, 27, and 30) as well as 
EC50 values obtained from the growth curve experiments in S. cerevisiae 
RJY1942 (Sens.) and RJY1941 (cont.).  All values are represented in μM 
concentrations.  The increased detection sensitivity of the FCA allowed for the 
determination of standard deviation.  
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Figure 4.8.  Inhibition of Erf2 Autopalmitoylation Measured by a Gel-based 
Assay.  An orthogonal screen of steady-state Erf2 autopalmitoylation with 100 μ
M of each of the ten individual compounds (43, 27, 19, 13, 22, 34, 14, 25, 30, 
and 28) was separated by SDS-PAGE.  The average relative BODIPY® 
fluorescence from three reactions that co-migrated with Erf2 is presented as a 
fraction of vehicle control (V; 5% DMF) +/- standard deviation.  A reaction lacking 
Erf2 ( - ) represents baseline activity in the assay.  100 μM 2-BP is a control for 
inhibition of Erf2 steady-state autopalmitoylation. 
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Figure 4.9.  Inhibition of Erf2 Autopalmitoylation Dose Responsiveness on 
Gel-based Assay.  An orthogonal screen of steady-state Erf2 autopalmitoylation 
of each of the ten individual compounds (43, 27, 19, 13, 22, 34, 14, 25, 30, and 
28) was separated by SDS-PAGE.  The average relative BODIPY® fluorescence 
from three reactions that co-migrated with Erf2 is presented as a fraction of 
vehicle control (V; 5% DMF) +/- standard deviation.  A reaction lacking Erf2 ( - ) 
represents baseline activity in the assay.  100 μM 2-BP is a control for inhibition 
of Erf2 steady-state autopalmitoylation.  Compounds were screened at 25 μM 
(dark grey bars), 50 μM (light grey bars), and 100 μM (white bars) compared to 
2-BP.  A reaction lacking Erf2 ( - ) represents baseline activity in the assay.   
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Figure 4.10.  Michaelis-Menten Plots for Compounds 13 and 25, and 2-BP.  
The velocity of Erf2 autopalmitoylation as altered by the addition of the inhibitors 
at 100 μM (filled circles), 50 μM (empty triangles), 25 μM (filled squares), and 
vehicle control (1% DMF; empty diamonds) for compounds 13 and 25, and 2-BP. 
The velocity of Erf2 autopalmitoylation was detected as an increase in 
fluorescence over time. Vmax is the maximum velocity of the reaction, and KM is 
the substrate concentration that allows the reaction to reach a velocity that is 
50% of the Vmax. On the Michaelis-Menten Plot, a competitive inhibitor would 
increase KM without altering Vmax, whereas an uncompetitive inhibitor would 
result in a decrease of Vmax without altering the KM of the reaction. 
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Figure 4.11.  Inhibition of Palmitoyl-CoA Concentration Dependent 
Palmitoylation of Erf2 by Compound 13. Orthogonal screen of steady-state 
Erf2 autopalmitoylation with compound 13 at 25 μM, 50 μM and 100 μM was 
separated by SDS-PAGE.  The average relative BODIPY® fluorescence from 
three reactions that co-migrated with Erf2 is presented as a fraction of vehicle 
control (VC; 5% DMF) for each concentration of BODIPY®-C12-CoA +/- standard 
deviation.  A reaction lacking Erf2 ( - ) represents baseline activity in the assay.  
Prior experiments in this study used 100 μM Compound 13 with 40 μM 
BODIPY®-C12-CoA. 
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Figure 4.12.  Inhibition of Ras Palmitoylation-sensitized Yeast Growth.   
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Figure 4.12.  (Continued).  A. A Representation of the yeast strains RJY1942 
(Sensitized Strain) and RJY1941 (Control Strain).  RJY1942 lacks a ras1 gene, 
and has a ras2 mutation resulting in a yeast strain dependent on Ras2 
palmitoylation for viability as previously described [33, 34, 149].  RJY1941 
similarly lacks ras1 and has the ras2 mutation, but has Ras2 re-introduced to 
overcome the dependence on Ras2 palmitoylation.  B. The EC50 for each of the 
individual compounds was established by graphing the logarithmic growth of S. 
cerevisiae strain, RJY1941 (solid lines and solid circles) and RJY1942 (hashed 
lines and open circles), versus the concentration of each compound. The curves 
were used to extrapolate the EC50 values are presented for 2-BP and the ten 
compounds identified in this study.  Values were normalized to visually compare 
relative log of the growth rate of each compound and 2-BP.   
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Figure 4.13.  Purified Compounds Inhibit Palmitoylated Ras-dependent 
Growth in Yeast.  A representative (n=3) spot assay of cytotoxic effects in wild 
type (RJY1941) S. cerevisiae is compared to that of the palmitoylation-dependent 
(RJY1942) strain.  Liquid cultures containing the shown inhibitors were spotted 
onto selective media and incubated at 30˚C for 3 days. The concentrations used 
in the liquid cultures were 2.5 μM, 5 μM, 10 μM, and 20 μM in 1% DMF 
(Vehicle). 
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Figure 4.14.  Synthetic Scheme of Bis-cyclic Piperazines.  A, 5% 
DIEA/DCM; B, Fmoc-Lys(Boc)-OH, DIC, HOBt, DMF; C, 20% Piperidine/DMF; 
D, R1COOH, DIC, HOBt, DMF; E, 55% TFA/DCM; F, Boc-AA(R2), DIC, HOBt, 
DMF; G, R3COOH, DIC, HOBt, DMF; H, BH3-THF, 65˚C, 96 hours; I, 
Piperidine, 65˚C, 24 hours; J, Oxalyldiimidazole, DMF; K, HF, anisole, 0˚C.   
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CHAPTER 5 
 
Discussion of the Fluorescent-based Coupled Assay and Inhibitor Screens  
 
5.1 Key Words and Abbreviations 
Enzyme Inhibitor, High-throughput Screen, Palmitoylation, zDHHC; 2-BP, 2-
Bromopalmitate; AD, Alzheimer’s Disease; ER, Estrogen Receptor; HD, 
Huntington’s Disease; HTS, High-throughput Screen; PAT, Protein Acyl 
Transferase; PM, Plasma Membrane; PTM, Post-translational Modification; SAR, 
Structure-Activity Relationship; XLID, X-linked Intellectual Disability 
 
5.2 The Challenge of Ras as a Therapeutic Target   
Despite considerable effort and investment of resources a therapeutic strategy 
that targets the most frequently mutated oncogenes in cancer, the three Ras 
genes, has eluded investigators [102, 117, 265].  When targeting the activation of 
Ras, researchers attempted to design a GTP-mimetic to target the GTPase 
activity of Ras similar to ATP-mimetics that inhibit kinases. Unfortunately, GTP is 
present at high concentrations within the cell and binds with a picomolar affinity 
making it virtually impossible to compete with [102, 117].  Attempts to inhibit 
specific GEFs and block the removal of GDP from the active site following the 
intrinsic GTPase activity was also ineffective [118, 119].  It is unclear if oncogenic 
Ras depends on GEFs in the same manner that wild-type Ras does [118, 119]. 
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Following the failure to target the activation of Ras, many researchers looked to 
target the downstream signaling pathways of Ras.  Curiously, early work to 
identify agents that blocked Raf kinase in Ras-transformed cells resulted in the 
activation of the pathway [266, 267].  Alternatively, inhibitors designed against 
MAP kinase and phosphatidyl inositol 3-kinase had no significant clinical activity.  
Feedback loops and poor therapeutic windows account for the failure to target 
those pathways [102].  In the context of inhibiting the Raf pathway, it was 
observed that unprocessed Ras was capable of binding to Raf, but not of 
activating it [266].  This garnered interest for targeting the PTMs of Ras. 
Inhibitors of FTase were encouraging in the mouse model but were ineffective in 
the clinical setting due to the ability of GGTase to restore the activity of K- and N-
Ras after FTase inhibitor treatment [102, 117].  Curiously, attempts at inhibiting 
either RCE1 or ICMT resulted in an increase in Ras-mediated tumorigenesis 
[102, 117].  Thus, the final step in Ras processing, palmitoylation, has become 
an intriguing target candidate to block the oncogenic activity of Ras.  
 
5.3 Discussion of a Fluorescent-based Coupled Assay for Erf2 
Autopalmitoylation 
To fully understand palmitoylation and screen for inhibitors of palmitoylation there 
is a need for a reliable HTS. A coupled assay developed by Dr. David Mitchell 
was subsequently adapted and optimized for its use in a high-throughput screen 
(HTS) format (see Chapter and [147]).  The adapted assay has allowed us to 
effectively determine the kinetic parameters of PATs, elucidate the lipid donor 
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specificity of the reaction, and determine the mode of action of 2-bromopalmitate 
(2-BP) [147].  Now that it has been established and validated, the assay can be 
used to characterize any zDHHC PAT.  
In this project, the assay was used to screen for inhibitors of Erf2 
autopalmitoylation. The availability of a HTS format for zDHHC PAT kinetics 
increases the chance of detecting a specific inhibitor of protein palmitoylation.  
One drawback of this assay is its specificity to the autopalmitoylation reaction, 
and not the transfer of the palmitoyl moiety to the protein substrate.   
Currently, there are no HTS techniques developed to evaluate the transfer step 
of palmitoylation.  The lack of sequence consensus for palmitoylation sites 
makes it difficult to design a HTS capable of evaluating different palmitoylation 
substrates.  The release of CoASH during autopalmitoylation is critical for the 
ability to couple the α-KDH reaction to autopalmitoylation.  Unfortunately, no 
metabolite is released during the transfer step of palmitoylation that could be 
exploited for a HTS. 
An inhibitor of autopalmitoylation would reduce the palmitoyl moiety available for 
transfer to a protein substrate, and is a viable means of inhibiting overall protein 
palmitoylation.  Given the difficulty in designing a HTS for the transfer step of 
palmitoylation, having an autopalmitoylation assay amenable to a HTS format is 
a convenient means to evaluate overall protein palmitoylation.  
 
 
 
	 144 
5.4 Optimizing Inhibition 
When designing or screening for PAT inhibitors, one must consider two 
properties; specificity and effectiveness.  There are certain points to consider 
during the screening process to eliminate compounds that lack in either.  This 
section describes pan assay interference compounds (PAINS), and guidelines for 
determining which compounds will be more easily absorbed and processed, 
allowing for more efficient inhibition [268, 269]. 
In a typical academic screening library, 5-12% of compounds are PAINS [270, 
271].  PAINS encompass 400 structural classes [270, 271].  Most PAINS function 
as chemicals rather than discriminating drugs, and frequently have more than 
one interference mechanism [268].  Often PAINS will interfere with many other 
proteins [268].  False positives result from interactions with toxic or reactive 
metals used to synthesize the screening library, interactions with the assay 
reagents, coating a protein, sequestering metal ions, or due to non-specific 
chemical reactions [268, 270-273]. To avoid PAINS, one should be mindful of 
similar structures or substructures the literature to see if it interacts with unrelated 
proteins.  There are some disreputable structures that Baell et al. highlight as the 
most frequent PAINS: toxoflavin, isothiazolones, curcumin, hydroxyphenyl 
hydrazones, ene-rhodanine, phenol-sulphonamides, enones, quinones and 
catechols [268, 270-273].  Finally, assays should be assessed and results should 
be obtained via at least two different assays that establish results by different 
means [268]. 
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Lipinski’s Rule of Five is based on the observation that most orally administered 
drugs are relatively small, and moderately lipophilic [244].  This has no relevance 
to pharmacological activity, but rather an increased chance that the drug will 
have better absorption, distribution, metabolism, and excretion.  The Rule of Five 
suggests that an effective inhibitor should have no more than 5 hydrogen bond 
donors (-OH or –NH), no more than 10 hydrogen bond acceptors (total O or N), a 
molecular mass ≤500 g/mol, and an octanol-water partition coefficient logP≤5 
[244].  Small peptide molecules are gaining favor in drug design but often are 
limited by poor pharmacokinetic profiled due to poor membrane permeability 
[274].  The introduction of hydrogen bond acceptor-donor pairs in small peptide 
molecules can improve membrane permeability without diminishing drug-like 
properties [274].  Drug Affinity Responsive Target Stability relies on the 
protection against proteolysis to identify potential protein targets for small 
molecules [275]. 
In summary, the lead compound may be a false positive acting independently of 
the target.  Some characteristics tend to make compounds more easily absorbed 
and processed, thus allowing for greater efficacy.  Baell, et al., and Lipinski have 
described precautions and methods for the optimization of drug design [244, 268, 
270-273]. 
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5.5 Discussion of Erf2 Autopalmitoylation Inhibition by Fungal 
Metabolites 
Dr. Baker and collaborators at the Department of Chemistry and the Center for 
Drug Discovery and Innovation at the University of South Florida have provided 
Florida mangrove fungal extract metabolite library.  The metabolites extracted 
from fungal isolates by ethyl acetate may contain non-polar natural products, 
lipids, small peptide chains, and possibly DNA intercalators.  The fungal extracts 
are a subset of a larger project and were previously screened for toxicity in a 
parasite bioassay. The samples provided exhibited cytotoxicity towards J774 
macrophage cells and were not eligible for further investigation for anti-parasitic 
leads but were of interest in target-based anti-cancer bioassays.  The extract 
samples resulted in at least a 20% reduction of Erf2 autopalmitoylation on the 
fluorescent-based coupled assay, with a majority exceeding a 50% reduction in 
Erf2 autopalmitoylation. The control experiment lacking Erf2 demonstrated that 
all of the extracts had minimal background fluorescence, but only three samples 
had a 40-fold higher background fluorescence compared to vehicle control (5% 
DMSO).  Only 11/81 samples screened had an effect on α -KDH activity, 
suggesting that the remaining samples were eliciting their effects on the 
fluorescent-based coupled assay through inhibition of Erf2 autopalmitoylation, 
and not the other elements of the assay.  This was validated for the lead eight 
extracts via the orthogonal gel-based assay of Erf2 steady-state 
autopalmitoylation. 
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Overall, the fungal metabolite screen on the fluorescent-based coupled assay 
validated the use of the assay to accurately identify inhibitors of Erf2 
autopalmitoylation in a HTS format.  This was the first time we demonstrated 
inhibition of Erf2 steady-state autopalmitoylation on the gel-based assay. The 
results are encouraging for the future optimization of these samples, but also for 
the exploitation of natural products as modulators of protein palmitoylation.  
The next phase for the fungal metabolite samples is to fractionate the lead 
extracts metabolites.  First, the samples will be crudely separated on natural 
product medium pressure liquid chromatography (NP MPLC).  Then, the samples 
will be fractionated by reverse phase HPLC.  Metabolites identified in this study 
will be optimized for structure-activity relationship (SAR).  The lead individual 
metabolites will then be screened against other zDHHC PATs to reveal if they 
are specific to Erf2 or are pan inhibitors of zDHHC PATs.   
 
5.6 Discussion of Erf2 Autopalmitoylation Inhibition by a Scaffold 
Ranking Library 
A unique scaffold ranking library from the Torrey Pines Institute for Molecular 
Studies was applied to the fluorescent-based coupled assay.  In a typical HTS 
approach to detect enzymatic inhibitors, millions of samples would be screened 
to identify a lead compound.  Only after lead compounds are identified would 
SAR be applied to further enhance the effectiveness of the inhibitor.  Due to the 
organization of millions of compounds by core scaffold features, one can screen 
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millions of compounds and perform SAR early on in the screening process, while 
only examining hundreds of samples, effectively reversing the typical process.  
A group of ten bis-cyclic piperazines from the scaffold ranking library were 
identified in the fluorescent-based coupled assay.  These bis-cyclic piperazines 
inhibited Erf2 autopalmitoylation to an equal or greater extent than 2-BP, and 
through a different mode of action.  Piperazine analogs have previously been 
demonstrated as effective drug-like compounds [252-254].  The bis-cyclic 
piperazine compounds identified in this study inhibit Erf2 autopalmitoylation in the 
μM range but ideally we would like to improve them through SAR so that they 
inhibit Erf2 autopalmitoylation in the nM range. 
The major considerations for SAR optimization are varying functional groups (to 
improve bonds and interactions with the binding pocket), simplifying the 
structure, and adding rigidity to the structure through the addition of rigid 
functional groups, ring structures, or steric interactions.  As mentioned prior, 
some level of SAR was performed in earlier screens due to the design of the 
scaffold ranking library.  The scaffold ranking library allowed for the optimization 
of the functional groups during preliminary screens but there is still a need to fine 
tune the lead compounds.  
One consideration for optimizing the compounds would be to manipulate the 
symmetry of the compounds.  Without the R-groups, bis-cyclic piperazine has a 
symmetric structure.  The R1 and R3 groups are on opposing ends, and share 
the same lead functional groups increasing the structural symmetry.  Compounds 
13, 14, and 25 all have the same functional group at the R2 position but differ at 
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their R1 and R3 positions.  Compound 13 has the same functional group at R1 
and R3 positions.  Compound 14 has the same functional group on position R1 
as compound 13 but a different functional group on the R3 position.  Compound 
25 has the same functional groups as Compound 14 but on the opposing 
positions.  When comparing these three compounds, compound 13 has a mild 
inhibitory advantage over the two non-symmetrical compounds.  Thus, it would 
be of interest to adjust the other non-symmetrical compounds to be more 
symmetrical and observe any effects on their ability to inhibitor Erf2 
autopalmitoylation.  
Another consideration for optimizing the bis-cyclic piperazine compounds would 
be to modify the functional group at the R2 position.  Of the three variable 
positions, R2 seems to have the lowest effect on overall efficacy.  One way the 
R2 position could be modified would be to remove it altogether.  Another would 
be to put a functional group reminiscent of palmitate or coenzyme A at the R2 
position.  There is no structural information for where the bis-cyclic piperazines 
are interacting with Erf2.  If the inhibitors are binding at a different active site than 
palmitoyl-CoA, then modifying the R2 position to mimic palmitate or coenzyme A 
could sequester the inhibitor away from its active site.  Conversely, the modified 
inhibitor may inhibit preferentially to this new position but it may be acting 
mechanistically similar to the current protein palmitoylation inhibitors, which 
presumably act through substrate recognition [201, 204, 205]. 
Although the bis-cyclic piperazines were identified in this study due to their 
inhibitory effects on Erf2 autopalmitoylation, it is not yet known if they act 
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specifically on Erf2, on zDHHC PATs, on CoA-dependent enzymes, or if they are 
as non-specific as 2-BP.  The next step for the bis-cyclic piperazines will be to 
evaluate the specificity of these compounds for Erf2 versus other zDHHC PATs 
on the fluorescent-based coupled assay. A possible mode to detect their 
interactions could be to modify them for use as probes.  Analogs of 2-BP and 
cerulenin analog have been used as a probes for protein palmitoylation in cells 
[190, 206].  The 2-BP analog probe detected zDHHC PAT enzymes, transporters 
and many validated palmitoylated proteins [206].  The cerulenin analog probe 
detected zDHHC PATs and over 200 palmitoylated proteins [190].  Unfortunately, 
the probes were not very specific.  The 2-BP analog had no observable 
preference for enzymes dependent on CoA, and the cerulenin analog was not 
specific to active zDHHC PATs and detected those with mutations to the catalytic 
cysteines [190].  The inhibitors described in this study could be similarly modified 
to their detect interactions, and for use as a probe of palmitoylation in future 
studies.  With the similarity between the bis-cyclic piperazine compounds, there 
is the potential to fine tune inhibition per zDHHC PAT where similar compounds 
may target similar binding locations but with preference for one zDHHC PAT over 
the others. 
 
5.7 Implications of Palmitoylation Modulation for Therapeutic 
Intervention of Disease 
While research to clarify the role of palmitoylation is ongoing, the complexity of its 
involvement is clear.  Some diseases involve the dysregulation of specific 
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zDHHC PATs whereas the zDHHC PAT is unknown for other diseases, but 
proteins critical to the disease are modified by palmitoylation.  In the context of 
oncogenesis there are incidences of an increase in expression (zDHHC9, 
zDHHC11, and zDHHC16), incidences of a decrease in expression (zDHHC2, 
and zDHHC3), incidences of an increase of either expression or activity 
(zDHHC7 and zDHHC21), and even incidences of an increase in expression in 
one tumor type and a decrease in expression in another tumor type (zDHHC14) 
(Table 1.1).  Due to the variable means that palmitoylation is implicated in 
disease, the design of a therapeutic intervention needs to be specific and 
precise.  Ideally, there would be a set of modulators for palmitoylation rather than 
just one.  Thus within the set, some modulators could increase the palmitoylation 
activity and others would decrease the palmitoylation activity.  This will require a 
level of specificity not yet established.   
Encouragingly, a reliable method to purify stable, active zDHHC PATs has been 
developed, along with a validated HTS method to identify inhibitors. Counter 
screens, orthogonal assays, and cell-based assays are established to 
characterize and analyze candidate inhibitors.  These techniques will help 
overcome the current failure to find a desired high affinity, specific inhibitors, and 
aid to fill in the gaps of knowledge for protein palmitoylation. At least 22 zDHHC 
PATs have been identified in humans but relatively little more is known about 
them [41].  The fluorescent-based coupled assay described in Chapter 2 was 
implemented to characterize the kinetic effects of zDHHC9 mutations that have 
been implicated in X-Linked Intellectual Disability (XLID) [53].  Mutations in other 
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zDHHC9 PATs have been implicated in a variety of diseases and disorders; all of 
which can be kinetically characterized with this assay.  The assay can also be 
applied to validating zDHHC PAT complex formations, validating predicted 
inhibitors, and screening countless more chemical libraries for new and improved 
inhibitors. 
Furthermore, the studies described in Chapters 3 and 4 led to the identification of 
fungal metabolites and a family of bis-cyclic piperazines that inhibit Erf2 
autopalmitoylation.  The inhibitors identified in this study represent a necessary 
first step toward the development of a novel drug therapy against oncogenic Ras 
for the treatment of colon cancer.  They could also be the next probes of 
palmitoylation for use in the research setting.  
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